# Comparative Analysis of Audited Results from TennCare MCOs



September 2013

2013 Annual

# HEDIS/ CAHPS Report

prepared by

## **Table of Contents**

List of Tables	4
List of Figures	5
Acknowledgements/Copyrights	9
Acronyms and Initialisms	10
Executive Summary	13
Background	14
HEDIS Measures—Domains of Care	14
Effectiveness of Care Measures	14
Prevention and Screening	. 15
Children/ Adolescents (WCC)	
Childhood Immunization Status (CIS)	
Human Papillomavirus Vaccine for Female Adolescents (HPV)	
Lead Screening in Children (LSC)	
Breast Cancer Screening (BCS)	. 16
Cervical Cancer Screening (CCS)	. 16
Chlamydia Screening in Women (CHL)	. 16
Respiratory Conditions	. 16
Appropriate Testing for Children With Pharyngitis (CWP)	. 16
Appropriate Treatment for Children With Upper Respiratory Infection (URI)	. 16
Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis (AAB)	. 16
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)	
Pharmacotherapy Management of COPD Exacerbation (PCE)	
Use of Appropriate Medications for People With Asthma (ASM)	
Medication Management for People With Asthma (MMA)	
Asthma Medication Ratio (AMR)	
Cardiovascular Conditions	
Cholesterol Management for Patients With Cardiovascular Conditions (CMC)	
Controlling High Blood Pressure (CBP)	
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)	. 18
Diabetes	
Comprehensive Diabetes Care (CDC)	. 18
Musculoskeletal Conditions	)18
Behavioral Health	
Antidepressant Medication Management (AMM)	
Follow-Up Care for Children Prescribed ADHD Medication (ADD)	
Follow-Up After Hospitalization for Mental Illness (FUH)	

Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are	
Using Antipsychotic Medications (SSD)	
Schizophrenia (SMC)	. 20
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SA.	A)20
Medication Management	
Annual Monitoring for Patients on Persistent Medications (MPM)	. 20
Measures Collected Through CAHPS Health Plan Survey	
Access/Availability of Care Measures	<i>20</i>
Adults' Access to Preventive/Ambulatory Health Services (AAP)	
Children and Adolescents' Access to Primary Care Practitioners (CAP) Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	
(IET)	
Prenatal and Postpartum Care (PPC)	
Utilization and Relative Resource Use	
Utilization	. 22
Utilization measures are designed to capture the frequency of certain services provided by the organization. Frequency of Ongoing Prenatal Care (FPC)	22
Well-Child Visits in the First 15 Months of Life (W15)	
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34)	
Adolescent Well-Care Visits (AWC)	. 22
Relative Resource Use	. 22
Experience of Care	22
CAHPS Health Plan Survey 5.0H Adult Version (CPA)	
Getting Needed Care	
Customer Service	. 24
Getting Care Quickly	
How Well Doctors Communicate	
Shared Decision Making	
Additional Questions	
CAHPS Health Plan Survey 5.0H Child Version: General Population (CPC)	
Customer Service	
Getting Care Quickly	
How Well Doctors Communicate	
Shared Decision Making	. 25
Additional Questions	. 25
CAHPS Health Plan Survey 5.0H Child Version: Children With Chronic Conditions (CCC)	. 26
Access to Prescription Medicines	
Access to Specialized Services	
Family-Centered Care: Getting Needed Information	
Family-Centered Care: Personal Doctor or Nurse Who Knows Child	
Family-Centered Care: Coordination of Care for Children With Chronic Condition	ns27

Results	28
Statewide Performance	28
Individual Plan Performance	34
HEDIS Trending Since 2006	43
Effectiveness of Care Measures—Prevention and Screening	43
Effectiveness of Care Measures—Respiratory Conditions	63
Effectiveness of Care Measures—Cardiovascular Conditions	73
Effectiveness of Care Measures—Diabetes	
Effectiveness of Care Measures—Musculoskeletal Conditions	
Effectiveness of Care Measures—Behavioral Health	
Effectiveness of Care Measures—Medication Management	
Access/Availability of Care Measures	
Utilization and Relative Resource Use	
APPENDIX A   2013 HEDIS Additional Measures, Rates and Benchn	<i>1arks</i> 1
Utilization Measures	
Frequency of Selected Procedure (FSP)	
Ambulatory Care (AMB)	
Identification of Alcohol and Other Drug Services (IAD)	
Mental Health Utilization (MPT)	1
Antibiotic Utilization (ABX)	
Utilization Measures: Plan-Specific Rates/National Benchmarks	2
APPENDIX B   HEDIS 2012 National Medicaid Means and Percentile	s1
APPENDIX C   MCO Population Reported in Member Months	1
List of Tables	
LIST OF Tables	
Table 2-1a. HEDIS 2013 State to National Rates: Effectiveness of Care Measures .	28
Table 2-1b. HEDIS 2013 State to National Rates: Effectiveness of Care Measure W	/here
Lower Rates Indicate Better Performance	
Table 2-2. HEDIS 2013 State to National Rates: Access/Availability of Care Measures	33
Table 2-3. HEDIS 2013 State to National Rates: Utilization Measures	33
Table 2-4. MCO HEDIS 2013 Rating Determination	34
Table 2-5a. HEDIS 2013 Plan-Specific Rates: Effectiveness of Care Measures	34
Table 2-5b. HEDIS 2013 Plan-Specific Rates: Effectiveness of Care Measure Where Rates Indicate Better Performance	
Table 2-6. HEDIS 2013 Plan-Specific Rates: Access/Availability of Care Measures .	39
Table 2-7. HEDIS 2013 Plan-Specific Rates: Use of Services Measures	39

Table 2-	8. MCO 2013 CAHPS Rating Determination
Table 2-	9. 2013 CAHPS 5.0H Adult Medicaid Survey Results
Table 2-	10. 2013 CAHPS 5.0H Child Medicaid Survey Results (General Population) 41
Table 2-	11. 2013 CAHPS 5.0H Child Medicaid Survey Results (Children with Chronic Conditions)
Table A.	HEDIS 2013 Plan-Specific Rates with National Benchmarks: Utilization Measures
Table B.	HEDIS 2012 National Medicaid Means and PercentilesB-1
Table C.	HEDIS 2013 MCO Population Reported in Member Months by Age and SexC-1
Lic	t of Figures
LI3	t of figures
Fig. 1.	HEDIS 2010–2013 Adult BMI Assessment (ABA) Statewide Weighted Rates 43
Fig. 2.	HEDIS 2010–2013 Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)—BMI Percentile: 3–11 years Statewide Weighted Rates
Fig. 3.	HEDIS 2010–2013 WCC—BMI Percentile: 12–17 years Statewide Weighted Rates 44
Fig. 4.	HEDIS 2010–2013 WCC—BMI Percentile: Total Statewide Weighted Rates 45
Fig. 5.	HEDIS 2010–2013 WCC—Counseling for Nutrition: 3–11 years Statewide Weighted Rates
Fig. 6.	HEDIS 2010–2013 WCC—Counseling for Nutrition: 12–17 years Statewide Weighted Rates
Fig. 7.	HEDIS 2010–2013 WCC—Counseling for Nutrition: Total Statewide Weighted Rates46
Fig. 8.	HEDIS 2010–2013 WCC—Counseling for Physical Activity: 3–11 years Statewide Weighted Rates
Fig. 9.	HEDIS 2010–2013 WCC—Counseling for Physical Activity: 12–17 years Statewide Weighted Rates
Fig. 10.	HEDIS 2010–2013 WCC—Counseling for Physical Activity: Total Statewide Weighted Rates
Fig. 11.	HEDIS 2006, 2007, 2010–13 Childhood Immunization Status (CIS)—DTaP Statewide Weighted Rates
Fig. 12.	HEDIS 2006, 2007, 2010-13 CIS-IPV Statewide Weighted Rates
Fig. 13.	HEDIS 2006, 2007, 2010-13 CIS-MMR Statewide Weighted Rates
Fig. 14.	HEDIS 2006, 2007, 2010-13 CIS—HiB Statewide Weighted Rates 50
Fig. 15.	HEDIS 2006, 2007, 2010–13 CIS—HepB Statewide Weighted Rates 50
Fig. 16.	HEDIS 2006, 2007, 2010–13 CIS—VZV Statewide Weighted Rates 51
Fig. 17.	HEDIS 2006, 2007, 2010–13 CIS—PCV Statewide Weighted Rates
Fig. 18.	HEDIS 2010–13 CIS—HepA Statewide Weighted Rates

Fig.	19.	HEDIS 2010–13 CIS—RV Statewide Weighted Rate	52
Fig.	20.	HEDIS 2010–13 CIS—Flu Statewide Weighted Rates	53
Fig.	21.	HEDIS 2006, 2007, 2010–13 CIS—Combination 2 Statewide Weighted Rates	53
Fig.	22.	HEDIS 2006, 2007, 2010–13 CIS—Combination 3 Statewide Weighted Rates	54
Fig.	23.	HEDIS 2010–13 CIS—Combination 4 Statewide Weighted Rates	54
Fig.	24.	HEDIS 2010–13 CIS—Combination 5 Statewide Weighted Rates	55
Fig.	25.	HEDIS 2010–13 CIS—Combination 6 Statewide Weighted Rates	55
Fig.	26.	HEDIS 2010–13 CIS—Combination 7 Statewide Weighted Rates	56
Fig.	27.	HEDIS 2010–13 CIS—Combination 8 Statewide Weighted Rates	56
Fig.	28.	HEDIS 2010–13 CIS—Combination 9 Statewide Weighted Rates	57
Fig.	29.	HEDIS 2010–13 CIS—Combination 10 Statewide Weighted Rates	57
Fig.	30.	HEDIS 2010–13 Immunizations for Adolescents (IMA)—Meningococcal Statewide Weighted Rates	
Fig.	31.	HEDIS 2010–13 IMA—Tdap/Td Statewide Weighted Rates	58
Fig.	32.	HEDIS 2010–13 IMA— Combination 1 Statewide Weighted Rates	59
Fig.	33.	HEDIS 2012–13 Human Papillomavirus Vaccine for Female Adolescents (HPV) Statewide Weighted Rates	59
Fig.	34.	HEDIS 2010–13 Lead Screening in Children (LSC) Statewide Weighted Rates	60
Fig.	35.	HEDIS 2010-13 Breast Cancer Screening (BCS) Statewide Weighted Rates	60
Fig.	36.	HEDIS 2006, 2007, 2010–13 Cervical Cancer Screening (CCS) Statewide Weighte Rates	
Fig.	37.	HEDIS 2006, 2007, 2010–13 Chlamydia Screening in Women (CHL)—16–20 years Statewide Weighted Rates	
Fig.	38.	HEDIS 2010–13 CHL—21–24 years Statewide Weighted Rates	62
Fig.	39.	HEDIS 2010–13 CHL—Total Statewide Weighted Rates	62
Fig.	40.	HEDIS 2006, 2007, 2010–13 Appropriate Testing for Children With Pharyngits (CWP) Statewide Weighted Rates	63
Fig.	41.	HEDIS 2006, 2007, 2010–13 Appropriate Treatment for Children With Upper Respiratory Infection (URI) Statewide Weighted Rates	63
Fig.	42.	HEDIS 2010–13 Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis (AAB) Statewide Weighted Rates	
Fig.	43.	HEDIS 2006, 2007, 2010–13 Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR) Statewide Weighted Rates	64
Fig.	44.	HEDIS 2010–13 Pharmacotherapy Management of COPD Exacerbation (PCE)— Systemic corticosteriod Statewide Weighted Rates	65
Fig.	45.	HEDIS 2010–13 PCE—Bronchodilator Statewide Weighted Rates	65
Fig.	46.	HEDIS 2010–13 Use of Appropriate Medications for People With Asthma (ASM)—5 11 years Statewide Weighted Rates	
Fig.	47.	HEDIS 2012–13 ASM—12–18 years Statewide Weighted Rates	66

Fig.	48.	HEDIS 2012–13 ASM—19–50 years Statewide Weighted Rates	67
Fig.	49.	HEDIS 2012–13 ASM—51–64 years Statewide Weighted Rates	67
Fig.	50.	HEDIS 2012–13 ASM—Total years Statewide Weighted Rates	68
Fig.	51.	HEDIS 2012–13 Medication Management for People With Asthma (MMA)— Medication Compliance 50%: 5–11 years Statewide Weighted Rates	68
Fig.	52.	HEDIS 2012–13 MMA—Medication Compliance 50%: 12–18 years Statewide Weighted Rates	69
Fig.	53.	HEDIS 2012–13 MMA—Medication Compliance 50%: 19–50 years Statewide Weighted Rates	69
Fig.	54.	HEDIS 2012–13 MMA—Medication Compliance 50%: 51–64 years Statewide Weighted Rates	70
Fig.	55.	HEDIS 2012–13 MMA—Medication Compliance 50%: Total Statewide Weighted Rates	70
Fig.	56.	HEDIS 2012–13 MMA—Medication Compliance 75%: 5–11 years Statewide Weighted Rates	71
Fig.	57.	HEDIS 2012–13 MMA—Medication Compliance 75%: 12–18 years Statewide Weighted Rates	71
Fig.	58.	HEDIS 2012–13 MMA—Medication Compliance 75%: 19–50 years Statewide Weighted Rates	72
Fig.	59.	HEDIS 2012–13 MMA—Medication Compliance 75%: 51–64 years Statewide Weighted Rates	72
Fig.	60.	HEDIS 2012–13 MMA—Medication Compliance 75%: Total Statewide Weighted Rates	73
Fig.	61.	HEDIS 2006, 2007, 2010–13 Cholesterol Management for Patients With Cardiovascular Conditions (CMC)—LDL-C Screening Statewide Weighted Rates	73
Fig.	62.	HEDIS 2006, 2007, 2010–13 CMC—LDL-C Control (<100 mg/dL) Statewide Weighted Rates	74
Fig.	63.	HEDIS 2006, 2007, 2010–13 Controlling High Blood Pressure (CBP) Statewide Weighted Rates	74
Fig.	64.	HEDIS 2006, 2007, 2010–13 Persistence of Beta-Blocker Treatment After a Hear Attack (PBH) Statewide Weighted Rates	
Fig.	65.	HEDIS 2006, 2007, 2010–13 Comprehensive Diabetes Care (CDC)—HbA1c Testir Statewide Weighted Rates	_
Fig.	66.	HEDIS 2007, 2010–13 CDC—HbA1c Control (<7.0%) Statewide Weighted Rates.	76
Fig.	67.	HEDIS 2010-13 CDC—HbA1c Control (<8.0%) Statewide Weighted Rates	76
Fig.	68.	HEDIS 2006, 2007, 2010–13 CDC—Retinal Eye Exam Performed Statewide Weighted Rates	77
Fig.	69.	HEDIS 2006, 2007, 2010–13 CDC—LDL-C Screening Statewide Weighted Rates	77
Fig.	70.	HEDIS 2006, 2007, 2010–13 CDC—LDL-C Control (<100 mg/dL) Statewide Weighted Rates	78

Fig. 71.	HEDIS 2006, 2007, 2010–13 CDC—Medical Attention for Nephropathy Statewide Weighted Rates
Fig. 72.	HEDIS 2007, 2010–13 CDC—Blood Pressure Control (<140/80 mm Hg) Statewide Weighted Rates
Fig. 73.	HEDIS 2007, 2010–13 CDC—Blood Pressure Control (<140/90 mm Hg) Statewide Weighted Rates
Fig. 74.	HEDIS 2006, 2007, 2010–13 CDC—HbA1c Poor Control (>9.0%) Statewide Weighted Rates*
Fig. 75.	HEDIS 2006, 2007, 2010–13 Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART) Statewide Weighted Rates80
Fig. 76.	HEDIS 2006, 2007, 2010–13 Use of Imaging Studies for Low Back Pain (LBP) Statewide Weighted Rates
Fig. 77.	HEDIS 2010–13 Antidepressant Medication Management (AMM)—Effective Acute Phase Treatment Statewide Weighted Rates81
Fig. 78.	HEDIS 2010–13 AMM—Effective Continuation Phase Treatment Statewide Weighted Rates
Fig. 79.	HEDIS 2010–13 Follow-Up Care for Children Prescribed ADHD Medication (ADD)— Initiation Phase Statewide Weighted Rates
Fig. 80.	HEDIS 2010–13 ADD—Continuation and Maintenance Phase Statewide Weighted Rates
Fig. 81.	HEDIS 2010–13 Follow-Up After Hospitalization for Mental Illness (FUH)—7-day follow-up Statewide Weighted Rates
Fig. 82.	2010–13 FUH—30-day follow-up Statewide Weighted Rates
Fig. 83.	HEDIS 2006, 2007, 2010–13 Annual Monitoring for Patients on Persistent Medications (MPM)—ACE Inhibitors or ARBs Statewide Weighted Rates
Fig. 84.	HEDIS 2006, 2007, 2010–13 MPM—Digoxin Statewide Weighted Rates 85
Fig. 85.	HEDIS 2006, 2007, 2010–13 MPM—Diuretics Statewide Weighted Rates 85
Fig. 86.	HEDIS 2006, 2007, 2010–13 MPM—Anticonvulsants Statewide Weighted Rates 86
Fig. 87.	HEDIS 2006, 2007, 2010–13 MPM—Total Statewide Weighted Rates
Fig. 88.	HEDIS 2006, 2007, 2010–13 Adults' Access to Preventive/Ambulatory Health Services (AAP)—20–44 years Statewide Weighted Rates
Fig. 89.	HEDIS 2006, 2007, 2010-13 AAP-45-64 years Statewide Weighted Rates 87
Fig. 90.	HEDIS 2006, 2007, 2010–13 Children and Adolescents' Access to Primary Care Practitioners (CAP)—12–24 months Statewide Weighted Rates
Fig. 91.	HEDIS 2006, 2007, 2010-13 CAP-25 months-6 years Statewide Weighted Rates88
Fig. 92.	HEDIS 2006, 2007, 2010-13 CAP-7-11 years Statewide Weighted Rates 89
Fig. 93.	HEDIS 2006, 2007, 2010-13 CAP-12-19 years Statewide Weighted Rates 89
Fig. 94.	HEDIS 2010–13 Initiation and Engagement of Alcohol and Other Drug (AOD)  Dependence Treatment (IET)—Initiation of AOD Treatment: 13–17 years Statewide  Weighted Rates

Fig.	95.	HEDIS 2010–13 IET—Initiation of AOD Treatment: ≥18 years Statewide Weighted Rates90	
Fig.	96.	HEDIS 2010–13 IET—Initiation of AOD Treatment: Total Statewide Weighted Rates 9	1
Fig.	97.	HEDIS 2010–13 IET—Engagement of AOD Treatment: 13–17 years Statewide Weighted Rates91	
Fig.	98.	HEDIS 2010–13 IET—Engagement of AOD Treatment: ≥18 years Statewide Weighted Rates92	
Fig.	99.	HEDIS 2010–13 IET—Engagement of AOD Treatment: Total Statewide Weighted Rates92	
Fig.	100.	HEDIS 2006, 2007, 2010–13 Prenatal and Postpartum Care (PPC)—Timeliness of Prenatal Care Statewide Weighted Rates93	
Fig.	101.	HEDIS 2006, 2007, 2010–13 PPC—Postpartum Care Statewide Weighted Rates 93	
Fig.	102	HEDIS 2006, 2007, 2010–13 Call Answer Timeliness (CAT) Statewide Weighted Rates94	
Fig.	103.	HEDIS 2006, 2007, 2010–13 Frequency of Ongoing Prenatal Care (FPC) ≥ 81 percent Statewide Weighted Rates94	
Fig.	104.	HEDIS 2006, 2007, 2010–13 Well-Child Visits in the First 15 Months of Life (W15)—6 or More Visits Statewide Weighted Rates	
Fig.	105.	HEDIS 2006, 2007, 2010–13 Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34)—Statewide Weighted Rates95	
Fig.	106.	HEDIS 2006, 2007, 2010–13 Adolescent Well-Care Visits (AWC) Statewide Weighted Rates96	

# Acknowledgements/Copyrights

**CAHPS**<sup>®</sup> refers to the Consumer Assessment of Healthcare Providers and Systems and is a registered trademark of the Agency for Healthcare Research and Quality (AHRQ).

**HEDIS**<sup>®</sup> refers to the Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).

NCQA HEDIS Compliance Audit $^{TM}$  is a trademark of NCQA.

 $Qsource^{\text{(B)}}$  is a registered trademark.

# **Acronyms and Initialisms**

AAB Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis
AAP Adults' Access to Preventive/Ambulatory Health Services
ABA
ABXAntibiotic Utilization
ACE Angiotensin Converting Enzyme
ADD Follow-Up Care for Children Prescribed ADHD Medication
ADHD Attention-Deficit/Hyperactivity Disorder
AHRQ Agency for Healthcare Research and Quality
AMB Ambulatory Care
Amerigroup
AMI Acute Myocardial Infarction
AMMAntidepressant Medication Management
AMR Asthma Medication Ratio
AOD
ARBAngiotensin Receptor Blocker
ART Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis
ASM Use of Appropriate Medications for People With Asthma
AWC
BCS Breast Cancer Screening
BlueCare-East/-West
BMI Body Mass Index
BPBlood Pressure
C&M Continuation and Maintenance
CABG Coronary Artery Bypass Graft
CAHPS Consumer Assessment of Healthcare Providers and Systems
CAP Children and Adolescents' Access to Primary Care Practitioners
CAT
CBP Controlling High Blood Pressure
CCC
CCS
CDC

### Acronyms and Initialisms

CHI	Chlamydia Screening in Women
	Childhood Immunization Status
	ement for Patients With Cardiovascular Conditions
	CAHPS Health Plan Survey 5.0H Adult Version
	CAHPS Health Plan Survey 5.0H Child Version
	Chronic Obstructive Pulmonary Disease
	. Appropriate Testing for Children With Pharyngitis
	doing business as
	Disease-Modifying Anti-Rheumatic Drug
	theria, Tetanus and Acellular Pertussis Vaccination
	Emergency Department
	Influenza
	Frequency of Ongoing Prenatal Care
	Frequency of Selected Procedure
	. Follow-Up After Hospitalization for Mental Illness
	called Glycosylated Hemoglobin, Glycohemoglobin
	Healthcare Effectiveness Data and Information Set
	Hepatitis A
•	Hepatitis B
	H Influenza Type B Vaccination
	nan Papillomavirus Vaccine for Female Adolescents
	. Identification of Alcohol and Other Drug Services
	n and Engagement of AOD Dependence Treatment
	Immunizations for Adolescents
IP; IPUInpa	atient; IP Utilization – General Hospital/Acute Care
IPV	Polio Vaccination
IVD	Ischemic Vascular Disease
LBP	Use of Imaging Studies for Low Back Pain
LDL-C	Low Density Lipoprotein-Cholesterol
LSC	Lead Screening in Children
MCO	Managed Care Organization
MMA	Medication Management for People With Asthma
MMR	Measles, Mumps and Rubella Vaccination

MPMAnnual Monitoring for Patients on Persistent Medications
MPT Mental Health Utilization
MRI
MSC Medical Assistance With Smoking and Tobacco Use Cessation
NANot Applicable
NCQA
OB/GYN Obstetrician/Gynecologist
Pap Papanicolaou Test
PBHPersistence of Beta-Blocker Treatment After a Heart Attack
PCE Pharmacotherapy Management of COPD Exacerbation
PCI Percutaneous Coronary Interventions
PCP Primary Care Practitioner
PCVPneumococcal Conjugate Vaccination
PMPY Per Member Per Year
PPC Prenatal and Postpartum Care
RVRotavirus
SAA Adherence to Antipsychotic Medications for Individuals With Schizophrenia
SMCCardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia
SMDDiabetes Monitoring for People With Diabetes and Schizophrenia
SPRUse of Spirometry Testing in the Assessment and Diagnosis of COPD
SSD Diabetes Screening for People With Schizophrenia or Bipolar Disorder
StrepStreptococcus
Td; Tdap Tetanus, Diphtheria Toxoids Vaccine; Td and Acellular Pertussis Vaccine
TennCareTennessee Department of Finance and Administration, Bureau of TennCare
TennCare Select
UnitedHealthcare-East/-Middle/-WestUnitedHealthcare Plan of the River Valley, Inc. d.b.a. UnitedHealthcare-East in the Tennessee East Grand Region d.b.a. UnitedHealthcare-Middle in the Tennessee Middle Grand Region d.b.a. UnitedHealthcare-West in the Tennessee West Grand Region
URI Appropriate Treatment for Children With Upper Respiratory Infection
VZVChicken Pox Vaccination
W15 Well-Child Visits in the First 15 Months of Life
W34 Well-Child Visits in the Third, Fourth, Fifth, and Sixth Years of Life
WCC Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents Who Are Using Antipsychotic Medications

# **Executive Summary**

Medicaid managed care organizations (MCOs) in Tennessee are required to report a full Healthcare Effectiveness Data and Information Set (HEDIS) as a part of the state's accreditation mandates. The HEDIS requirement is an integral part of the accreditation process of the National Committee for Quality Assurance (NCQA). In 2006, Tennessee became the first state in the nation requiring all MCOs to become accredited by NCQA, an independent, nonprofit organization that assesses and scores MCO performance in the areas of quality improvement, utilization management, provider credentialing, and member rights and responsibilities.

HEDIS standardized measures of MCO performance allow comparisons to national averages/benchmarks and between the state's MCOs, as well as tracking over time. The Consumer Assessment of Healthcare Providers and Systems (CAHPS) set of standardized surveys is included in HEDIS to measure members' satisfaction with their care. This report summarizes the results of the HEDIS 2013 reporting year for HEDIS/CAHPS by the MCOs contracting with the Tennessee Department of Finance and Administration, Bureau of TennCare (TennCare). TennCare uses the information contained herein to help assess health plan performance and to reward, via pay-for-performance initiatives, those that are demonstrating significant improvement.

For an overview of the performance of Tennessee's MCOs, a calculated weighted average of the scores of all those reporting is provided alongside national averages in the **Statewide Performance** section. MCO-specific measures are presented in the **Individual Plan Performance** section for cross-comparison across the state's MCOs with color-coding for national and state benchmark comparison where available/applicable. The weighted average performances of the state's health plans on certain measures are presented in the **HEDIS Trending Since 2006** section. **Appendix A** contains a comprehensive table of plan-specific results for the HEDIS 2013 Utilization Measures and HEDIS 2012 national benchmarks. The table in **Appendix B** contains the HEDIS 2012 National Medicaid Means and Percentiles for reference to these benchmarks, and the table in **Appendix C** reveals MCO populations reported by health plans in member months by age and sex for 2013.

# **Background**

### **HEDIS Measures—Domains of Care**

The Healthcare Effectiveness Data and Information Set (HEDIS) is an important tool designed to ensure that purchasers and consumers have the information they need to reliably compare the performance of managed healthcare plans. Standardized methodologies ensure the integrity of measure reporting and help purchasers make more reliable, relevant comparisons between health plans. HEDIS measures are subject to a National Committee for Quality Assurance (NCQA) HEDIS Compliance Audit that must be conducted by an NCQA-certified HEDIS Compliance Auditor under the auspices of an NCQA-licensed organization. This ensures the integrity of the HEDIS collection and calculation process at each managed care organization (MCO) through an overall information systems capabilities assessment, followed by an evaluation of the ability to comply with HEDIS specifications.

The HEDIS rates presented in this report refer to data collected during the review period of the previous calendar year (CY), from January 1 to December 31. For HEDIS 2013 results, CY2012 was the review period. Similarly, the comparative data presented in this report from the HEDIS 2012 Medicaid Means and Percentiles reflect data procured during CY2011.

For HEDIS 2013, there were a total of 80 measures (Commercial, Medicare and Medicaid) across five domains of care:

- Effectiveness of Care
- Access/Availability of Care
- Utilization and Relative Resource Use
- Experience of Care [Consumer Assessment of Healthcare Providers and Systems (CAHPS) Survey Results]
- Health Plan Descriptive Information

The following brief descriptions of selected HEDIS measures were extracted from NCQA's *HEDIS 2013 Volume 2: Technical Specifications*, which includes additional information related to each measure. The measures presented in this report reflect data submitted from the following domains of care: Effectiveness of Care, Access/Availability of Care, Utilization and Relative Resource Use, and Experience of Care (CAHPS Survey Results).

### Effectiveness of Care Measures

The Effectiveness of Care domain contains measures that look at the clinical quality of care delivered within an MCO. Measures in this domain address four aspects of care:

- 1. How well the MCO delivers preventive services and keeps its members healthy
- 2. Whether the most up-to-date treatments are being offered to treat acute episodes of illness and help members get better

- 3. The process by which care is delivered to people with chronic diseases and how well the MCO's healthcare delivery system helps members cope with illness
- 4. Whether appropriate treatment and/or testing was provided to members

Starting with HEDIS 2008 reporting, Effectiveness of Care measures were grouped into more specific clinical categories: Prevention and Screening, Respiratory Conditions, Cardiovascular Conditions, Diabetes, Musculoskeletal Conditions, Behavioral Health, Medication Management, and measures collected through the CAHPS Health Plan Survey. Only certain measures from these categories are presented in this report. Select Utilization Measures are included in Appendix A.

### **Prevention and Screening**

### Adult BMI Assessment (ABA)

The percentage of members 18 to 74 years of age who had an outpatient visit and who had their body mass index (BMI) documented during the measurement year or the year prior to the measurement year.

### Weight Assessment and Counseling for Nutrition and Physical Activity for Children/ Adolescents (WCC)

The percentage of members three to 17 years of age who had an outpatient visit with a primary care practitioner (PCP) or obstetrician/gynecologist (OB/GYN) and who had evidence of BMI percentile documentation, counseling for nutrition and counseling for physical activity during the measurement year. *Note: Because BMI norms for youth vary with age and gender, this measure evaluated whether BMI percentile is assessed rather than an absolute BMI value.* 

### **Childhood Immunization Status (CIS)**

The percentage of children two years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV); one measles, mumps and rubella (MMR); three H influenza type B (HiB); three hepatitis B (HepB), one chicken pox (VZV); four pneumococcal conjugate (PCV); two hepatitis A (HepA); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday. The measure calculates a rate for each vaccine and nine separate combination rates. HepA, RV, flu, and Combinations four through 10 were added in HEDIS 2010. Following is the list of Combination vaccinations for CIS:

- Combination 2: DTaP, IPV, MMR, HiB, HepB and VZV
- Combination 3: DTaP, IPV, MMR, HiB, HepB, VZV and PCV
- Combination 4: DTaP, IPV, MMR, HiB, HepB, VZV, PCV and HepA
- Combination 5: DTaP, IPV, MMR, HiB, HepB, VZV, PCV and RV
- Combination 6: DTaP, IPV, MMR, HiB, HepB, VZV, PCV and Flu
- Combination 7: DTaP, IPV, MMR, HiB, HepB, VZV, PCV, HepA and RV
- Combination 8: DTaP, IPV, MMR, HiB, HepB, VZV, PCV, HepA and Flu
- Combination 9: DTaP, IPV, MMR, HiB, HepB, VZV, PCV, RV and Flu
- Combination 10: DTaP, IPV, MMR, HiB, HepB, VZV, PCV, HepA, RV and Flu

### Immunizations for Adolescents (IMA)

The percentage of adolescents 13 years of age who had one dose of meningococcal vaccine and one tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap) or one tetanus, diphtheria toxoids vaccine (Td) by their 13th birthday. The measure calculates a rate for each vaccine and one combination (Meningococcal, Tdap/Td) rate.

### Human Papillomavirus Vaccine for Female Adolescents (HPV)

The percentage of female adolescents 13 years of age who had three doses of the human papillomavirus (HPV) vaccine by their 13th birthday.

### Lead Screening in Children (LSC)

The percentage of children two years of age who had one or more capillary or venous lead blood tests for lead poisoning by their second birthday.

### **Breast Cancer Screening (BCS)**

The percentage of women 40 to 69 years of age who had a mammogram to screen for breast cancer during the measurement year or the year prior to the measurement year.

### **Cervical Cancer Screening (CCS)**

The percentage of women 21 to 64 years of age who received one or more Papanicolaou (Pap) tests to screen for cervical cancer during the measurement year or the two years prior to the measurement year.

### Chlamydia Screening in Women (CHL)

The percentage of women 16 to 24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year. This measure calculates a total rate as well as two age stratifications: 16- to 20- and 21- to 24-year-old women.

### **Respiratory Conditions**

### Appropriate Testing for Children With Pharyngitis (CWP)

The percentage of children two to 18 years of age who were diagnosed with pharyngitis, were dispensed an antibiotic and received a group A streptococcus (strep) test for the episode. A higher rate represents better performance (i.e., appropriate testing).

### Appropriate Treatment for Children With Upper Respiratory Infection (URI)

The percentage of children three months to 18 years of age who were given a diagnosis of upper respiratory infection and were not dispensed an antibiotic prescription. This measure is reported as an inverted rate [1 - (numerator/eligible population)], with a higher rate indicating appropriate treatment of children with URI (i.e., the proportion for whom antibiotics were not prescribed).

### Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis (AAB)

The percentage of adults 18 to 64 years of age with a diagnosis of acute bronchitis who were not dispensed an antibiotic prescription. This measure is reported as an inverted rate

[1 - (numerator/eligible population)], with a higher rate indicating appropriate treatment of adults with acute bronchitis (i.e., the proportion for whom antibiotics were not prescribed).

### Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)

The percentage of members 40 years of age and older with a new diagnosis or newly active chronic obstructive pulmonary disease (COPD) who received appropriate spirometry testing to confirm the diagnosis.

### Pharmacotherapy Management of COPD Exacerbation (PCE)

The percentage of COPD exacerbation for members 40 years of age and older who had an acute inpatient (IP) discharge or emergency department (ED) encounter between January 1 and November 30 of the measurement year and who were dispensed appropriate medication. Two rates are reported:

- Dispensed a systemic corticosteroid within 14 days of the event
- Dispensed a bronchodilator within 30 days of the event

Note: The eligible population for this measure is based on acute IP discharge and ED visits, not on members. The denominator may include multiple events for the same individual.

### Use of Appropriate Medications for People With Asthma (ASM)

The percentage of members five to 64 years of age during the measurement year who were identified as having persistent asthma and who were appropriately prescribed medication during the measurement year. This measure calculates a total rate as well as four age stratifications: 5- to 11-, 12- to 18-, 19- to 50- and 51- to 64-year-olds.

### Medication Management for People With Asthma (MMA)

The percentage of members five to 64 years of age during the measurement year who were identified as having persistent asthma and were dispensed appropriate medications that they remained on during the treatment period. Two rates are reported:

- The percentage of members who remained on an asthma controller medication for at least 50 percent of their treatment period
- The percentage of members who remained on an asthma controller medication for at least 75 percent of their treatment period

### Asthma Medication Ratio (AMR)

The percentage of members 5–64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year. This measure calculates a total rate as well as four age stratifications: 5-to 11-, 12- to 18-, 19- to 50- and 51- to 64-year-olds.

### **Cardiovascular Conditions**

### **Cholesterol Management for Patients With Cardiovascular Conditions (CMC)**

The percentage of members 18 to 75 years of age who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary

interventions (PCI) from January 1 to November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year, who had each of the following:

- Low density lipoprotein-cholesterol (LDL-C) screening performed during the measurement year
- LDL-C control (<100 mg/dL) for the most recent LDL-C screening</li>

### **Controlling High Blood Pressure (CBP)**

The percentage of members 18 to 85 years of age who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately controlled (<140/90) during the measurement year.

### Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)

The percentage of members 18 years of age and older during the measurement year who were hospitalized and discharged alive from July 1 of the year prior to the measurement year to June 30 of the measurement year with a diagnosis of AMI and who received persistent beta-blocker treatment for six months after discharge.

### **Diabetes**

### Comprehensive Diabetes Care (CDC)

The percentage of members 18 to 75 years of age with diabetes (type 1 and type 2) who had each of the following during the measurement year:

- Hemoglobin A1c (HbA1c) testing
- HbA1c poor control (>9.0 percent) for the most recent HbA1c test<sup>1</sup>
- HbA1c control (<7.0 percent) for the most recent HbA1c test</li>
- ♦ HbA1c control (<8.0 percent) for the most recent HbA1c test
- An eye exam (retinal or dilated) for diabetic retinal disease performed [or a negative retinal exam (no evidence of retinopathy) in the year prior to the measurement year]
- LDL-C screening performed
- LDL-C control (<100 mg/dL) for the most recent LDL-C screening</li>
- Medical attention for nephropathy that includes a nephropathy screening test or evidence of nephropathy
- Blood pressure control (<140/80 mm Hg) for the most recent reading</li>
- Blood pressure control (<140/90 mm Hg) for the most recent reading</li>

### Musculoskeletal Conditions

### Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)

The percentage of members who were diagnosed with rheumatoid arthritis and were dispensed at least one ambulatory prescription for a disease modifying anti-rheumatic drug (DMARD).

### Use of Imaging Studies for Low Back Pain (LBP)

The percentage of members with primary diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis. This measure is reported as an

<sup>&</sup>lt;sup>1</sup> For this indicator, a lower rate indicates better performance (i.e., low rates of poor control indicate better care).

inverted rate [1 - (numerator/eligible population)]. A higher rate indicates appropriate treatment of low back pain (i.e., the proportion for whom imaging studies did not occur).

### **Behavioral Health**

### **Antidepressant Medication Management (AMM)**

The percentage of members 18 years of age and older who were diagnosed with a new episode of major depression and treated with antidepressant medication, and remained on an antidepressant medication treatment. Two rates are reported:

- Effective Acute Phase Treatment (on medication for at least 84 days/12 weeks)
- Effective Continuation Phase Treatment (for at least 180 days/6 months)

### Follow-Up Care for Children Prescribed ADHD Medication (ADD)

The percentage of children newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period (where members diagnosed with narcolepsy are excluded from the denominator if optional exclusions are applied). One of these visits must have been within the Intake Period and within 30 days of the earliest ambulatory prescription dispensed for ADHD medication, at which time the member must have been 6 to 12 years of age with a Negative Medication History. Two rates are reported:

- *Initiation Phase*—The percentage of members who had one follow-up visit with a practitioner with prescribing authority during the 30-day Initiation Phase
- Continuation and Maintenance (C&M) Phase—The percentage of members who remained on the medication at least 210 days and who had at least two follow-up visits with a practitioner within 270 days (nine months) of the end of the Initiation Phase, in addition to the Initiation Phase visit

### Follow-Up After Hospitalization for Mental Illness (FUH)

The percentage of discharges for members six years of age and older who were hospitalized for treatment of selected mental health disorders and had an outpatient visit, an intensive outpatient encounter or partial hospitalization with a mental health practitioner. Two rates are reported as the percentage of discharges for which the member received follow-up within:

seven days of discharge

30 days of discharge

# Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

The percentage of members 18–64 years of age with schizophrenia or bipolar disorder, who were dispensed an antipsychotic medication and had a diabetes screening test during the measurement year.

### Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)

The percentage of members 18–64 years of age with schizophrenia and diabetes, who had both an LDL-C test and an HbA1c test during the measurement year.

# Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)

The percentage of members 18–64 years of age with schizophrenia and cardiovascular disease, who had an LDL-C test during the measurement year.

### Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)

The percentage of members 19–64 years of age during the measurement year with schizophrenia who were dispensed and remained on an antipsychotic medication for at least 80 percent of their treatment period.

### **Medication Management**

### **Annual Monitoring for Patients on Persistent Medications (MPM)**

The percentage of members 18 years of age and older who received at least 180 treatment days of ambulatory medication therapy for a select therapeutic agent during the measurement year and at least one therapeutic monitoring event for the therapeutic agent in the measurement year. For each product line, four separate rates and a total are reported:

- Annual monitoring for members on angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blocker (ARB)
- Annual monitoring for members on digoxin
- Annual monitoring for members on diuretics
- Annual monitoring for members on anticonvulsants
- Total rate (the sum of the four numerators divided by the sum of the four denominators)

### Measures Collected Through CAHPS Health Plan Survey

### Medical Assistance With Smoking and Tobacco Use Cessation (MSC)

This measure is collected using the survey methodology to arrive at a rolling average that represents the percentage of members 18 years of age and older who are current smokers or tobacco users seen by the MCO during the measurement year. For these members, the following facets of providing medical assistance with cessation are assessed:

- Advising Smokers and Tobacco Users to Quit—Those who received advice to quit
- Discussing Cessation Medications—Those for whom cessation medications were recommended or discussed
- Discussing Cessation Strategies Those for whom cessation methods or strategies were provided or discussed

### Access/Availability of Care Measures

The measures in the Access/Availability of Care domain evaluate how members access important and basic services of their MCO. Included are measures of overall access, how many members are actually using basic MCO services, and the use and availability of specific services.

### Adults' Access to Preventive/Ambulatory Health Services (AAP)

The percentage of members 20 years and older who had an ambulatory or preventive care visit during the measurement year. The MCO reports three age stratifications and a total rate. Rates for adults 65 years of age and older, however, are not included in this report as those services would be provided by Medicare. Because the total rate would include this age group, it has been excluded from this report as well.

- ♦ 20–44 years of age
- ♦ 65 years of age and older

- ♦ 45–64 years of age
- ♦ Total

### Children and Adolescents' Access to Primary Care Practitioners (CAP)

The percentage of members 12 months to six years who had a visit with a PCP during the measurement year, and members 7–19 years who had a visit with a PCP during the measurement year or the year prior. The MCO reports four separate percentages:

- ♦ 12–24 months
- ♦ 7–11 years

- 25 months–6 years
- ♦ 12–19 years

### Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET)

The percentage of adolescent and adult members age 13 and older who demonstrated a new episode of alcohol or other drug (AOD) dependence and received the following:

- Initiation of AOD Treatment—Percentage who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or patient hospitalization within 14 days of diagnosis
- Engagement of AOD Treatment—Percentage who, in addition to initiating treatment, had two or more services with an AOD diagnosis within 30 days of the initiation visit

The MCO reports three separate percentages: 13–17; ≥18; and a Total rate.

### Prenatal and Postpartum Care (PPC)

The percentage of deliveries of live births between November 6 of the year prior to the measurement year and November 5 of the measurement year. For these women, the measure assesses the following facets of prenatal and postpartum care:

- Timeliness of Prenatal Care—The percentage of deliveries that received a prenatal care visit
  as a member of the MCO in the first trimester or within 42 days of enrollment in the MCO
- ◆ *Postpartum Care*—The percentage of deliveries that had a postpartum visit on or between 21 and 56 days after delivery

### Call Answer Timeliness (CAT)

The percentage of calls received by the MCO's Member Services call centers (during operating hours) during the measurement year that were answered by a live voice within 30 seconds.

# **Utilization and Relative Resource Use Utilization**

# Utilization measures are designed to capture the frequency of certain services provided by the organization. Frequency of Ongoing Prenatal Care (FPC)

The percentage of members who delivered a child between November 6 of the year prior to the measurement year and November 5 of the measurement year and who received the expected number of prenatal care visits, adjusted for gestational age and the month of pregnancy that the member enrolled in the MCO. This measure uses the same denominator as the Prenatal and Postpartum Care measure. Rates are reported by the percentage of expected visits:

< 21 percent</p>

- ♦ 41–60 percent
- ♦ ≥81 percent

- ♦ 21–40 percent
- ♦ 61–80 percent

### Well-Child Visits in the First 15 Months of Life (W15)

The percentage of members who turned 15 months old during the measurement year and who had the following number of well-child visits with a PCP during their first 15 months of life: zero, one, two, three, four, five, or six or more.

### Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34)

The percentage of members who were three to six years of age who received one or more well-child visits with a PCP during the measurement year.

### **Adolescent Well-Care Visits (AWC)**

The percentage of enrolled members who were 12–21 years of age who had at least one comprehensive well-care visit with a PCP or an OB/GYN practitioner during the measurement year.

### Relative Resource Use

These measures are detailed in a separate annual Relative Resource Use Report.

### Experience of Care

The CAHPS Health Plan Survey 5.0H Adult Version (CPA) and 5.0H Child Version (CPC) are tools for measuring consumer healthcare satisfaction with the quality of care and customer service provided by their health plans. Topics include the following:

- Getting Needed Care
- Customer Service
- Getting Care Quickly
- How Well Doctors Communicate
- Shared Decision Making
- Rating of Personal Doctor
- Rating of Specialist Seen Most Often

- Rating of All Health Care<sup>2</sup>
- Rating of Health Plan

<sup>&</sup>lt;sup>2</sup> While healthcare is the standard usage adopted for this report, health care is used when it follows AHRQ measure names.

The CAHPS Consortium decided in 2002 to integrate a new set of items in the 3.0H version of the CAHPS Health Plan Survey child questionnaires (now 5.0H) to better address the needs of children with chronic conditions, who are commonly referred to as children with special healthcare needs. Known as the Children With Chronic Conditions (CCC) Survey set, these items include supplemental questions focused on topics with special relevance to children with chronic conditions. The CCC set is designed for children who have a chronic physical, developmental, behavioral or emotional condition and who also require health and related services of a type or amount beyond that generally required by children.

All CAHPS surveys must be administered by an NCQA-certified survey vendor using an NCQA-approved protocol of administration to ensure that results are collected in a standardized way and can be compared across plans. Standard NCQA protocols for administering CAHPS surveys include a mixed-model mail/telephone protocol and a mail-only protocol. The surveys contained within this domain are designed to provide standardized information about members' experiences with their MCOs. NCQA worked with the Agency for Healthcare Research and Quality (AHRQ) to develop these surveys.

For a plan's results to be considered reliable, the Medicaid MCO must follow one of the standard CAHPS protocols or an enhanced protocol approved by NCQA, or must achieve a 45-percent response rate using an alternative protocol. For more detail regarding this calculation methodology and the questions used in each composite, see *HEDIS 2013, Volume 3: Specifications for Survey Measures*. MCO results from the CPA, CPC and CCC surveys were evaluated for this report.

### **CAHPS Health Plan Survey 5.0H Adult Version (CPA)**

The CPA includes five composite categories: Getting Needed Care, Customer Service, Getting Care Quickly, How Well Doctors Communicate and Shared Decision Making. Each composite category represents an overall aspect of plan quality and is comprised of similar questions. For each composite, an overall score is computed. Composites are comprised of two or more questions about a similar topic, measured on one of the two scales:

- 1. For Getting Needed Care, Customer Service, Getting Care Quickly and How Well Doctors Communicate
  - Never

Usually

Sometimes

Always

- 2. For Shared Decision Making
  - Different
- A Little
- A Lot

- Not at All
- Some

For any given question used in a composite, the percentage of respondents answering in a certain way is calculated for each plan. Summary rates represent the percentage of members who responded in the most positive way, as defined by NCQA. The following descriptions provide a brief explanation of the four composite categories and additional questions.

### **Getting Needed Care**

The Getting Needed Care composite measures how often in the last six months the members were able to get care when attempting to do so. The summary rate represents the percentage of members who responded 'Always' or 'Usually.'

### **Customer Service**

The Customer Service composite measures how often members were able to get information and to get help from customer service in the last six months. The summary rate represents the percentage of members who responded 'Always' or 'Usually.'

### **Getting Care Quickly**

The Getting Care Quickly composite measures how often the members received care or advice in a reasonable time, including office waiting room experiences. The summary rate represents the percentage of members who responded 'Always' or 'Usually.'

### **How Well Doctors Communicate**

The How Well Doctors Communicate composite measures how often providers listen, explain, and spend enough time with and show respect for what members have to say. The summary rate represents the percentage of members who responded 'Always' or 'Usually.'

### **Shared Decision Making**

The Shared Decision Making composite measures how often doctors offered choices regarding healthcare, mentioned the good and bad things associated with each treatment option, the extent to which doctors requested input regarding healthcare preferences, and how often doctors involved members in the decision-making process, according to their preference. The summary rate represents the percentage of members who responded 'A Lot.'

### **Additional Ouestions**

There are four additional questions with responses scaled 0–10 in the CPA: *Rating of Personal Doctor, Rating of Specialist Seen Most Often, Rating of All Health Care* and *Rating of Health Plan.* Zero represents 'worst possible' and 10 represents 'best possible.' The summary rate represents the percentage of respondents who rated the question 9 or 10.

# CAHPS Health Plan Survey 5.0H Child Version: General Population (CPC)

The CPC set includes five composite categories. Each composite category represents an overall aspect of plan quality and is comprised of similar questions. For each composite, an overall score is computed. Composites are comprised of two or more questions about a similar topic, on one of the two scales:

- 1. For Getting Needed Care, Customer Service, Getting Care Quickly and How Well Doctors Communicate
  - Never
  - Sometimes

- Usually
- Always

2. For Shared Decision Making

◆ Different◆ A Little◆ A Lot

Not at All ◆ Some

For any given question used in a composite, the percentage of respondents answering in a certain way is calculated for each plan. Summary rates represent the percentage of members who responded in the most positive way, as defined by NCQA. The following provides a brief description of the four composite categories and additional questions, as well as the scoring methodology for each.

### **Getting Needed Care**

The Getting Needed Care composite measures how often in the last six months members were able to get care from doctors and specialists when attempting to do so. The summary rate represents the percentage of members who responded 'Always' or 'Usually.'

### **Customer Service**

The Customer Service composite measures how often members were able to get information and to get help from customer service in the last six months. The summary rate represents the percentage of members who responded 'Always' or 'Usually.'

### **Getting Care Quickly**

The Getting Care Quickly composite measures how often the members received care or advice in a reasonable time, including office waiting room experiences. The summary rate represents the percentage of members who responded 'Always' or 'Usually.'

### **How Well Doctors Communicate**

The How Well Doctors Communicate composite measures how often providers listen, explain and spend enough time with and show respect for what members have to say. The summary rate represents the percentage of members who responded 'Always' or 'Usually.'

### **Shared Decision Making**

The Shared Decision Making composite measures how often doctors offered choices regarding healthcare, mentioned the good and bad things associated with each treatment option, the extent to which doctors requested input regarding healthcare preferences, and how often doctors involved members in the decision-making process, according to their preference. The summary rate represents the percentage of members who responded 'A Lot.'

### **Additional Questions**

There are four additional questions with responses scaled 0–10 in the CPC: Rating of Personal Doctor, Rating of Specialist Seen Most Often, Rating of All Health Care and Rating of Health Plan. Zero represents 'worst possible' and 10 represents 'best possible.' The summary rate represents the percentage of respondents who rated the question 9 or 10.

# CAHPS Health Plan Survey 5.0H Child Version: Children With Chronic Conditions (CCC)

The CCC Survey set includes supplemental questions focused on topics with special relevance to children with chronic conditions. Results include the same ratings, composites and individual question summary rates as those reported for the CPC. Additionally, five CCC composites summarize satisfaction with basic components of care essential for successful treatment, management and support of children with chronic conditions. These topics are reflected in the following composite measures presented in this report:

- 1. Access to Prescription Medicines
- 2. Access to Specialized Services
- 3. Family-Centered Care: Getting Needed Information
- 4. Family-Centered Care: Personal Doctor Who Knows Child
- 5. Family-Centered Care: Coordination of Care for Children With Chronic Conditions

The first three composites for CCC are responded to as:

Never

Usually

Sometimes

Always

The last two composites for CCC are responded to as:

♦ Yes ♦ No

### **Access to Prescription Medicines**

The Access to Prescription Medicines composite measures how often members were able to obtain prescription medicine and assistance if they experienced an access problem. The summary rate represents the percentage of members who responded 'Always' or 'Usually.'

### **Access to Specialized Services**

The Access to Specialized Services composite measures how often members were able to obtain special medical equipment, therapy, and treatment or counseling, and assistance if they experienced an access problem. The summary rate represents the percentage of members who responded 'Always' or 'Usually.'

### Family-Centered Care: Getting Needed Information

The Family-Centered Care: Getting Needed Information composite measures how often doctors made it easy to discuss questions or concerns, how often members received the needed information from health providers, and how often healthcare questions were answered by providers. The summary rate represents the percentage of members who responded 'Always' or 'Usually.'

### Family-Centered Care: Personal Doctor or Nurse Who Knows Child

The Family-Centered Care: Personal Doctor or Nurse Who Knows Child composite measures whether or not providers discussed the child's feelings, growth and behavior, and if the provider understands how the medical or behavioral conditions affect both the child's and

family's day-to-day life. The summary rate represents the percentage of members who responded 'Yes.'

### Family-Centered Care: Coordination of Care for Children With Chronic Conditions

The Family-Centered Care: Coordination of Care for Children With Chronic Conditions composite measures whether or not doctors or other health providers assisted, if needed, in contacting the child's school or daycare and if anyone from the health plan, doctor's office or clinic assisted in coordinating the child's care among different providers or services. The summary rate represents the percentage of members who responded 'Yes.'

### Results

### Statewide Performance

In conjunction with NCQA accreditation, MCOs are required to submit a full set of audited HEDIS measures to NCQA and TennCare each year. For HEDIS 2013, this included the health plans in all three Grand Regions: Amerigroup Community Care, Inc. (Amerigroup); Volunteer State Health Plan, Inc. (BlueCare-East, BlueCare-West and TennCareSelect); and UnitedHealthcare Plan of the River Valley, Inc. (UnitedHealthcare-East, UnitedHealthcare-Middle and UnitedHealthcare-West).

**Tables 2-1** (a and b), **2-2** (a and b) and **2-3** summarize the weighted average TennCare score for each of the selected HEDIS 2012 and HEDIS 2013 measures as well as the HEDIS 2012 Medicaid National Average. The Medicaid National Average represents the sum of the reported rates divided by the total number of health plans reporting the rate. Weighted state rates are determined by applying the size of the eligible population within each plan to their overall results. Using this methodology, plan-specific findings contribute to the TennCare statewide estimate, proportionate to eligible population size.

Where possible in **Tables 2-1** (a and b), **2-2** (a and b) and **2-3**, the statewide changes for each measure reported during both HEDIS 2012 and HEDIS 2013 are presented. The column titled 'Change 2012 to 2013' indicates whether there was an improvement (♠) or a decline (♣) in statewide performance for the measure from HEDIS 2012 to HEDIS 2013.

Table 2-1a. HEDIS 2013 State to National Rates: Effectiveness of Care Measures							
Marriage	Weighted State Rate		HEDIS 2012	Change			
Measure	2012	2013	National Medicaid Avg.	2012 to 2013			
Prevention a	nd Screenin	g					
Adult BMI Assessment (ABA)	59.17%	70.95%	52.57%	•			
Weight Assessment and Counseling for Nutrition (WCC):	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC):						
BMI Percentile: 3-11 years	39.57%	49.42%	45.84%	•			
12–17 years	43.38%	49.74%	46.56%	•			
Total	40.91%	49.52%	45.99%	•			
Counseling for Nutrition: 3-11 years	58.43%	59.90%	51.58%	•			
12–17 years	51.03%	55.01%	46.92%	•			
Total	56.30%	58.28%	50.08%	•			
Counseling for Physical Activity: 3-11 years	39.13%	45.54%	39.37%	•			
12–17 years	40.29%	48.02%	43.23%	•			
Total	39.63%	46.36%	40.63%	•			

Manager	Weighted	State Rate	HEDIS 2012	Change
Measure	2012	2013	National Medicaid Avg.	2012 to 2013
Childhood Immunization Status (CIS)*:		_		_
DTaP	79.52%	80.17%	79.81%	•
IPV	93.94%	93.86%	90.54%	
MMR	90.05%	91.44%	90.87%	•
HiB	93.90%	93.73%	90.98%	•
НерВ	92.27%	93.33%	88.78%	•
VZV	90.88%	90.72%	90.47%	•
PCV	81.69%	82.42%	79.28%	•
НерА	43.31%	89.55%	39.16%	•
RV	66.23%	68.43%	62.35%	•
Flu	38.38%	43.74%	44.81%	•
Combination 2	75.37%	76.28%	74.48%	•
Combination 3	72.01%	73.02%	70.64%	•
Combination 4	40.13%	71.63%	34.19%	•
Combination 5	54.64%	56.98%	51.88%	•
Combination 6	32.90%	37.88%	37.93%	•
Combination 7	31.79%	56.13%	27.09%	•
Combination 8	20.83%	37.24%	20.89%	•
Combination 9	26.98%	31.99%	30.48%	•
Combination 10	17.54%	31.53%	17.30%	•
Immunizations for Adolescents (IMA):	-	•		-
Meningococcal	60.34%	65.69%	63.18%	•
Tdap/Td	76.12%	83.31%	75.80%	•
Combination 1	58.66%	64.40%	60.54%	•
Human Papillomavirus Vaccine for Female Adolescents (HPV)	15.07%	16.78%	17.71%	•
Lead Screening in Children (LSC)	71.65%	72.18%	67.81%	•
Breast Cancer Screening (BCS)	42.68%	44.27%	50.43%	1
Cervical Cancer Screening (CCS)	67.73%	67.92%	66.72%	1
Chlamydia Screening in Women (CHL):				
16–20 years	54.48%	53.62%	54.91%	
21–24 years	62.52%	62.58%	63.43%	•
Total	57.75%	57.39%	58.00%	-

	Weighted	State Rate	HEDIS 2012	Change				
Measure	2012	2013	National Medicaid Avg.	2012 to 2013				
Respirator	y Conditions							
Appropriate Testing for Children With Pharyngitis (CWP)	75.27%	76.03%	66.66%	•				
Appropriate Treatment for Children With Upper Respiratory Infection (URI)	74.21%	74.84%	85.32%	•				
Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis (AAB)	21.92%	24.39%	24.30%	•				
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)	35.36%	34.40%	32.02%	2.02%				
Pharmacotherapy Management of COPD Exacerb	ation (PCE):							
Systemic corticosteriod	45.55%	47.81%	64.11%	1				
Bronchodilator	72.13%	73.48%	80.45%	•				
Use of Appropriate Medications for People With	Asthma (ASM)	):						
5–11 years	93.42%	92.78%	90.51%	•				
12–18 years	87.89%	87.59%	86.61%	•				
19–50 years	59.16%	58.73%	74.72%	•				
51–64 years	55.76%	52.84%	72.94%	•				
Total	85.29%	84.68%	84.99%	•				
Medication Management for People With Asthma	(MMA):							
Medication Compliance 50%: 5-11 years	54.78%	54.30%	50.35%	•				
12–18 years	49.54%	51.55%	49.01%	•				
19–50 years	45.06%	48.18%	56.13%	•				
51–64 years	62.50%	59.02%	71.11%	•				
Total	52.22%	52.85%	52.31%	•				
Medication Compliance 75%: 5-11 years	30.08%	30.45%	28.15%	•				
12–18 years	26.67%	29.09%	27.18%	•				
19–50 years	26.28%	27.46%	34.81%	•				
51–64 years	35.58%	36.10%	49.81%	•				
Total	28.71%	29.79%	30.26%	•				
Asthma Medical Ratio (AMR)**:								
5–11 years		74.99%						
12–18 years		64.33%						
19–50 years		30.97%						
51–64 years		32.81%						
Total		63.66%						

Table 2-1a. HEDIS 2013 State to Nationa	Weighted :		HEDIS 2012	Change			
Measure	2012	2013	National Medicaid Avg.	2012 to			
Cardiovascula							
Cholesterol Management for Patients With Cardio			C):				
LDL-C Screening	82.65%	83.10%	81.99%	•			
LDL-C Control (<100 mg/dL)	39.23%	38.65%	42.08%	•			
Controlling High Blood Pressure (CBP)	55.99%	55.82%	56.78%	•			
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)	75.06%	74.54%	80.49%				
Diab	etes						
Comprehensive Diabetes Care (CDC):							
HbA1c Testing	80.55%	80.32%	82.53%				
HbA1c Control (<7.0%)	37.34%	38.54%	35.42%	<b>1</b>			
HbA1c Control (<8.0%)	48.08%	48.58%	48.08%	•			
Retinal Eye Exam Performed	37.64%	37.66%	53.35%	•			
LDL-C Screening	75.53%	76.44%	75.00%	•			
LDL-C Control (<100 mg/dL)	32.00%	31.36%	35.23%	•			
Medical Attention for Nephropathy	75.02%	76.22%	77.84%	1			
Blood Pressure Control (<140/80 mm Hg)	38.03%	36.97%	39.41%	•			
Blood Pressure Control (<140/90 mm Hg)	59.72%	59.03%	60.95%	•			
Musculoskele	tal Conditio	าร					
Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)	58.66%	58.91%	68.88%	•			
Use of Imaging Studies for Low Back Pain (LBP)	68.03%	66.91%	75.78%				
Behavior	al Health						
Antidepressant Medication Management (AMM):							
Effective Acute Phase Treatment	47.12%	49.10%	51.11%	•			
Effective Continuation Phase Treatment	28.50%	30.78%	34.43%	•			
Follow-Up Care for Children Prescribed ADHD Med	dication (ADE	<b>)</b> ):					
Initiation Phase	38.28%	46.02%	38.83%	•			
Continuation and Maintenance Phase	47.21%	57.54%	45.87%	•			
Follow-Up After Hospitalization for Mental Illness	(FUH):						
7-day follow-up	45.73%	48.03%	46.50%	•			
30-day follow-up	66.83%	68.80%	64.99%	•			

Table 2-1a. HEDIS 2013 State to National Rates: Effectiveness of Care Measures									
M	Weighted S	State Rate	HEDIS 2012	Change					
Measure	2012	2013	National Medicaid Avg.	2012 to 2013					
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (SSD)**		80.40%							
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD) * *		67.69%							
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)**		80.00%							
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)**		61.91%							
Medication I	Management	t e							
Annual Monitoring for Patients on Persistent Med	lications (MPN	VI):							
ACE Inhibitors or ARBs	90.78%	90.61%	85.86%	•					
Digoxin	90.76%	92.31%	90.28%	<b>1</b>					
Diuretics	90.57%	91.00%	85.39%	•					
Anticonvulsants	75.00%	72.89%	65.16%						
Total	88.78%	88.86%	83.86%	•					
Measures Collected Through CAHPS Health Plan Survey									
Medical Assistance With Smoking and Tobacco Use Cessation (MSC):									
Advising Smokers and Tobacco Users to Quit	72.12%***	74.87%	74.55%	•					
Discussing Cessation Medications	38.84%***	42.11%	44.29%	•					
Discussing Cessation Strategies	37.03%***	36.87%	40.29%	•					

<sup>\*</sup>Measure specification changed for HEDIS 2013. HepA dose requirements changed from two doses to at least one dose; hence, trend with caution.

For the Effectiveness of Care Measure—Comprehensive Diabetes Care: HbA1c Poor Control (> 9.0 percent) presented in **Table 2-1b**, a lower rate (particularly one below the national average) is an indication of better performance (1). A decrease in rates from the prior year also indicates improvement.

Table 2-1b. HEDIS 2013 State to National Rates: Effectiveness of Care Measure
Where Lower Rates Indicate Better Performance

Weighted State Rate
Measure

Weighted State Rate
2012

National
Medicaid Avg. 2013

 Comprehensive Diabetes Care (CDC):
 44.78%
 43.22%
 43.04%
 ♠

<sup>\* \*</sup>First year measurement

<sup>\*\*\*</sup> The denominator was not available; hence, the average is not weighted.

Tables 2-2 summarize results for the Access/Availability Domain of Care.

Table 2-2. HEDIS 2013 State to National Rates: Access/Availability of Care Measures								
Measure	Weighted \$	State Rate	HEDIS 2012 National	Change 2012 to				
weasure	2012	2013	Medicaid Avg.	2012 10				
Adults' Access to Preventive/Ambulatory Health	Services (AAF	P):						
20-44 years	80.62%	80.66%	80.04%	•				
45–64 years	86.34%	87.27%	86.05%	<b>1</b>				
Children and Adolescents' Access to Primary Care	Practitioners	s (CAP):						
12–24 months	97.14%	96.94%	96.07%					
25 months-6 years	90.37%	90.51%	88.19%	<b>1</b>				
7–11 years	93.14%	93.47%	89.54%	•				
12–19 years	90.18%	90.38%	87.89%	<b>1</b>				
Initiation and Engagement of Alcohol and Other I	Orug (AOD) D	ependence T	reatment (IET)	:				
Initiation of AOD Treatment: 13–17 years	53.33%	48.57%	40.49%	•				
≥18 years	42.54%	36.78%	39.38%	•				
Total	43.38%	37.62%	39.19%	•				
Engagement of AOD Treatment: 13-17 years	31.07%	27.90%	17.37%	•				
≥18 years	12.34%	9.82%	11.49%					
Total	13.80%	11.10%	11.93%	•				
Prenatal and Postpartum Care (PPC):								
Timeliness of Prenatal Care	79.83%	79.51%	82.75%					
Postpartum Care	61.06%	59.90%	64.12%					
Call Answer Timeliness (CAT)	88.47%	89.18%	83.21%	<b>1</b>				

**Table 2-3** summarizes results for the Utilization measures included in the Utilization and Relative Resource Domain of Care.

Table 2-3. HEDIS 2013 State to National Rates: Utilization Measures									
Measure	Weighted \$	State Rate	HEDIS 2012	Change					
ivieasui e	2012	2013	National Medicaid Avg.	2012 to 2013					
Frequency of Ongoing Prenatal Care (FPC):									
≥ 81 percent	58.29%	61.60%	60.93%	•					
Well-Child Visits in the First 15 Months of Life (W	/15):								
6 or More Visits	62.36%	62.32%	61.75%	•					
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34)	72.69%	71.68%	72.03%	+					
Adolescent Well-Care Visits (AWC)	45.95%	44.53%	49.71%	+					

### Individual Plan Performance

This section is intended to provide an overview of individual plan performance using appropriate available comparison data. The results highlight those areas where each MCO is performing in relation to the HEDIS 2012 National Medicaid Means and Percentiles for select MCO-reported HEDIS measures. Qsource uses these data to determine overall TennCare plan performance to the highest and lowest percentiles. The percentiles are statistical values that represent the distribution of data. For example, the 50th percentile represents the point at which half of the reported rates are below and half of the reported rates are above that value.

**Tables 2-5** (a and b), **2-6** (a and b) and **2-7** display the plan-specific performance rates for each measure selected from the Effectiveness of Care and Access/Availability of Care domains and Utilization measures. **Table 2-4** details the color-coding used in **Tables 2-5** through **2-7** to indicate the rating of the MCO percentile achieved, and provides additional related comments. HEDIS measure results with an 'NA' indicate that there were fewer than 30 people in the denominator and hence results are not presented. While Medical Assistance With Smoking and Tobacco Use Cessation is an Effectiveness of Care measure, results are reported through the CPA as noted in **Tables 2-1a** and **2-5a**.

Table 2-4. MCO HEDIS 2013 Rating Determination								
Color Designation	Percentile MCO Achieved	Additional Comments						
	Greater than 75th	No additional comments						
	25th to 75th	No additional comments						
	Less than 25th	No additional comments						
NA	Not Applicable	The measure was not applicable (NA) because there were fewer than 30 people in the denominator.						
	No Rating Available	Benchmarking data were not available.						

Table 2-5a. HEDIS 2013 Plan-Specific Rates: Effectiveness of Care Measures									
	BlueCare-		Care-	T0	UnitedHealthcare-			HEDIS 2012	
Measure	Ameri- group	East	West	TennCare <i>Select</i>	East	Middle	West	National Medicaid 50th Percentile	
Prevention and Screening									
Adult BMI Assessment (ABA)	77.21%	65.68%	78.98%	56.59%	67.56%	73.98%	63.50%	57.94%	
Weight Assessment and Counse	ling for N	utrition a	and Physi	cal Activ	ity for Cl	nildren/A	dolesce	nts (WCC):	
BMI Percentile: 3-11 years	55.45%	43.86%	65.38%	53.56%	35.71%	40.42%	53.98%	47.52%	
12–17 years	54.26%	46.03%	64.80%	50.00%	35.85%	39.52%	58.20%	49.42%	
Total	55.09%	44.53%	65.21%	52.07%	35.77%	40.15%	55.23%	47.45%	
Counseling for Nutrition: 3–11 years	63.37%	59.65%	58.39%	51.88%	55.95%	63.76%	59.86%	57.09%	
12–17 years	62.02%	53.17%	60.80%	48.26%	47.80%	48.39%	62.30%	50.00%	
Total	62.96%	57.66%	59.12%	50.36%	52.80%	59.12%	60.58%	54.88%	

Table 2-5a. HEDIS 2013 Plan-Specific Rates: Effectiveness of Care Measures										
	_	Blue	Care-			edHealth	care-	HEDIS 2012		
Measure	Ameri- group	East	West	TennCare Select	East	Middle	West	National Medicaid 50th		
								Percentile		
Counseling for Physical Activity: 3–11 years	60.73%	45.26%	34.97%	29.29%	40.87%	51.22%	43.60%	42.17%		
12–17 years	58.91%	48.41%	40.00%	36.05%	48.43%	42.74%	58.20%	47.00%		
Total	60.19%	46.23%	36.50%	32.12%	43.80%	48.66%	47.93%	43.29%		
Childhood Immunization Status (CIS)*:										
DTaP	86.53%	81.51%	76.40%	77.62%	82.48%	81.51%	72.02%	80.63%		
IPV	96.25%	95.38%	94.65%	92.94%	93.92%	93.43%	88.81%	92.21%		
MMR	93.16%	92.46%	93.67%	91.00%	91.24%	89.78%	87.83%	91.65%		
HiB	96.03%	95.38%	94.89%	93.43%	94.16%	93.19%	87.83%	92.46%		
НерВ	95.58%	94.65%	94.65%	91.73%	92.94%	91.24%	90.75%	90.75%		
VZV	93.38%	90.51%	93.19%	91.00%	90.02%	90.75%	85.40%	91.22%		
PCV	86.31%	83.70%	81.27%	78.83%	83.94%	84.91%	73.72%	80.93%		
НерА	92.49%	91.00%	90.27%	87.83%	88.81%	88.56%	85.64%	38.32%		
RV	74.17%	70.32%	65.45%	51.34%	66.42%	75.18%	59.85%	63.70%		
Flu	57.84%	46.72%	27.98%	50.85%	44.04%	54.74%	25.79%	44.90%		
Combination 2	84.33%	76.89%	73.72%	73.24%	78.10%	77.62%	66.18%	75.35%		
Combination 3	81.24%	72.99%	70.32%	69.59%	75.43%	75.67%	61.56%	71.93%		
Combination 4	79.91%	71.78%	68.61%	66.91%	73.97%	74.70%	60.10%	33.92%		
Combination 5	66.45%	56.93%	53.04%	42.09%	57.18%	62.77%	46.23%	52.92%		
Combination 6	51.88%	39.17%	24.09%	42.09%	39.90%	46.96%	21.41%	37.57%		
Combination 7	65.78%	55.96%	52.07%	40.63%	55.96%	62.29%	45.50%	26.03%		
Combination 8	51.21%	38.69%	23.11%	40.63%	39.42%	46.23%	21.17%	20.88%		
Combination 9	44.59%	32.36%	21.17%	27.01%	32.60%	41.12%	18.25%	29.79%		
Combination 10	44.15%	31.87%	20.44%	26.28%	32.36%	40.63%	18.00%	16.51%		
Immunization for Adolescents (	IMA):									
Meningococcal	67.82%	71.84%	65.76%	62.65%	60.88%	70.92%	54.99%	64.23%		
Tdap/Td	87.50%	87.11%	86.10%	77.64%	79.22%	85.20%	74.70%	78.83%		
Combination 1	67.59%	71.05%	65.01%	60.44%	59.66%	68.11%	53.28%	62.29%		
Human Papillomavirus Vaccine for Female Adolescents (HPV)	17.36%	19.22%	14.60%	19.22%	18.73%	17.52%	11.92%	18.09%		
Lead Screening in Children (LSC)	75.50%	72.51%	73.72%	73.48%	73.97%	70.07%	66.67%	71.41%		
Breast Cancer Screening (BCS)	42.53%	48.51%	45.78%	52.68%	44.02%	42.74%	38.99%	50.46%		
Cervical Cancer Screening (CCS)	70.28%	69.77%	68.97%	55.08%	61.06%	72.51%	63.61%	69.10%		
Chlamydia Screening in Women	(CHL):									
16–20 years	53.23%	49.16%	59.11%	52.17%	48.74%	54.27%	57.72%	54.18%		
21–24 years	62.56%	59.16%	68.02%	43.33%	56.42%	61.77%	65.11%	64.36%		
Total	57.25%	53.45%	63.26%	52.05%	51.73%	57.58%	61.06%	58.40%		

Table 2-5a. HEDIS 2	013 Pla	n-Specif	ic Rates	: Effect	iveness	of Car	e Meası	ures	
		Blue	Care-			edHealth	care-	HEDIS 2012	
Measure	Ameri- group	East	West	TennCare Select	East	Middle	West	National Medicaid 50th Percentile	
Respiratory Conditions									
Appropriate Testing for Children with Pharyngitis (CWP)	81.17%	74.23%	77.63%	74.37%	70.43%	79.08%	72.20%	70.00%	
Appropriate Treatment for Children with Upper Respiratory Infection (URI)	78.36%	71.97%	70.23%	75.28%	69.86%	79.34%	75.45%	85.34%	
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (AAB)	22.50%	27.42%	24.46%	73.17%	17.90%	26.19%	24.80%	22.14%	
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)	29.29%	37.31%	36.27%	NA	31.69%	35.02%	38.65%	31.90%	
Pharmacotherapy Management	of COPD	Exacerba	tion (PCE	:):					
Systemic corticosteroid	48.90%	39.96%	44.72%	NA	53.99%	49.60%	46.57%	66.67%	
Bronchodilator	72.18%	65.40%	71.69%	NA	76.19%	78.89%	77.02%	82.22%	
Use of Appropriate Medications	for Peopl	e with As	thma (A	SM):					
5–11 years	91.65%	95.59%	89.93%	92.87%	95.52%	91.37%	91.48%	91.59%	
12–18 years	87.39%	88.99%	88.23%	87.35%	89.48%	84.39%	85.92%	86.96%	
19–50 years	57.11%	60.69%	58.56%	82.14%	61.67%	53.09%	59.73%	75.53%	
51–64 years	55.07%	51.16%	57.75%	NA	56.00%	45.83%	50.88%	73.81%	
Total	83.09%	88.64%	83.17%	90.15%	86.01%	80.47%	82.65%	85.87%	
Medication Management for Peo	ple With	Asthma (	(MMA):					ı	
Medication Compliance 50%: 5-11 years	54.38%	59.45%	47.31%	60.75%	58.48%	52.84%	46.13%	50.89%	
12–18 years	49.91%	53.48%	47.71%		54.17%			48.92%	
19–50 years	47.89%	58.36%	43.52%		51.43%		38.07%	56.51%	
51–64 years	52.63%	NA	68.29%	NA		57.58%	NA	73.03%	
Total  Medication Compliance 75%: 5-11 years	52.27% 28.60%	57.55% 35.59%	47.32% 24.02%			51.84% 29.38%		52.31% 27.25%	
12–18 years	25.39%	32.49%	25.61%	37.16%	31.18%	30.02%	21.69%	25.63%	
19–50 years	26.44%	33.45%	21.26%		30.00%		22.48%		
51–64 years	39.47%	NA	34.15%	NA	45.24%	33.33%	NA	50.00%	
Total	27.62%	34.42%	24.33%	38.48%	32.67%	29.53%	22.79%	29.14%	
Asthma Medical Ratio (AMR)*:									
5–11 years	71.94%	81.49%	67.23%	78.58%	81.89%	71.18%	71.97%		
12–18 years	61.66%	67.85%	60.29%	69.66%	70.71%	58.90%	61.84%		
19–50 years	30.36%	34.87%	28.49%	57.69%	39.42%	27.56%	20.95%		
51–64 years	31.88%	30.95%	37.14%	NA	38.67%	35.21%	19.64%		
Total	60.45%	70.99%	57.67%	74.13%	69.18%	58.18%	57.88%		

		Blue	Care-		Unite	edHealth	care-	HEDIS 2012			
Measure	Ameri- group	East	West	TennCare Select		Middle	West	National Medicaid 50th Percentile			
Cardiovascular Conditions											
Cholesterol Management for Pat	ients wit	h Cardio	/ascular (	Condition	s (CMC)	:					
LDL-C Screening	84.42%	81.27%	83.21%	NA	84.67%	81.51%	84.67%	82.48%			
LDL-C Control (<100 mg/dL)	41.40%	34.55%	24.82%	NA	45.99%	45.74%	35.52%	42.39%			
Controlling High Blood Pressure (CBP)	48.78%	58.93%	52.81%	33.64%	60.73%	56.93%	54.01%	57.52%			
Persistence of Beta-Blocker Treatment after a Heart Attack (PBH)	66.67%	83.87%	78.00%	NA	78.90%	71.15%	69.14%	83.47%			
		D	iabetes								
Comprehensive Diabetes Care (	CDC):										
HbA1c Testing	79.35%	81.56%	78.33%	80.71%	82.31%	79.87%	79.23%	82.38%			
HbA1c Control (<7.0%)	36.24%	46.44%	33.56%	30.46%	37.16%	38.83%	35.35%	36.72%			
HbA1c Control (<8.0%)	48.14%	52.59%	42.58%	32.68%	50.77%	49.10%	46.54%	48.72%			
Retinal Eye Exam Performed	32.10%	39.34%	38.94%	59.45%	36.28%	39.62%	37.31%	52.88%			
LDL-C Screening	73.11%	76.66%	75.91%	62.20%	76.92%	77.69%	78.33%	76.16%			
LDL-C Control (<100 mg/dL)	27.93%	27.67%	24.09%	12.60%	36.67%	39.10%	32.31%	35.86%			
Medical Attention for Nephropathy	73.25%	78.67%	77.73%	62.60%	77.69%	73.59%	75.38%	78.71%			
Blood Pressure Control (<140/80 mm Hg)	37.74%	37.61%	31.36%	33.86%	38.33%	41.03%	34.74%	39.10%			
Blood Pressure Control (<140/90 mm Hg)	58.54%	60.23%	53.94%	45.67%	60.26%	63.72%	56.54%	63.50%			
	Mu	sculoske	eletal Co	nditions							
Disease-Modifying Anti- Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)	62.61%	55.12%	51.80%	NA	66.86%	56.76%	59.30%	69.28%			
Use of Imaging Studies for Low Back Pain (LBP)	69.48%	64.71%	68.41%	67.77%	63.14%	66.82%	69.64%	75.67%			
		Behav	ioral Hea	alth							
Antidepressant Medication Mana	agement	(AMM):									
Effective Acute Phase Treatment	52.10%	48.39%	46.42%	51.22%	51.13%	47.06%	48.02%	49.42%			
Effective Continuation Phase Treatment	35.68%	28.93%	27.49%	26.83%	32.02%	28.17%	32.07%	32.42%			
Follow-Up Care for Children Pres	scribed A	DHD Med	lication (	ADD):							
Initiation Phase	60.54%	43.80%	31.72%	34.38%	51.80%	53.78%	41.39%	39.19%			
Continuation and Maintenance Phase	70.02%	52.53%	41.41%	46.39%	63.92%	63.94%	58.44%	47.09%			
Follow-Up After Hospitalization											
7-day follow-up	58.00%	38.15%	31.65%	36.83%	47.37%	53.38%	65.64%	46.06%			
30-day follow-up	77.08%	65.85%	56.45%	59.15%	67.93%	72.82%	77.61%	67.65%			

Table 2-5a. HEDIS 2013 Plan-Specific Rates: Effectiveness of Care Measures												
	A ma a mi	BlueCare-		TennCare		edHealth	care-	HEDIS 2012				
Measure	Ameri- group	East	West	Select	East	Middle	West	National Medicaid 50th Percentile				
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic												
Medication (SSD) * *	80.94%	81.87%	77.27%	80.00%	82.56%	84.95%	73.41%					
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)**	69.33%	71.04%	60.08%	80.56%	71.79%	71.43%	61.31%					
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)**	83.33%	76.47%	78.05%	NA	NA	79.07%	81.58%					
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)**	63.06%	59.81%	59.36%	70.24%	62.78%	62.38%	61.93%					
Medication Management												
Annual Monitoring for Patients of	n Persist	tent Medi	cations (	MPM):								
ACE Inhibitors or ARBs	88.81%	90.48%	91.26%	89.32%	91.50%	89.68%	91.82%	86.89%				
Digoxin	89.29%	93.02%	92.31%	NA	95.51%	92.31%	90.24%	90.95%				
Diuretics	89.05%	91.26%	90.90%	94.32%	91.89%	90.63%	91.43%	86.40%				
Anticonvulsants	70.85%	72.86%	70.96%	76.30%	74.67%	74.35%	71.08%	65.29%				
Total	87.02%	88.93%	89.00%	81.72%	90.08%	88.44%	89.42%	84.81%				
Measures	Collect	ed Throu	ıgh CAH	PS Heal	th Plan	Survey						
Medical Assistance with Smoking	g and Tol	bacco Use	e Cessatio	on (MSC)	:							
Advising Smokers and Tobacco Users to Quit	76.90%	81.40%	75.45%	61.74%	77.31%	79.85%	71.43%	75.11%				
Discussing Cessation Medications	42.64%	47.79%	46.98%	33.33%	45.16%	42.23%	36.67%	44.50%				
Discussing Cessation Strategies	36.59%	44.72%	39.86%	38.05%	35.63%	34.02%	29.25%	40.65%				

<sup>\*</sup>Measure specification changed for HEDIS 2013. HepA dose requirements changed from two doses to at least one dose; hence, trend with caution

For the Effectiveness of Care Measure—Comprehensive Diabetes Care: HbA1c Poor Control (> 9.0 percent) presented in **Table 2-5b**, a lower rate (particularly one below the national 50th percentile) is an indication of better performance. For example, a rate in the 10th percentile is better than a rate in the 90th percentile.

Table 2-5b. HEDIS 2013 Plan-Specific Rates: Effectiveness of Care Measure Where Lower Rates Indicate Better Performance									
Measure	0	Blue	Care-	UnitedHealthcare-			HEDIS 2012		
	Ameri- group	East	West	TennCare Select	East	Middle	West	National Medicaid 50th Percentile	
Comprehensive Diabetes Care (CDC):									
HbA1c Poor Control (>9.0%)	42.64%	39.19%	50.91%	62.60%	40.64%	41.67%	46.03%	41.68%	

<sup>\*\*</sup>First year measurement

Table 2-6. HEDIS 2013	Plan-Sp	oecific R	ates: A	ccess/A	vailabil	ity of C	are Mea	asures		
	Ameri-	Blue	Care	TennCare	Unit	edHealth	care	HEDIS 2012		
Measure	group	-East	-West	Select	East	Middle	West	National Medicaid 50th Percentile		
Adults' Access to Preventive/Ambulatory Health Services (AAP):										
20-44 years	80.70%	83.11%	80.29%	69.15%	80.17%	84.16%	75.17%	82.34%		
45–64 years	84.68%	90.50%	85.91%	73.50%	87.63%	90.61%	82.44%	87.31%		
Children and Adolescents' Acces	s to Prim	ary Care	Practitio	ners (CAI	P):					
12-24 months	97.34%	97.48%	96.23%	95.42%	96.45%	97.52%	96.73%	97.02%		
25 months-6 years	91.43%	91.32%	89.51%	91.71%	88.92%	91.66%	89.38%	89.19%		
7–11 years	93.71%	93.64%	94.12%	93.24%	91.47%	94.24%	93.26%	90.58%		
12–19 years	91.31%	91.31%	90.35%	87.58%	89.68%	92.25%	88.45%	89.21%		
Initiation and Engagement of Al	cohol and	d Other D	rug (AOE	) Depend	dence Tr	eatment	(IET):			
Initiation of AOD Treatment: 13–17 years	47.45%	40.66%	48.48%	52.31%	50.72%	49.82%	52.71%	42.03%		
≥18 years	38.69%	37.92%	34.99%	43.37%	38.92%	31.21%	39.67%	39.02%		
Total	39.19%	38.12%	35.73%	48.24%	39.57%	32.13%	40.42%	38.80%		
Engagement of AOD Treatment: 13-17 years	30.98%	25.83%	19.19%	29.86%	35.14%	29.24%	20.69%	16.57%		
≥18 years	12.65%	11.12%	8.70%	15.75%	8.96%	8.60%	7.89%	11.40%		
Total	13.70%	12.16%	9.28%	23.43%	10.40%	9.61%	8.62%	11.72%		
Prenatal and Postpartum Care (	Prenatal and Postpartum Care (PPC):									
Timeliness of Prenatal Care	81.94%	87.33%	72.62%	68.49%	86.91%	79.02%	67.88%	86.13%		
Postpartum Care	58.56%	68.46%	59.90%	51.26%	63.95%	57.56%	49.15%	64.98%		
Call Answer Timeliness (CAT)	90.39%	91.68%	91.36%	91.74%	87.49%	87.49%	87.49%	85.37%		

Table 2-7. HEDIS 2013 Plan-Specific Rates: Use of Services Measures										
Measure	A	Blue	Care	TennCare		edHealth	HEDIS 2012			
	Ameri- group	-East	-West	Select	East	Middle	West	National Medicaid 50th Percentile		
Frequency of Ongoing Prenatal Care (FPC):										
≥ 81 percent	66.67%	77.63%	54.28%	44.54%	72.10%	54.15%	42.34%	64.65%		
Well-Child Visits in the First 15 I	Months o	f Life (W´	15):							
6 or More Visits	64.30%	69.85%	49.88%	48.66%	71.64%	66.49%	52.80%	62.95%		
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34)	76.16%	69.85%	73.10%	74.43%	68.06%	69.72%	72.26%	72.26%		
Adolescent Well-Care Visits (AWC)	53.47%	43.07%	45.99%	46.23%	36.74%	45.01%	41.36%	49.65%		

**Tables 2-9** through **2-11** display the plan-specific performance rates for the CAHPS survey results. **Table 2-8** details the color-coding and the MCO rating scale, as well as any additional comments, used in **Tables 2-9** through **2-11** to indicate the rating achieved. CAHPS measure results with an 'NA' indicate that there were fewer than 100 valid responses and hence results are not presented. For all CAHPS survey results, performance is measured against the calculated statewide average. The 2012 National Medicaid CAHPS Benchmarking data were obtained from Quality Compass this year; previously benchmarking data were obtained from AHRQ's website: www.cahps.ahrq.gov.

T.	Table 2-8. MCO 2013 CAHPS Rating Determination											
<b>Color Designation</b>	Rating Scale	Additional Comments										
	Greater than one standard deviation above the statewide average	No additional comments										
	Within one standard deviation above or below the statewide average	No additional comments										
•	Greater than one standard deviation below the statewide average	No additional comments										
NA	Not Applicable	The survey question was not applicable (NA) because there were less than 100 valid responses.										
	No Rating Available	Benchmarking data were not available.										

Table 2-9. 2013 CAHPS 5.0H Adult Medicaid Survey Results											
Amerigroup	BlueCare		TennCare <i>Select</i>	Unit	edHealthc	are	Statewide	2012 National Medicaid CAHPS			
Amengroup	-East	-West	Termical e Select	-East	-Middle	-West	Average	Benchmarking			
1. Getting Needed Care (Always + Usually)											
83.56%	86.50%	82.36%	85.17%	83.30%	84.77%	80.31%	83.71%	75.50%			
2. Getting Care Quickly (Always + Usually)											
82.60%	86.82%	83.49%	85.00%	83.35%	82.89%	80.53%	83.53%	80.33%			
3. How Well Doctors Communicate (Always + Usually)											
89.78%	89.99%	91.36%	91.42%	90.61%	89.63%	87.64%	90.06%	87.81%			
4. Customer S	4. Customer Service (Always + Usually)										
84.96%	86.31%	87.30%	87.64%	91.98%	86.87%	88.42%	87.64%	80.42%			
5. Shared Dec	ision Mak	ing* (A lo	t/Yes)			-					
47.88%	49.75%	49.19%	50.79%	48.48%	49.97%	42.73%	48.40%	60.87%			
6. Rating of A	II Health C	Care (9+1	0)		-	-					
46.23%	54.27%	54.81%	48.20%	51.82%	48.36%	48.69%	50.34%	49.74%			
7. Rating of P	ersonal Do	octor (9+	10)			-					
59.58%	68.78%	67.27%	67.02%	64.23%	59.48%	61.31%	63.95%	61.82%			
8. Rating of S	pecialist S	een Most	Often (9+10)								
61.65%	70.00%	63.52%	67.36%	66.82%	65.15%	69.43%	66.28%	62.07%			

	Table 2-9. 2013 CAHPS 5.0H Adult Medicaid Survey Results											
Amerigroup BlueCare		Care	TennCare <i>Select</i>	Unit	tedHealthc	are	Statewide	2012 National Medicaid CAHPS				
Amerigroup	-East	-West	Termicare Select	-East	-Middle	-West	Average	Benchmarking				
9. Rating of Health Plan (9+10)												
54.42%	67.43%	66.37%	54.93%	60.99%	56.97%	55.59%	59.53%	55.56%				

<sup>\*</sup>The measurement scale changed; hence, trend with caution.

In **Tables 2-10** and **2-11** the National Medicaid CAHPS Benchmarking data for the 5.0H Child Medicaid Survey aggregate results from the surveys for General Population (CPC) and Children With Chronic Conditions (CCC) and are acceptable as benchmarks for both. There are no benchmarking data specific to the supplemental questions in the CCC Survey set.

Table 2-10. 2013 CAHPS 5.0H Child Medicaid Survey Results (General Population)										
Amerigroup	BlueCare		TennCare <i>Select</i>	Unit	tedHealthc	are	Statewide	2012 National Medicaid CAHPS		
Amengroup	-East	-West	Termical e Select	-East	-Middle	-West	Average	Benchmarking		
1. Getting Ned	eded Care	(Always -	+ Usually)							
90.07%	90.50%	84.89%	90.37%	90.55%	93.85%	87.90%	89.73%	79.25%		
2. Getting Car	e Quickly	(Always -	+ Usually)							
91.96%	94.24%	91.11%	90.35%	91.50%	94.30%	89.77%	91.89%	87.28%		
3. How Well Doctors Communicate (Always + Usually)										
93.28%	94.71%	94.28%	92.84%	94.77%	92.86%	91.94%	93.53%	91.79%		
4. Customer S	4. Customer Service (Always + Usually)									
90.69%	91.41%	90.03%	89.29%	87.66%	87.72%	88.00%	89.26%	83.02%		
5. Shared Dec	ision Mak	ing* (A lo	ot/Yes)							
56.62%	53.79%	NA	56.99%	56.15%	60.20%	54.79%	56.42%	68.41%		
6. Rating of A	II Health (	Care (9+1	0)							
71.30%	71.68%	71.77%	66.14%	64.34%	71.71%	63.31%	68.61%	64.02%		
7. Rating of P	ersonal D	octor (9+	10)			-				
75.55%	75.89%	76.40%	72.00%	69.82%	77.62%	68.07%	73.62%	72.08%		
8. Rating of S	pecialist S	Seen Most	Often (9+10)							
NA	NA	NA	77.61%	NA	NA	NA	77.61%	67.33%		
9. Rating of H	ealth Plar	n (9+10)								
73.01%	77.29%	76.60%	72.43%	68.00%	76.96%	67.36%	73.09%	67.40%		

<sup>\*</sup>The measurement scale changed; hence, trend with caution.

Table 2-11. 2013 CAHPS 5.0H Child Medicaid Survey Results (Children with Chronic Conditions)											
	Blue				tedHealthc		Statewide	2012 National			
Amerigroup	-East	-West	TennCare <i>Select</i>	-East	-Middle	-West	Average	Medicaid CAHPS Benchmarking			
1. Getting Nee	eded Care	(Always	+ Usually)								
92.12%	91.50%	93.78%	90.25%	90.03%	90.37%	88.49%	90.93%	80.80%			
2. Getting Car	e Quickly	(Always -	+ Usually)			_					
93.08%	93.28%	93.85%	92.55%	92.83%	95.92%	91.81%	93.33%	90.28%			
3. How Well D	3. How Well Doctors Communicate (Always + Usually)										
90.76%	94.29%	95.25%	93.81%	93.60%	94.61%	92.03%	93.48%	92.84%			
4. Customer S	ervice (A	lways + U	sually)								
90.93%	91.35%	91.38%	90.10%	93.21%	89.07%	88.98%	90.72%	82.15%			
5. Shared Dec	ision Mak	ing* (A lo	t/Yes)								
54.94%	63.00%	55.21%	62.49%	55.62%	66.67%	57.95%	59.41%	70.28%			
6. Rating of A	II Health (	Care (9+1	0)								
65.56%	66.59%	70.54%	65.80%	63.62%	68.96%	59.27%	65.76%	62.47%			
7. Rating of P	ersonal D	octor (9+	10)								
74.20%	71.46%	78.57%	74.17%	70.70%	77.15%	70.98%	73.89%	73.13%			
8. Rating of S	pecialist S	Seen Most	Often (9+10)								
NA	75.00%	68.00%	79.67%	70.22%	70.00%	69.40%	72.05%	68.41%			
9. Rating of H	ealth Plar	า (9+10)									
68.34%	72.98%	74.87%	72.26%	66.13%	73.92%	67.65%	70.88%	64.49%			
10. Access to	Specialize	ed Service	s (Always + Usua	ally)							
NA	81.78%	NA	80.41%	77.50%	NA	NA	79.90%	76.46%			
11. Family-Ce	ntered Ca	re: Persor	nal Doctor or Nur	se Who Kı	nows Chil	d (Yes)					
89.27%	92.14%	90.45%	89.59%	88.28%	89.54%	87.57%	89.55%	89.15%			
12. Family-Ce	ntered Ca	re: Coord	ination of Care fo	r Children	With Chr	onic Cond	ditions (Yes	)			
80.25%	76.16%	NA	81.44%	70.47%	78.70%	NA	77.40%				
13. Family-Ce	ntered Ca	re: Gettin	g Needed Inform	ation (Alv	vays + Us	ually)					
88.37%	90.41%	94.05%	90.18%	91.48%	93.15%	87.01%	90.66%	89.72%			
14. Access to	Prescripti	on Medici	nes (Always + Us	sually)							
91.98%	94.19%	94.93%	93.23%	94.03%	95.36%	91.01%	93.53%	90.49%			

<sup>\*</sup>The measurement scale changed; hence, trend with caution.

## **HEDIS Trending Since 2006**

Each year of HEDIS reporting, Qsource has calculated statewide weighted averages for each measure by applying the size of the eligible population for each measure within a health plan to its rate. Using this methodology, plan-specific findings can be estimated from an overall TennCare statewide level, with each reporting health plan contributing to the statewide estimate proportionate to its eligible population size.

Trending for first-time measures—those reported for the first time in this year's HEDIS/CAHPS report—is not possible and, therefore, not presented in this section. Remaining measures are plotted to reflect the statewide performance of TennCare MCOs since reporting began in 2006, except where measures were not reported for a particular year as stated in footnotes. In 2008 there was implementation of new health plans in the Middle Grand Region that were not required to be NCQA accredited until December 2009. Similarly, there was implementation of new health plans in 2009 in the West Grand Region that were not required to be accredited until December 2010. The data would not have been reported by these MCOs for 2008 or 2009, respectively; hence, no 2008 or 2009 statewide weighted rates are presented.

## Effectiveness of Care Measures—Prevention and Screening

Fig. 1. HEDIS 2010–2013 Adult BMI Assessment (ABA) Statewide Weighted Rates




Fig. 2. HEDIS 2010–2013 Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)—BMI Percentile: 3–11 years Statewide Weighted Rates




Fig. 3. HEDIS 2010–2013 WCC—BMI Percentile: 12–17 years Statewide Weighted Rates




Fig. 4. HEDIS 2010–2013 WCC—BMI Percentile: Total Statewide Weighted Rates





Fig. 5. HEDIS 2010–2013 WCC—Counseling for Nutrition: 3–11 years Statewide Weighted Rates



100% 90% 80% 70% 55.01% 60% 51.03% 50% 39.52% 40% 30% 20.79% 20% 10% 0% 2010 2011 2012 2013 **HEDIS Report Year** 

Fig. 6. HEDIS 2010–2013 WCC—Counseling for Nutrition: 12–17 years Statewide Weighted Rates




Fig. 7. HEDIS 2010–2013 WCC—Counseling for Nutrition: Total Statewide Weighted Rates

Fig. 8. HEDIS 2010–2013 WCC—Counseling for Physical Activity: 3–11 years Statewide Weighted Rates





Fig. 9. HEDIS 2010–2013 WCC—Counseling for Physical Activity: 12–17 years Statewide Weighted Rates



100% 90% 80% 70% 60% Rate 46.36% 50% 39.63% 40% 30.94% 30% 18.58% 20% 10% 0% 2010 2011 2012 2013 **HEDIS Report Year** 

Fig. 10. HEDIS 2010–2013 WCC—Counseling for Physical Activity: Total Statewide Weighted Rates




Fig. 11. HEDIS 2006, 2007, 2010–13 Childhood Immunization Status (CIS)—DTaP Statewide Weighted Rates





Fig. 12. HEDIS 2006, 2007, 2010-13 CIS-IPV Statewide Weighted Rates









Fig. 14. HEDIS 2006, 2007, 2010-13 CIS-HiB Statewide Weighted Rates

Fig. 15. HEDIS 2006, 2007, 2010-13 CIS-HepB Statewide Weighted Rates







Fig. 16. HEDIS 2006, 2007, 2010-13 CIS-VZV Statewide Weighted Rates

Fig. 17. HEDIS 2006, 2007, 2010–13 CIS—PCV Statewide Weighted Rates



100% 89.55% 90% 80% 70% 60% 50% 43.18% 43.31% 40.57% 40% 30% 20% 10% 0% 2010 2011 2012 2013 **HEDIS Report Year** 

Fig. 18. HEDIS 2010–13 CIS—HepA Statewide Weighted Rates

Footnote: First year measurement data collection implemented in 2010. Hep A dose requirements changed in 2013 from two doses to at least one dose; hence, trend with caution.




Fig. 19. HEDIS 2010–13 CIS—RV Statewide Weighted Rate




Fig. 20. HEDIS 2010-13 CIS-Flu Statewide Weighted Rates




Fig. 21. HEDIS 2006, 2007, 2010–13 CIS—Combination 2 Statewide Weighted Rates





Fig. 22. HEDIS 2006, 2007, 2010–13 CIS—Combination 3 Statewide Weighted Rates

Fig. 23. HEDIS 2010-13 CIS—Combination 4 Statewide Weighted Rates



Footnote: First year measurement data collection implemented in 2010. HepA dose requirements changed in 2013 from two doses to at least one dose; hence, trend with caution.




Fig. 24. HEDIS 2010-13 CIS—Combination 5 Statewide Weighted Rates




Fig. 25. HEDIS 2010–13 CIS—Combination 6 Statewide Weighted Rates




Fig. 26. HEDIS 2010–13 CIS—Combination 7 Statewide Weighted Rates

Footnote: First year measurement data collection implemented in 2010. HepA dose requirements changed in 2013 from two doses to at least one dose; hence, trend with caution.




Fig. 27. HEDIS 2010–13 CIS—Combination 8 Statewide Weighted Rates

Footnote: First year measurement data collection implemented in 2010. HepA dose requirements changed in 2013 from two doses to at least one dose; hence, trend with caution.




Fig. 28. HEDIS 2010-13 CIS—Combination 9 Statewide Weighted Rates




Fig. 29. HEDIS 2010-13 CIS—Combination 10 Statewide Weighted Rates

Footnote: First year measurement data collection implemented in 2010. HepA dose requirements changed in 2013 from two doses to at least one dose; hence, trend with caution.

100% 90% 80% 70% 65.69% 60.34% 60% 47.58% 50% 39.91% 40% 30% 20% 10% 0% 2011 2013 2010 2012 **HEDIS Report Year** 

Fig. 30. HEDIS 2010–13 Immunizations for Adolescents (IMA)— Meningococcal Statewide Weighted Rates




Fig. 31. HEDIS 2010-13 IMA—Tdap/Td Statewide Weighted Rates

100% 90% 80% 70% 64.40% 58.66% 60% 50% 43.16% 40% 35.02% 30% 20% 10% 0% 2010 2011 2012 2013 **HEDIS Report Year** 

Fig. 32. HEDIS 2010-13 IMA— Combination 1 Statewide Weighted Rates




Fig. 33. HEDIS 2012–13 Human Papillomavirus Vaccine for Female Adolescents (HPV) Statewide Weighted Rates

100% 90% 80% 72.18% 70.87% 71.65% 70% 65.72% 60% 50% 40% 30% 20% 10% 0% 2011 2010 2012 2013 **HEDIS Report Year** 

Fig. 34. HEDIS 2010–13 Lead Screening in Children (LSC) Statewide Weighted Rates




Fig. 35. HEDIS 2010–13 Breast Cancer Screening (BCS) Statewide Weighted Rates

Footnote: Age stratification changed in 2009; as such, no comparative data are available from previous years.

Fig. 36. HEDIS 2006, 2007, 2010–13 Cervical Cancer Screening (CCS) Statewide Weighted Rates





Fig. 37. HEDIS 2006, 2007, 2010–13 Chlamydia Screening in Women (CHL)—16–20 years Statewide Weighted Rates






Fig. 38. HEDIS 2010-13 CHL-21-24 years Statewide Weighted Rates

Footnote: Age stratification changed in 2009; as such, no comparative data are available from previous years.




Fig. 39. HEDIS 2010-13 CHL—Total Statewide Weighted Rates

Footnote: Age stratification changed in 2009; as such, no comparative data are available from previous years.

## **Effectiveness of Care Measures—Respiratory Conditions**

Fig. 40. HEDIS 2006, 2007, 2010–13 Appropriate Testing for Children With Pharyngits (CWP) Statewide Weighted Rates





Fig. 41. HEDIS 2006, 2007, 2010–13 Appropriate Treatment for Children With Upper Respiratory Infection (URI) Statewide Weighted Rates



100% 90% 80% 70% 60% Rate 50% 40% 33.46% 30% 24.39% 21.51% 21.92% 20% 10% 0% 2012 2010 2011 2013 **HEDIS Report Year** 

Fig. 42. HEDIS 2010–13 Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis (AAB) Statewide Weighted Rates

Footnote: Inverted the measure rate in 2008; as such, no comparative data are available from previous years.




Fig. 43. HEDIS 2006, 2007, 2010–13 Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR) Statewide Weighted Rates

Fig. 44. HEDIS 2010–13 Pharmacotherapy Management of COPD Exacerbation (PCE)—Systemic corticosteriod Statewide Weighted Rates





Fig. 45. HEDIS 2010-13 PCE-Bronchodilator Statewide Weighted Rates



94.88% 100% 93.80% 93.42% 92.78% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 2013 2010 2011 2012 **HEDIS Report Year** 

Fig. 46. HEDIS 2010–13 Use of Appropriate Medications for People With Asthma (ASM)—5–11 years Statewide Weighted Rates

Footnote: Measure specification changed in 2010; as such, no comparative data are available from previous years.




Fig. 47. HEDIS 2012–13 ASM—12–18 years Statewide Weighted Rates

Footnote: Age stratification changed in 2012; as such, no comparative data are available from previous years.




Fig. 48. HEDIS 2012-13 ASM-19-50 years Statewide Weighted Rates

Footnote: Age stratification changed in 2012; as such, no comparative data are available from previous years.




Fig. 49. HEDIS 2012-13 ASM-51-64 years Statewide Weighted Rates

Footnote: Age stratification changed in 2012; as such, no comparative data are available from previous years.

100% 90% 85.29% 84.68% 80% 70% 60% 50% 40% 30% 20% 10% 0% 2012 2013 **HEDIS Report Year** 

Fig. 50. HEDIS 2012–13 ASM—Total years Statewide Weighted Rates

Footnote: Age stratification changed in 2012; as such, no comparative data are available from previous years.




Fig. 51. HEDIS 2012–13 Medication Management for People With Asthma (MMA)—Medication Compliance 50%: 5–11 years Statewide Weighted Rates

100% 90% 80% 70% 60% 51.55% 49.54% 50% 40% 30% 20% 10% 0% 2012 2013 **HEDIS Report Year** 

Fig. 52. HEDIS 2012–13 MMA—Medication Compliance 50%: 12–18 years Statewide Weighted Rates




Fig. 53. HEDIS 2012–13 MMA—Medication Compliance 50%: 19–50 years Statewide Weighted Rates

100% 90% 80% 70% 62.50% 59.02% 60% 50% 40% 30% 20% 10% 0% 2012 2013 **HEDIS Report Year** 

Fig. 54. HEDIS 2012–13 MMA—Medication Compliance 50%: 51–64 years Statewide Weighted Rates




Fig. 55. HEDIS 2012–13 MMA—Medication Compliance 50%: Total Statewide Weighted Rates

0%

100% 90% 80% 70% 60% 40% 30.08% 30.08% 30.45%

Fig. 56. HEDIS 2012–13 MMA—Medication Compliance 75%: 5–11 years Statewide Weighted Rates

Footnote: First year measurement data collection implemented in 2012

2012




Fig. 57. HEDIS 2012–13 MMA—Medication Compliance 75%: 12–18 years Statewide Weighted Rates

**HEDIS Report Year** 

Footnote: First year measurement data collection implemented in 2012

2013

100% 90% 80% 70% 60% 50% 40% 27.46% 26.28% 30% 20% 10% 0% 2012 2013 **HEDIS Report Year** 

Fig. 58. HEDIS 2012–13 MMA—Medication Compliance 75%: 19–50 years Statewide Weighted Rates




Fig. 59. HEDIS 2012–13 MMA—Medication Compliance 75%: 51–64 years Statewide Weighted Rates

100% 90% 80% 70% 60% 50% 40% 29.79% 28.71% 30% 20% 10% 0% 2012 2013 **HEDIS Report Year** 

Fig. 60. HEDIS 2012–13 MMA—Medication Compliance 75%: Total Statewide Weighted Rates

Footnote: First year measurement data collection implemented in 2012

#### **Effectiveness of Care Measures—Cardiovascular Conditions**

Fig. 61. HEDIS 2006, 2007, 2010–13 Cholesterol Management for Patients With Cardiovascular Conditions (CMC)—LDL-C Screening Statewide Weighted Rates




Fig. 62. HEDIS 2006, 2007, 2010–13 CMC—LDL-C Control (<100 mg/dL) Statewide Weighted Rates




Fig. 63. HEDIS 2006, 2007, 2010–13 Controlling High Blood Pressure (CBP) Statewide Weighted Rates






Fig. 64. HEDIS 2006, 2007, 2010–13 Persistence of Beta-Blocker Treatment After a Heart Attack (PBH) Statewide Weighted Rates



## **Effectiveness of Care Measures—Diabetes**

Fig. 65. HEDIS 2006, 2007, 2010–13 Comprehensive Diabetes Care (CDC)—HbA1c Testing Statewide Weighted Rates



100% 90% 80% 70% 60% 50% 38.54% 37.02% 37.34% 40% 34.64% 30% 21.22% 20% 10% 0% 2007 2010 2011 2012 2013 **HEDIS Report Year** 

Fig. 66. HEDIS 2007, 2010–13 CDC—HbA1c Control (<7.0%) Statewide Weighted Rates

Footnote: First year measurement data collection implemented in 2007.




Fig. 67. HEDIS 2010–13 CDC—HbA1c Control (<8.0%) Statewide Weighted Rates

Footnote: First year measurement data collection implemented in 2009.

Fig. 68. HEDIS 2006, 2007, 2010–13 CDC—Retinal Eye Exam Performed Statewide Weighted Rates




Fig. 69. HEDIS 2006, 2007, 2010–13 CDC—LDL-C Screening Statewide Weighted Rates




Fig. 70. HEDIS 2006, 2007, 2010–13 CDC—LDL-C Control (<100 mg/dL) Statewide Weighted Rates





Fig. 71. HEDIS 2006, 2007, 2010–13 CDC—Medical Attention for Nephropathy Statewide Weighted Rates



100% 90% 80% 70% 60% Rate 50% 38.03% 36.97% 35.56% 40% 29.14% 30% 23.42% 20% 10% 0% 2007 2010 2011 2012 2013

**HEDIS Report Year** 

Fig. 72. HEDIS 2007, 2010–13 CDC—Blood Pressure Control (<140/80 mm Hg) Statewide Weighted Rates

Footnote: First year measurement data collection implemented in 2007.




Fig. 73. HEDIS 2007, 2010–13 CDC—Blood Pressure Control (<140/90 mm Hg) Statewide Weighted Rates


Footnote: First year measurement data collection implemented in 2007.

100% 90% 80% 70% 62.57% 58.90% 60% Rate 47.85% 50% 45.61% 44.78% 43.22% 40% 30% 20% 10% 0% 2006 2007 2010 2011 2012 2013 **HEDIS Report Year** 

Fig. 74. HEDIS 2006, 2007, 2010–13 CDC—HbA1c Poor Control (>9.0%) Statewide Weighted Rates\*

#### **Effectiveness of Care Measures—Musculoskeletal Conditions**

Fig. 75. HEDIS 2006, 2007, 2010–13 Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART) Statewide Weighted Rates



<sup>\*</sup>Lower rates for this measure indicate better performance.


100% 90% 75.26% 80% 73.85% 68.19% 67.88% 68.03% 66.91% 70% 60% 50% 40% 30% 20% 10% 0% 2007 2010 2011 2012 2006 2013 **HEDIS Report Year** 

Fig. 76. HEDIS 2006, 2007, 2010–13 Use of Imaging Studies for Low Back Pain (LBP) Statewide Weighted Rates

Footnote: United American Healthcare Corporation did not report this measure in 2007; hence, it was excluded from statewide weighted average calculation.

#### Effectiveness of Care Measures—Behavioral Health

Fig. 77. HEDIS 2010–13 Antidepressant Medication Management (AMM)— Effective Acute Phase Treatment Statewide Weighted Rates



100% 90% 80% 70% 60% 50% 40% 32.03% 30.78% 28.23% 28.50% 30% 20% 10% 0% 2010 2011 2012 2013 **HEDIS Report Year** 

Fig. 78. HEDIS 2010–13 AMM—Effective Continuation Phase Treatment Statewide Weighted Rates




Fig. 79. HEDIS 2010–13 Follow-Up Care for Children Prescribed ADHD Medication (ADD)—Initiation Phase Statewide Weighted Rates

Fig. 80. HEDIS 2010–13 ADD—Continuation and Maintenance Phase Statewide Weighted Rates

100%





Fig. 81. HEDIS 2010–13 Follow-Up After Hospitalization for Mental Illness (FUH)—7-day follow-up Statewide Weighted Rates






Fig. 82. 2010–13 FUH—30-day follow-up Statewide Weighted Rates

# **Effectiveness of Care Measures—Medication Management**

Fig. 83. HEDIS 2006, 2007, 2010–13 Annual Monitoring for Patients on Persistent Medications (MPM)—ACE Inhibitors or ARBs Statewide Weighted Rates




Fig. 84. HEDIS 2006, 2007, 2010–13 MPM—Digoxin Statewide Weighted Rates





Fig. 85. HEDIS 2006, 2007, 2010–13 MPM—Diuretics Statewide Weighted Rates



100% 90% 75.42% 80% 75.48% 75.00% 72.89% 69.71% 70% 63.35% 60% 50% 40% 30% 20% 10% 0%


Fig. 86. HEDIS 2006, 2007, 2010–13 MPM—Anticonvulsants Statewide Weighted Rates

Fig. 87. HEDIS 2006, 2007, 2010–13 MPM—Total Statewide Weighted Rates

**HEDIS Report Year** 

2010

2011



2006

2007

2012

2013

## **Access/Availability of Care Measures**

Fig. 88. HEDIS 2006, 2007, 2010–13 Adults' Access to Preventive/Ambulatory Health Services (AAP)—20–44 years Statewide Weighted Rates





Fig. 89. HEDIS 2006, 2007, 2010–13 AAP—45–64 years Statewide Weighted Rates






Fig. 90. HEDIS 2006, 2007, 2010–13 Children and Adolescents' Access to Primary Care Practitioners (CAP)—12–24 months Statewide Weighted Rates

Fig. 91. HEDIS 2006, 2007, 2010–13 CAP—25 months–6 years Statewide Weighted Rates


2010

**HEDIS Report Year** 

2011

2012

2013



2006

2007

10%

0%

2006

100%
90%
85.10%
87.06%
80%
70%
60%
40%
30%
20%

2010


**HEDIS Report Year** 

2011

Fig. 92. HEDIS 2006, 2007, 2010–13 CAP—7–11 years Statewide Weighted Rates

Fig. 93. HEDIS 2006, 2007, 2010–13 CAP—12–19 years Statewide Weighted Rates

2007



2012

2013

Fig. 94. HEDIS 2010–13 Initiation and Engagement of Alcohol and Other Drug (AOD) Dependence Treatment (IET)—Initiation of AOD Treatment: 13–17 years Statewide Weighted Rates





Fig. 95. HEDIS 2010–13 IET—Initiation of AOD Treatment: ≥18 years Statewide Weighted Rates



100% 90% 80% 70% 60% 54.45% 46.48% 50% 43.38% 37.62% 40% 30% 20% 10% 0% 2010 2011 2012 2013 **HEDIS Report Year** 

Fig. 96. HEDIS 2010–13 IET—Initiation of AOD Treatment: Total Statewide Weighted Rates




Fig. 97. HEDIS 2010–13 IET—Engagement of AOD Treatment: 13–17 years Statewide Weighted Rates

100% 90% 80% 70% 60% Rate 50% 40% 30% 14.93% 20% 14.36% 12.34% 9.82% 10% 0% 2010 2011 2012 2013 **HEDIS Report Year** 

Fig. 98. HEDIS 2010–13 IET—Engagement of AOD Treatment: ≥18 years Statewide Weighted Rates




Fig. 99. HEDIS 2010–13 IET—Engagement of AOD Treatment: Total Statewide Weighted Rates

Fig. 100.HEDIS 2006, 2007, 2010–13 Prenatal and Postpartum Care (PPC)—Timeliness of Prenatal Care Statewide Weighted Rates




Fig. 101.HEDIS 2006, 2007, 2010–13 PPC—Postpartum Care Statewide Weighted Rates





Fig. 102.HEDIS 2006, 2007, 2010–13 Call Answer Timeliness (CAT) Statewide Weighted Rates



Footnote: United American Healthcare Corporation, Unison and Windsor did not report this measure in 2006; hence, these health plans were excluded from statewide weighted average calculation.

### **Utilization and Relative Resource Use**

Fig. 103.HEDIS 2006, 2007, 2010–13 Frequency of Ongoing Prenatal Care (FPC) ≥ 81 percent Statewide Weighted Rates




Fig. 104.HEDIS 2006, 2007, 2010–13 Well-Child Visits in the First 15 Months of Life (W15)—6 or More Visits Statewide Weighted Rates




Fig. 105.HEDIS 2006, 2007, 2010–13 Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34)—Statewide Weighted Rates





Fig. 106.HEDIS 2006, 2007, 2010–13 Adolescent Well-Care Visits (AWC) Statewide Weighted Rates



# **APPENDIX A** 2013 HEDIS Additional Measures, Rates and Benchmarks

#### **Utilization Measures**

Added Initially in 2009 Reporting

#### Frequency of Selected Procedure (FSP)

This measure summarized the utilization of frequently performed procedures that often show wide regional variation and have generated concern regarding potentially inappropriate utilization.

#### **Ambulatory Care (AMB)**

This measure summarizes utilization of ambulatory care in the following categories:

Outpatient Visits

♦ Emergency Department (ED) Visits

#### Inpatient Utilization – General Hospital/Acute Care (IPU)

This measure summarizes utilization of acute inpatient (IP) care and services in the following categories:

Total IP

Surgery

Medicine

Maternity

#### Identification of Alcohol and Other Drug Services (IAD)

This measure summarizes the number and percentage of members with an alcohol and drug (AOD) claim who received the following chemical dependency services during the measurement year:

Any services

Intensive outpatient or partial hospitalization

• IP

Outpatient or ED

#### Mental Health Utilization (MPT)

The number and percentage of members receiving the following mental health services during the measurement year:

Any services

Intensive outpatient or partial hospitalization

• IP

Outpatient or ED

#### **Antibiotic Utilization (ABX)**

This measure summarizes the following data on outpatient utilization of antibiotic prescriptions during the measurement year, stratified by age and gender:

- Average number of antibiotic prescription per member per year (PMPY)
- Average days supplied per antibiotic prescription
- Average number of prescription PMPY for antibiotic of concern
- Percentage of antibiotic of concern for all antibiotic prescriptions
- Average number of antibiotics PMPY reported by drug class:
  - For selected 'antibiotics of concern'
  - For all other antibiotics

## **Utilization Measures: Plan-Specific Rates/National Benchmarks**

In **Table A**, cells are shaded gray for those measures where age and/or sex segregation data were not available, and 'NA' is a representation of Not Applicable.

	Tal	ble A. H	EDIS 20	13 Plan-S	Specific R	ates wit	h Natior	nal Benc	hmarks:	Utilizat	tion Me	asures		
Measure by	Sex	Ameri-	Blue	Care	TennCare	Unit	tedHealth	care	Nationa	al Medicaio	HEDIS 2	2012 Mean	s and Per	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
Frequency of On	going l	Prenatal C	are (FPC):											
<21%	NA	8.80%	7.82%	13.94%	12.61%	9.38%	17.07%	20.19%	10.01%	2.43%	4.57%	6.58%	10.71%	19.11%
21–40%	NA	5.32%	3.23%	7.58%	9.66%	2.96%	4.63%	10.95%	6.52%	2.01%	3.23%	4.66%	7.30%	13.14%
41–60%	NA	6.71%	3.77%	9.78%	13.45%	5.19%	7.80%	13.87%	8.20%	3.89%	5.47%	7.50%	10.34%	14.01%
61–80%	NA	12.50%	7.55%	14.43%	20.17%	10.37%	16.34%	12.65%	14.45%	8.10%	11.34%	14.37%	17.79%	21.39%
≥81%	NA	66.67%	77.63%	54.28%	44.54%	72.10%	54.15%	42.34%	60.93%	39.42%	52.55%	64.65%	72.99%	82.75%
Well-Child Visits	in the	First 15 N	lonths of L	ife (W15):										
0 Visits	NA	1.01%	1.49%	0.24%	4.14%	1.19%	1.03%	1.22%	1.95%	0.46%	0.72%	1.22%	2.43%	3.89%
1 Visits	NA	2.78%	1.19%	2.92%	3.41%	0.90%	1.29%	3.65%	1.90%	0.44%	0.97%	1.57%	2.68%	3.65%
2 Visits	NA	2.78%	2.69%	4.87%	4.62%	3.58%	2.06%	6.57%	3.14%	1.20%	1.97%	2.92%	3.94%	5.14%
3 Visits	NA	5.06%	5.07%	7.79%	10.46%	5.37%	6.44%	9.98%	5.40%	2.62%	3.66%	4.74%	6.75%	9.49%
4 Visits	NA	9.87%	6.27%	15.82%	11.44%	7.76%	9.54%	11.19%	9.50%	5.11%	7.18%	8.78%	11.34%	13.14%
5 Visits	NA	14.18%	13.43%	18.49%	17.27%	9.55%	13.14%	14.60%	16.19%	10%	13.10%	16.30%	19.71%	21.96%
6 or More Visits	NA	64.30%	69.85%	49.88%	48.66%	71.64%	66.49%	52.80%	61.75%	43.80%	54.31%	62.95%	70.70%	77.31%
				Fi	requency	of Select	ed Proce	edures (F	SP)					
Bariatric weight	loss su	ırgery: Pro	ocedures /1	,000 Membe	er Years									
0–19		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
20–44	М	0.00	0.01	0.00	0.00	0.00	0.01	0.00	0.03	0.00	0.00	0.01	0.04	0.07
45–64		0.00	0.01	0.00	0.00	0.02	0.01	0.00	0.03	0.00	0.00	0.00	0.03	0.07
0–19		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01
20–44	F	0.02	0.01	0.00	0.00	0.06	0.07	0.01	0.11	0.00	0.02	0.06	0.16	0.29
45–64		0.03	0.03	0.00	0.00	0.04	0.03	0.00	0.11	0.00	0.00	0.07	0.16	0.34
Tonsillectomy: P	rocedur	es /1,000	Member Yea	ars										
0–9	M&F	0.80	1.33	0.66	1.37	1.20	0.96	0.63	0.74	0.28	0.50	0.76	0.94	1.19
10–19	IVIQI	0.44	0.60	0.32	0.42	0.66	0.52	0.30	0.36	0.12	0.20	0.36	0.51	0.60

	Tal	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	h Natior	nal Benc	hmarks:	Utilizat	tion Me	asures		
Measure by	C	Ameri-	Blue	Care	TennCare	Uni	tedHealth	care	Nationa	al Medicai	d HEDIS 2	2012 Mean	s and Per	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
Hysterectomy—A	Abdomi	inal (A) ar	nd Vaginal	(V): Proce	dures /1,000	Member Ye	ears							
A 15–44	F	0.24	0.15	0.17	0.03	0.32	0.36	0.20	0.20	0.08	0.14	0.20	0.25	0.31
A 45–64	Г	0.23	0.23	0.35	0.00	0.34	0.53	0.35	0.47	0.15	0.31	0.44	0.58	0.79
V 15–44	F	0.26	0.44	0.08	0.01	0.45	0.29	0.10	0.19	0.04	0.08	0.17	0.27	0.33
V 45-64	Г	0.32	0.31	0.13	0.47	0.32	0.37	0.09	0.27	0.00	0.13	0.22	0.32	0.59
Cholecystectomy	/—Opei	n (O) and	Closed (C)	/Laparoso	copic: Proced	dures /1,00	0 Member 1	Years						
O 30–64	M	0.09	0.05	0.06	0.69	0.05	0.05	0.00	0.04	0.00	0.00	0.03	0.06	0.08
O 15–44	F	0.00	0.01	0.03	0.10	0.01	0.01	0.02	0.02	0.00	0.01	0.02	0.02	0.04
O 45–64	F	0.08	0.03	0.08	0.47	0.04	0.02	0.10	0.04	0.00	0.00	0.04	0.07	0.10
C 30-64	М	0.45	0.58	0.21	2.30	0.54	0.60	0.23	0.36	0.13	0.21	0.34	0.42	0.56
C 15-44	F	0.94	1.11	0.58	1.34	1.31	1.07	0.56	0.77	0.45	0.57	0.75	0.93	1.21
C 45-64	F	0.78	1.09	0.51	2.34	1.09	0.89	0.58	0.74	0.35	0.54	0.74	0.86	1.15
Back Surgery: Pr	ocedure	es /1,000 N	Nember Yea	rs										
20. 44	M	0.45	0.46	0.34	0.06	0.55	0.64	0.16	0.31	0.06	0.16	0.28	0.44	0.58
20–44	F	0.37	0.29	0.15	0.16	0.33	0.41	0.12	0.20	0.05	0.10	0.19	0.28	0.34
4E / 4	М	1.04	0.67	0.40	0.00	0.87	1.18	0.26	0.66	0.16	0.34	0.61	0.83	1.15
45–64	F	0.82	0.70	0.44	0.00	0.91	1.33	0.53	0.52	0.00	0.32	0.50	0.74	0.94
Mastectomy: Pro	cedures	5 /1,000 Me	ember Years	S										
15–44	F	0.04	0.04	0.04	0.00	0.05	0.06	0.01	0.02	0.00	0.01	0.02	0.03	0.05
45–64	F	0.42	0.52	0.58	0.00	0.32	0.51	0.21	0.22	0.00	0.05	0.13	0.21	0.41
Lumpectomy: Pro	ocedure	s /1,000 N	lember Yeal	rs										
15–44	F	0.16	0.16	0.22	0.07	0.17	0.19	0.12	0.14	0.07	0.11	0.15	0.18	0.22
45–64	Г	0.77	0.87	1.36	0.00	0.41	0.83	0.51	0.50	0.14	0.33	0.46	0.62	0.99
					Ambul	atory Ca	re: Total	(AMB)						
Outpatient Visits	: Visits	/1.000 Mei	mber Month	ıs										
<1	NA	790.86	824.13	689.82	1034.59	760.97	767.73	652.88	737.13	497.82	650.72	751.41	826.54	888.01
1–9	NA	323.17	348.35	295.77	462.89	300.39	323.64	265.01	301.03	209.11	258.60	299.61	335.35	359.83
10–19	NA	254.47	293.72	239.06	308.80	240.14	249.22	194.01	231.46	156.97	198.55	229.40	256.81	300.88
20–44	NA	376.46	436.35	390.30	282.10	383.26	468.53	334.12	399.57	234.43	326.04	398.93	455.84	541.55
45–64	NA	667.37	806.33	700.53	515.34	678.19	835.52	593.91	586.04	405.71	501.15	588.57	689.85	742.84
65–74	NA	449.10	636.69	544.42	486.30	849.16	847.08	663.83	533.15	206.90	325.76	530.40	685.62	853.21
75–84	NA	288.16	207.41	472.69	0.00	766.58	737.48	544.94	540.26	223.58	357.73	492.16	647.91	847.06
≥85	NA	239.77	177.06	90.91	0.00	575.50	421.88	396.66	10358.39	0.00	190.48	378.66	605.26	733.33
Total	NA	366.83	420.68	351.43	384.78	375.55	409.68	311.06	353.74	261.52	301.57	347.76	388.71	436.59

	Та	ble A. H	EDIS 20°	13 Plan-	Specific R	ates wit	h Natior	nal Bencl	nmarks:	Utilizat	ion Me	asures		
Measure by	Carr	Ameri-	Blue	Care	TennCare	Unit	tedHealth	care	Nationa	al Medicaio	HEDIS 2	2012 Mear	ns and Per	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
ED Visits: Visits/1	,000 M	lember Mor	nths											
<1	NA	96.80	132.18	105.43	115.82	130.42	97.15	119.53	92.72	64.75	79.38	94.83	106.33	120.11
1–9	NA	53.44	74.91	53.61	70.25	72.39	55.36	56.53	48.72	33.18	42.85	48.71	55.67	66.01
10–19	NA	51.87	71.42	43.46	63.42	69.24	54.84	45.08	40.58	26.43	33.47	40.28	46.55	54.93
20–44	NA	119.69	143.10	108.69	91.15	144.41	133.54	108.72	100.18	62.94	78.60	103.27	120.72	139.26
45–64	NA	93.60	122.21	103.43	73.26	115.78	113.44	98.68	78.23	39.44	61.98	80.69	97.29	108.20
65–74	NA	28.38	69.06	52.82	95.89	88.51	77.77	66.04	41.79	0.00	16.14	33.74	51.43	80.88
75–84	NA	28.30	12.96	14.71	297.30	71.38	70.66	58.93		0.00		27.37	43.96	55.40
									31.64		16.37			
≥85	NA	22.73	4.02	0.00	0.00	56.01	39.63	43.32	27.49	0.00	0.00	21.72	37.52	52.07
Total	NA	75.25	99.77	71.45	69.01	97.43	82.69	73.55	62.39	42.03	52.45	63.15	72.77	80.04
			Inpa	itient Uti	lization — C	General H	lospital/	'Acute Ca	re: Tota	I (IPU)				
Total Inpatient														
Discharges: Disch	harges/	1,000 Men	nber Months	;										
<1	NA	10.02	10.47	9.33	40.20	10.34	8.15	7.95	11.40	5.28	7.16	9.51	12.02	16.33
1–9	NA	1.17	1.52	1.59	8.89	1.34	1.17	1.22	2.21	1.09	1.35	1.77	2.19	2.49
10–19	NA	3.06	3.39	3.16	6.29	3.25	3.18	3.15	3.17	2.00	2.49	3.01	3.60	4.45
20–44	NA	15.57	16.11	15.64	37.19	15.13	17.02	15.27	19.04	9.76	13.22	15.77	23.43	31.45
45–64	NA	26.32	24.34	27.47	34.80	25.15	25.69	24.05	18.59	6.64	10.47	18.38	25.65	29.74
65–74	NA	9.91	38.85	19.81	219.18	35.72	34.05	28.93	16.93	0.00	0.00	13.80	20.34	29.41
75–84	NA	10.29	9.26	21.01	486.49	38.72	40.10	34.31	20.54	0.00	6.90	16.21	22.47	33.20
≥85	NA	17.05	6.04	15.15	1000.00	39.44	26.68	26.17	40.16	0.00	0.00	18.11	32.36	44.94
Total	NA	7.69	8.54	7.94	10.24	9.04	8.49	7.87	7.84	4.98	6.36	7.72	8.62	10.62
<b>Days</b> : <i>Days/1,000</i>	Memb													
<1	NA	67.55	81.80	64.70	743.12	78.81	46.92	48.34	66.73	21.49	34.81	48.11	68.26	110.69
1–9	NA	3.76	4.86	5.06	56.27	4.03	3.82	4.08	7.02	2.99	3.86	5.05	6.52	8.68
10–19	NA	9.74	10.30	9.72	33.24	9.27	9.61	9.53	10.03	5.76	7.24	9.18	11.01	12.84
20–44	NA	52.38	52.54	53.15	149.37	54.74	51.31	50.66	58.33	30.56	41.12	52.34	71.02	98.20
45–64	NA	144.31	129.84	171.51	212.23	132.50	121.61	135.05	91.34	22.36	40.66	89.41	132.79	157.51
65–74	NA	40.09	251.08	162.67	1547.95	184.68	166.71	173.25	100.38	0.00	0.00	69.60	128.67	189.53
75–84	NA	30.02	57.41	140.76	2297.30	187.10	216.07	239.32	103.64	0.00	21.05	74.99	123.89	174.16
≥85	NA	112.50	30.18	125.54	8500.00	174.10	141.39	145.76	237.52	0.00	0.00	82.63	154.59	251.55
Total	NA	31.36	34.28	33.50	69.67	38.95	31.01	32.11	29.81	15.23	21.60	26.68	33.46	41.73

	Tal	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	h Natior	nal Bencl	nmarks:	Utilizat	tion Me	asures		
Measure by	Carr	Ameri-	Blue	Care	TennCare	Unit	tedHealth	care	Nationa	al Medicaio	HEDIS 2	2012 Mean	s and Per	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
Average Length	of Stay	: Average	# of Days											
<1	NA	6.74	7.81	6.93	18.48	7.62	5.76	6.08	5.50	3.22	4.23	5.02	6.27	7.94
1–9	NA	3.21	3.19	3.19	6.33	3.00	3.26	3.34	3.01	2.26	2.51	2.93	3.31	3.89
10–19	NA	3.18	3.03	3.08	5.29	2.85	3.02	3.03	3.11	2.44	2.78	3.05	3.29	3.55
20–44	NA	3.36	3.26	3.40	4.02	3.62	3.01	3.32	3.15	2.50	2.74	3.14	3.41	3.63
45–64	NA	5.48	5.33	6.24	6.10	5.27	4.73	5.62	4.70	3.34	4.13	4.85	5.34	5.82
65–74	NA	4.05	6.46	8.21	7.06	5.17	4.90	5.99	6.12	3.67	4.41	5.30	6.52	8.81
75–84	NA	2.92	6.20	6.70	4.72	4.83	5.39	6.98	5.06	3.24	4.00	4.99	5.82	6.80
≥85	NA	6.60	5.00	8.29	8.50	4.41	5.30	5.57	5.62	2.50	4.06	5.19	5.90	8.00
Unknown	NA	NA	NA	NA	NA	NA	NA	NA	2.00	2.00	2.00	2.00	2.00	2.00
Total	NA	4.08	4.02	4.22	6.80	4.31	3.65	4.08	3.64	2.76	3.18	3.67	4.01	4.25
Medicine														
Discharges: Discl	harges/	′1,000 Men	nber Months	;										
<1	NΑ	8.14	8.93	7.24	27.52	8.96	6.53	5.78	9.01	4.19	6.00	7.56	9.43	13.23
1–9	NA	0.88	1.18	1.15	6.24	1.04	0.88	0.87	1.77	0.78	1.03	1.41	1.80	2.19
10-19	NA	0.79	0.74	0.81	3.49	0.80	0.74	0.63	1.07	0.50	0.68	0.93	1.12	1.46
20–44	NA	3.42	3.71	3.57	10.91	4.06	3.60	3.52	4.05	1.73	2.60	3.64	4.93	6.57
45–64	NA	17.23	16.87	18.78	22.21	16.58	16.38	16.07	12.78	3.67	6.24	12.04	18.05	22.56
65–74	NA	6.76	28.06	13.21	136.99	26.45	22.61	20.66	11.89	0.00	0.00	9.19	14.56	21.77
75–84	NA	8.58	3.70	12.61	351.35	30.22	28.29	26.10	14.35	0.00	4.65	11.37	16.67	27.59
≥85	NA	14.77	6.04	10.82	500.00	34.31	18.29	22.11	22.61	0.00	0.00	13.02	25.79	33.82
Total	NA	3.07	3.53	3.20	5.79	4.30	3.30	3.15	3.51	1.30	2.20	3.14	3.90	5.59
<b>Days</b> : <i>Days/1,000</i>	) Memb	er Months									-		-	
<1	NA	40.80	62.20	27.62	309.91	58.62	28.68	20.18	38.42	16.64	21.85	31.77	41.18	58.09
1–9	NA	2.12	3.10	2.87	25.97	2.69	2.21	2.24	4.61	1.92	2.38	3.60	4.64	5.84
10–19	NA	2.38	2.24	2.44	15.21	2.34	2.25	2.12	3.29	1.41	1.91	2.70	3.61	4.57
20–44	NA	11.82	13.76	14.38	45.84	17.76	12.20	13.66	14.49	5.19	8.08	12.62	17.14	22.28
45–64	NA	70.76	72.50	85.94	87.45	67.52	57.22	69.21	53.36	11.87	20.83	49.40	74.16	100.79
65–74	NA	26.58	169.78	75.63	554.79	119.25	87.44	93.65	59.41	0.00	0.00	40.23	70.09	116.63
75–84	NA	26.59	14.81	54.62	1270.27	124.85	126.95	127.97	58.80	0.00	12.17	40.34	74.89	111.11
≥85	NA	103.41	30.18	58.44	4250.00	152.16	81.94	114.62	108.61	0.00	0.00	63.34	105.88	151.86
Total	NA	11.65	14.75	12.70	29.75	18.15	11.47	12.38	13.46	4.07	7.03	11.50	14.63	20.06

	Та	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	h Natior	nal Bencl	nmarks:	Utilizat	tion Me	asures		
Measure by		Ameri-	Blue	Care	TennCare	Uni	tedHealth	care	Nationa	al Medicaio	HEDIS 2	2012 Mean	s and Per	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
Average Length	of Stay	: Average	# of Days											
<1	NA	5.01	6.96	3.81	11.26	6.54	4.39	3.49	4.23	2.83	3.39	4.06	4.73	5.63
1–9	NA	2.39	2.62	2.49	4.16	2.58	2.50	2.57	2.55	2.07	2.25	2.49	2.76	3.07
10–19	NA	2.99	3.04	3.00	4.36	2.90	3.04	3.38	3.01	2.33	2.60	2.96	3.38	3.79
20–44	NA	3.45	3.71	4.03	4.20	4.38	3.39	3.88	3.45	2.58	2.96	3.40	3.86	4.22
45–64	NA	4.11	4.30	4.58	3.94	4.07	3.49	4.31	3.99	3.01	3.48	3.96	4.47	5.02
65–74	NA	3.93	6.05	5.73	4.05	4.51	3.87	4.53	5.42	3.10	3.76	4.33	5.29	6.08
75–84	NA	3.10	4.00	4.33	3.62	4.13	4.49	4.90	4.24	2.67	3.35	4.11	4.89	5.94
≥85	NA	7.00	5.00	5.40	8.50	4.44	4.48	5.18	4.89	2.25	3.29	4.13	5.52	7.80
Unknown	NA	NA	NA	NA	NA	NA	NA	NA	2.00	2.00	2.00	2.00	2.00	2.00
Total	NA	3.79	4.18	3.97	5.14	4.22	3.48	3.93	3.58	2.76	3.23	3.59	3.93	4.24
Surgery											-			
Discharges: Disch	harges/	′1,000 Men	nber Months	S										
<1	NA	1.88	1.54	2.09	12.68	1.38	1.62	2.17	2.29	0.48	1.05	1.47	2.27	3.62
1–9	NA	0.29	0.34	0.43	2.64	0.30	0.29	0.35	0.43	0.15	0.24	0.33	0.44	0.58
10–19	NA	0.44	0.51	0.42	1.78	0.49	0.41	0.47	0.52	0.28	0.35	0.45	0.55	0.63
20–44	NA	2.12	2.05	1.78	7.98	2.39	2.09	1.78	2.01	1.19	1.51	1.93	2.30	2.86
45–64	NA	9.05	7.36	8.60	12.36	8.41	9.21	7.90	5.62	2.38	4.06	5.69	7.46	8.51
65–74	NA	3.15	10.79	6.60	82.19	9.26	11.44	8.27	4.90	0.00	0.00	3.86	5.94	9.43
75–84	NA	1.72	5.56	8.40	135.14	8.50	11.80	8.21	6.14	0.00	0.00	4.43	6.84	10.20
≥85	NA	2.27	0.00	4.33	500.00	5.13	8.38	4.06	14.22	0.00	0.00	1.17	5.40	8.47
Total	NA	1.52	1.55	1.43	2.87	1.97	1.67	1.52	1.38	0.59	0.88	1.26	1.58	2.24
<b>Days</b> : Days/1,000	) Memb	er Months												
<1	NA	26.76	19.60	37.08	433.22	20.18	18.24	28.16	27.77	2.17	8.44	14.23	26.92	50.68
1–9	NA	1.64	1.76	2.19	30.31	1.33	1.61	1.85	2.37	0.55	1.01	1.46	2.07	3.44
10–19	NA	2.33	2.61	2.64	15.02	2.24	2.11	2.53	2.50	0.86	1.31	1.92	2.49	3.20
20–44	NA	13.88	13.37	12.75	62.14	16.07	10.17	12.56	10.02	4.50	6.34	9.03	12.36	16.34
45–64	NA	73.45	56.84	85.33	124.31	64.37	64.09	65.66	37.07	10.55	17.88	37.04	54.06	66.94
65–74	NA	13.51	81.29	87.03	993.15	65.43	79.27	79.60	39.04	0.00	0.00	24.24	47.29	74.72
75–84	NA	3.43	42.59	86.13	1027.03	62.25	89.12	111.34	44.64	0.00	0.00	28.12	45.44	73.83
≥85	NA	9.09	0.00	67.10	4250.00	21.94	59.45	31.14	105.61	0.00	0.00	5.18	40.02	85.42
Total	NA	11.45	10.97	12.48	35.92	14.11	10.53	11.91	8.57	2.58	4.68	7.12	10.18	14.95

	Та	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	h Natior	nal Benc	hmarks:	Utilizat	tion Me	asures		
Measure by	C	Ameri-	Blue	Care	TennCare	Uni	tedHealth	care	Nationa	al Medicaio	d HEDIS 2	2012 Mean	s and Per	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
Average Length	of Stay	<b>ı</b> : Average	# of Days											
<1	NA	14.25	12.73	17.70	34.15	14.67	11.27	12.98	11.17	4.75	6.84	9.90	13.45	19.00
1–9	NA	5.71	5.22	5.07	11.47	4.48	5.54	5.22	4.87	2.75	3.54	4.51	5.67	6.77
10–19	NA	5.33	5.12	6.28	8.43	4.59	5.20	5.35	4.50	2.80	3.34	4.32	5.18	5.81
20–44	NA	6.55	6.52	7.17	7.78	6.72	4.87	7.05	4.93	2.99	3.95	4.82	5.61	6.31
45–64	NA	8.12	7.72	9.93	10.06	7.65	6.96	8.32	6.31	3.75	4.91	6.56	7.58	8.54
65–74	NA	4.29	7.53	13.18	12.08	7.06	6.93	9.63	7.82	3.95	6.00	7.33	9.00	12.78
75–84	NA	2.00	7.67	10.25	7.60	7.32	7.55	13.56	7.65	3.88	5.51	7.00	9.00	9.90
≥85	NA	4.00	NA	15.50	8.50	4.27	7.09	7.67	9.04	4.25	5.57	7.07	10.78	14.58
Total	NA	7.53	7.09	8.74	12.54	7.15	6.28	7.84	5.98	3.73	4.77	6.04	6.92	7.65
Maternity (calc	ulated	using me	ember mo	nths for n	nembers 10	-64 years	:)							
Discharges: Disci	harges/	/1,000 Men	nber Months											
10–19	NA	1.83	2.15	1.93	1.01	1.95	2.04	2.05	1.57	0.58	1.13	1.55	2.00	2.47
20–44	NA	10.03	10.36	10.30	18.30	8.68	11.33	9.97	12.96	4.36	7.06	9.72	17.84	25.77
45–64	NA	0.04	0.10	0.09	0.23	0.15	0.09	0.08	0.15	0.00	0.02	0.06	0.11	0.23
Total	NA	5.20	5.52	5.44	2.61	4.44	5.96	5.24	5.25	1.88	3.71	4.75	6.59	9.65
<b>Days</b> : <i>Days/1,000</i>	Memb	er Months									-			
10–19	NA	5.03	5.44	4.64	3.01	4.69	5.24	4.88	4.20	1.55	3.02	4.03	5.36	6.62
20–44	NA	26.68	25.41	26.03	41.38	20.91	28.94	24.44	33.61	11.43	18.69	24.95	44.25	63.45
45–64	NA	0.10	0.50	0.23	0.46	0.61	0.30	0.18	0.40	0.00	0.05	0.15	0.37	0.74
Total	NA	13.91	13.65	13.64	6.56	10.72	15.24	12.79	13.66	5.21	9.84	12.53	17.18	24.60
Average Length	of Stay	: Average	# of Days								-			
10–19	NA	2.75	2.54	2.41	2.97	2.40	2.58	2.39	2.72	2.33	2.50	2.65	2.82	2.98
20–44	NA	2.66	2.45	2.53	2.26	2.41	2.55	2.45	2.63	2.32	2.49	2.64	2.75	2.93
45–64	NA	2.29	4.86	2.58	2.00	3.97	3.25	2.33	3.57	1.75	2.07	2.68	3.57	4.33
Unknown	NA	NA	NA	NA	NA	NA	NA	NA						
Total	NA	2.67	2.47	2.51	2.51	2.42	2.56	2.44	2.68	2.33	2.49	2.63	2.76	2.96

	Та	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	h Natior	nal Benc	hmarks:	Utiliza	tion Me	asures		
Measure by		Ameri-	Blue	Care	TennCare	Uni	tedHealth	care	Nationa	al Medicai	d HEDIS 2	2012 Mear	s and Per	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
			Ide	ntificatio	n of Alcoh	ol and O	ther Dru	g Service	es: Total	(IAD)				
Any Services														
<b>,</b>	М	0.04%	0.07%	0.05%	0.31%	0.05%	0.05%	0.02%	0.06%	0.01%	0.03%	0.05%	0.08%	0.14%
0–12	F	0.03%	0.05%	0.03%	0.25%	0.04%	0.02%	0.02%	0.04%	0.00%	0.02%	0.03%	0.05%	0.09%
	M&F	0.03%	0.06%	0.04%	0.28%	0.04%	0.04%	0.02%	0.05%	0.01%	0.03%	0.05%	0.07%	0.10%
	M	2.39%	3.02%	1.88%	7.30%	2.89%	2.43%	1.91%	2.54%	0.73%	1.54%	2.09%	3.24%	5.04%
13–17	F	1.35%	1.74%	0.92%	6.72%	1.61%	1.49%	0.78%	1.65%	0.62%	0.93%	1.43%	1.90%	2.44%
	M&F	1.87%	2.38%	1.39%	7.09%	2.24%	1.97%	1.34%	2.10%	0.77%	1.28%	1.86%	2.56%	3.86%
	M	4.86%	4.99%	4.13%	4.80%	5.44%	5.15%	4.45%	6.46%	2.09%	3.78%	5.54%	7.76%	12.00%
18–24	F	4.80%	6.26%	3.89%	4.25%	6.34%	5.17%	3.34%	4.81%	1.94%	3.30%	4.57%	6.05%	7.44%
	M&F	4.82%	5.88%	3.96%	4.60%	6.02%	5.17%	3.68%	5.38%	2.19%	3.63%	5.14%	6.64%	9.33%
	M	10.27%	9.31%	10.61%	2.36%	10.62%	11.29%	10.29%	11.34%	5.24%	7.53%	10.44%	13.87%	21.50%
25–34	F	8.18%	10.06%	6.61%	2.59%	9.09%	10.37%	5.58%	7.23%	3.28%	5.20%	7.09%	9.25%	11.39%
	M&F	8.63%	9.89%	7.17%	2.45%	9.45%	10.56%	6.29%	8.36%	3.69%	5.87%	7.83%	10.45%	14.40%
	M	14.47%	12.32%	14.71%	3.74%	13.20%	15.39%	15.25%	12.99%	5.58%	7.96%	12.80%	16.88%	20.73%
35–64	F	9.36%	8.59%	8.17%	1.49%	7.90%	12.60%	6.82%	7.78%	3.69%	5.19%	7.43%	9.30%	11.90%
	M&F	11.19%	9.81%	9.90%	2.61%	10.01%	13.54%	9.68%	9.78%	4.66%	6.15%	9.39%	12.02%	15.14%
	M	0.00%	4.19%	1.48%	0.00%	3.82%	7.16%	6.32%	4.16%	0.00%	0.00%	0.00%	4.07%	7.14%
≥65	F	0.94%	3.83%	2.01%	0.00%	2.08%	4.22%	2.74%	1.75%	0.00%	0.00%	0.00%	1.35%	2.42%
	M&F	0.56%	3.96%	1.84%	0.00%	2.66%	5.18%	3.78%	2.56%	0.00%	0.00%	0.00%	2.24%	4.77%
	M	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	M	3.15%	3.21%	2.52%	3.14%	3.92%	3.43%	3.15%	3.93%	0.86%	1.56%	2.89%	5.89%	8.03%
Total	F	3.65%	4.47%	3.23%	2.65%	3.99%	4.83%	2.70%	3.36%	1.31%	2.00%	2.94%	4.28%	5.93%
	M&F	3.44%	3.94%	2.95%	2.95%	3.96%	4.24%	2.88%	3.62%	1.25%	1.83%	2.80%	5.28%	6.59%
Inpatient														
_	M	0.00%	0.00%	0.01%	0.06%	0.01%	0.00%	0.01%	0.02%	0.00%	0.00%	0.01%	0.02%	0.04%
0–12	F	0.00%	0.00%	0.00%	0.03%	0.00%	0.00%	0.00%	0.01%	0.00%	0.00%	0.00%	0.02%	0.04%
	M&F	0.00%	0.00%	0.01%	0.05%	0.00%	0.00%	0.01%	0.02%	0.00%	0.00%	0.01%	0.02%	0.04%
	М	0.50%	0.40%	0.44%	1.09%	0.51%	0.53%	0.67%	0.46%	0.00%	0.19%	0.36%	0.56%	0.97%
13–17	F	0.39%	0.37%	0.29%	1.12%	0.35%	0.41%	0.32%	0.42%	0.07%	0.17%	0.32%	0.44%	0.87%
	M&F	0.44%	0.38%	0.36%	1.10%	0.43%	0.47%	0.49%	0.44%	0.09%	0.19%	0.35%	0.49%	0.91%

	Ta	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	h Natior	nal Benc	hmarks:	Utilizat	ion Me	asures		
Measure by	C	Ameri-	Blue	Care	TennCare	Uni	tedHealth	care	Nationa	al Medicaio	HEDIS 2	2012 Mear	s and Per	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
	М	1.59%	1.14%	1.35%	1.49%	1.89%	1.65%	1.70%	1.68%	0.46%	0.72%	1.25%	1.87%	3.27%
18–24	F	1.68%	2.53%	0.92%	1.57%	2.75%	1.82%	1.22%	1.97%	0.54%	0.90%	1.29%	2.04%	2.98%
	M&F	1.65%	2.12%	1.05%	1.52%	2.44%	1.77%	1.37%	1.86%	0.64%	0.91%	1.32%	2.16%	3.22%
	М	3.01%	2.65%	3.16%	0.59%	3.52%	3.54%	3.82%	2.72%	0.79%	1.69%	2.28%	3.54%	5.31%
25-34	F	2.51%	3.32%	1.45%	0.86%	3.91%	2.90%	1.73%	4.16%	0.79%	1.24%	1.91%	2.71%	3.45%
	M&F	2.62%	3.17%	1.69%	0.70%	3.82%	3.03%	2.04%	5.12%	0.89%	1.46%	2.05%	2.96%	4.02%
	М	5.78%	4.73%	6.36%	1.12%	5.79%	5.27%	6.66%	4.25%	1.23%	2.28%	4.07%	5.59%	7.33%
35–64	F	2.57%	2.67%	2.04%	0.00%	2.87%	3.39%	2.41%	21.17%	0.91%	1.46%	2.14%	2.73%	3.63%
	M&F	3.72%	3.35%	3.18%	0.56%	4.03%	4.03%	3.85%	40.47%	1.03%	1.72%	2.96%	3.97%	4.58%
	М	0.00%	4.19%	0.00%	0.00%	2.09%	2.84%	3.49%	0.96%	0.00%	0.00%	0.00%	1.14%	2.94%
≥65	F	0.94%	1.53%	0.67%	0.00%	1.17%	1.16%	1.15%	0.23%	0.00%	0.00%	0.00%	0.22%	1.08%
	M&F	0.56%	2.47%	0.46%	0.00%	1.48%	1.71%	1.83%	0.44%	0.00%	0.00%	0.00%	0.57%	1.58%
	М	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	М	1.09%	0.98%	0.92%	0.61%	1.50%	1.10%	1.30%	1.18%	0.18%	0.36%	0.89%	1.63%	2.35%
Total	F	1.10%	1.48%	0.77%	0.56%	1.57%	1.37%	0.93%	1.10%	0.39%	0.57%	0.83%	1.29%	1.73%
	M&F	1.09%	1.27%	0.83%	0.59%	1.54%	1.26%	1.08%	1.13%	0.27%	0.49%	0.86%	1.40%	2.06%
Intensive Outpat	tient/F	Partial Hos	pitalizatio											
	М	0.00%	0.000/	0.000/										
0 10		0.0070	0.00%	0.00%	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
0–12	F	0.00%	0.00%	0.00%	0.01% 0.02%	0.00% 0.00%	0.00%	0.00% 0.00%	0.00% 0.00%	0.00% 0.00%	0.00%	0.00%	0.00%	0.00%
0-12	F M&F													
0-12	-	0.00% 0.00% 0.83%	0.00% 0.00% 1.13%	0.00%	0.02% 0.01% 2.22%	0.00% 0.00% 1.02%	0.00% 0.00% 1.07%	0.00%	0.00% 0.00% 0.27%	0.00% 0.00% 0.00%	0.00%	0.00% 0.00% 0.04%	0.00% 0.00% 0.37%	0.00%
13–17	M&F M	0.00% 0.00% 0.83% 0.41%	0.00% 0.00% 1.13% 0.47%	0.00% 0.00% 0.47% 0.07%	0.02% 0.01% 2.22% 2.32%	0.00% 0.00% 1.02% 0.39%	0.00% 0.00% 1.07% 0.32%	0.00% 0.00% 0.37% 0.09%	0.00% 0.00% 0.27% 0.16%	0.00% 0.00% 0.00% 0.00%	0.00% 0.00% 0.00% 0.00%	0.00% 0.00% 0.04% 0.03%	0.00% 0.00% 0.37% 0.18%	0.00% 0.00% 1.02% 0.44%
	M&F M	0.00% 0.00% 0.83%	0.00% 0.00% 1.13%	0.00% 0.00% 0.47%	0.02% 0.01% 2.22%	0.00% 0.00% 1.02%	0.00% 0.00% 1.07%	0.00% 0.00% 0.37%	0.00% 0.00% 0.27% 0.16% 0.21%	0.00% 0.00% 0.00%	0.00% 0.00% 0.00%	0.00% 0.00% 0.04%	0.00% 0.00% 0.37%	0.00% 0.00% 1.02%
	M&F M	0.00% 0.00% 0.83% 0.41% 0.62%	0.00% 0.00% 1.13% 0.47% 0.80% 0.63%	0.00% 0.00% 0.47% 0.07%	0.02% 0.01% 2.22% 2.32%	0.00% 0.00% 1.02% 0.39% 0.70% 0.69%	0.00% 0.00% 1.07% 0.32%	0.00% 0.00% 0.37% 0.09%	0.00% 0.00% 0.27% 0.16% 0.21% 0.45%	0.00% 0.00% 0.00% 0.00%	0.00% 0.00% 0.00% 0.00%	0.00% 0.00% 0.04% 0.03%	0.00% 0.00% 0.37% 0.18% 0.27% 0.66%	0.00% 0.00% 1.02% 0.44%
	M&F M F M&F	0.00% 0.00% 0.83% 0.41% 0.62%	0.00% 0.00% 1.13% 0.47% 0.80%	0.00% 0.00% 0.47% 0.07% 0.27%	0.02% 0.01% 2.22% 2.32% 2.26%	0.00% 0.00% 1.02% 0.39% 0.70%	0.00% 0.00% 1.07% 0.32% 0.70%	0.00% 0.00% 0.37% 0.09% 0.22%	0.00% 0.00% 0.27% 0.16% 0.21%	0.00% 0.00% 0.00% 0.00% 0.00%	0.00% 0.00% 0.00% 0.00% 0.00%	0.00% 0.00% 0.04% 0.03% 0.04%	0.00% 0.00% 0.37% 0.18% 0.27%	0.00% 0.00% 1.02% 0.44% 0.69%
13–17	M&F M F M&F M F M&F	0.00% 0.00% 0.83% 0.41% 0.62% 0.62% 0.73% 0.70%	0.00% 0.00% 1.13% 0.47% 0.80% 0.63% 1.07% 0.94%	0.00% 0.00% 0.47% 0.07% 0.27% 0.39% 0.31% 0.33%	0.02% 0.01% 2.22% 2.32% 2.26% 0.64%	0.00% 0.00% 1.02% 0.39% 0.70% 0.69% 0.81%	0.00% 0.00% 1.07% 0.32% 0.70% 0.76% 0.97% 0.91%	0.00% 0.00% 0.37% 0.09% 0.22% 0.44% 0.27% 0.32%	0.00% 0.00% 0.27% 0.16% 0.21% 0.45% 0.34% 0.38%	0.00% 0.00% 0.00% 0.00% 0.00% 0.00%	0.00% 0.00% 0.00% 0.00% 0.00% 0.00%	0.00% 0.00% 0.04% 0.03% 0.04% 0.13% 0.15% 0.13%	0.00% 0.00% 0.37% 0.18% 0.27% 0.66% 0.61% 0.57%	0.00% 0.00% 1.02% 0.44% 0.69% 1.21% 1.06% 1.23%
13–17	M&F M F M&F M	0.00% 0.00% 0.83% 0.41% 0.62% 0.62% 0.73%	0.00% 0.00% 1.13% 0.47% 0.80% 0.63% 1.07% 0.94% 1.07%	0.00% 0.00% 0.47% 0.07% 0.27% 0.39% 0.31%	0.02% 0.01% 2.22% 2.32% 2.26% 0.64% 0.80%	0.00% 0.00% 1.02% 0.39% 0.70% 0.69% 0.87% 0.81%	0.00% 0.00% 1.07% 0.32% 0.70% 0.76% 0.97%	0.00% 0.00% 0.37% 0.09% 0.22% 0.44% 0.27%	0.00% 0.00% 0.27% 0.16% 0.21% 0.45% 0.34% 0.38% 0.82%	0.00% 0.00% 0.00% 0.00% 0.00% 0.00%	0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%	0.00% 0.00% 0.04% 0.03% 0.04% 0.13% 0.15%	0.00% 0.00% 0.37% 0.18% 0.27% 0.66% 0.61% 0.57% 1.25%	0.00% 0.00% 1.02% 0.44% 0.69% 1.21% 1.06%
13–17	M&F M F M&F M F M&F	0.00% 0.00% 0.83% 0.41% 0.62% 0.62% 0.73% 0.70%	0.00% 0.00% 1.13% 0.47% 0.80% 0.63% 1.07% 0.94%	0.00% 0.00% 0.47% 0.07% 0.27% 0.39% 0.31% 0.33%	0.02% 0.01% 2.22% 2.32% 2.26% 0.64% 0.80% 0.70%	0.00% 0.00% 1.02% 0.39% 0.70% 0.69% 0.81%	0.00% 0.00% 1.07% 0.32% 0.70% 0.76% 0.97% 0.91%	0.00% 0.00% 0.37% 0.09% 0.22% 0.44% 0.27% 0.32%	0.00% 0.00% 0.27% 0.16% 0.21% 0.45% 0.34% 0.38%	0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%	0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%	0.00% 0.00% 0.04% 0.03% 0.04% 0.13% 0.15% 0.13%	0.00% 0.00% 0.37% 0.18% 0.27% 0.66% 0.61% 0.57%	0.00% 0.00% 1.02% 0.44% 0.69% 1.21% 1.06% 1.23%
13–17 18–24	M&F M F M&F M F M&F	0.00% 0.00% 0.83% 0.41% 0.62% 0.62% 0.73% 0.70% 1.27%	0.00% 0.00% 1.13% 0.47% 0.80% 0.63% 1.07% 0.94% 1.07%	0.00% 0.00% 0.47% 0.07% 0.27% 0.39% 0.31% 0.33% 0.77%	0.02% 0.01% 2.22% 2.32% 2.26% 0.64% 0.80% 0.70% 0.00%	0.00% 0.00% 1.02% 0.39% 0.70% 0.69% 0.87% 0.81%	0.00% 0.00% 1.07% 0.32% 0.70% 0.76% 0.97% 0.91% 1.31%	0.00% 0.00% 0.37% 0.09% 0.22% 0.44% 0.27% 0.32% 0.79%	0.00% 0.00% 0.27% 0.16% 0.21% 0.45% 0.34% 0.38% 0.82% 0.53% 0.61%	0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%	0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%	0.00% 0.00% 0.04% 0.03% 0.04% 0.13% 0.15% 0.13% 0.36%	0.00% 0.00% 0.37% 0.18% 0.27% 0.66% 0.61% 0.57% 1.25%	0.00% 0.00% 1.02% 0.44% 0.69% 1.21% 1.06% 1.23% 2.26%
13–17 18–24	M&F M F M&F M F M&F	0.00% 0.00% 0.83% 0.41% 0.62% 0.73% 0.70% 1.27% 1.31%	0.00% 0.00% 1.13% 0.47% 0.80% 0.63% 1.07% 0.94% 1.07% 1.52%	0.00% 0.00% 0.47% 0.07% 0.27% 0.39% 0.31% 0.33% 0.77% 0.61%	0.02% 0.01% 2.22% 2.32% 2.26% 0.64% 0.80% 0.70% 0.00%	0.00% 0.00% 1.02% 0.39% 0.70% 0.69% 0.87% 0.81% 0.83% 1.37%	0.00% 0.00% 1.07% 0.32% 0.70% 0.76% 0.97% 0.91% 1.31% 1.26%	0.00% 0.00% 0.37% 0.09% 0.22% 0.44% 0.27% 0.32% 0.79% 0.62%	0.00% 0.00% 0.27% 0.16% 0.21% 0.45% 0.34% 0.38% 0.82% 0.53%	0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%	0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%	0.00% 0.00% 0.04% 0.03% 0.04% 0.13% 0.15% 0.13% 0.36% 0.21%	0.00% 0.00% 0.37% 0.18% 0.27% 0.66% 0.61% 0.57% 1.25% 0.94%	0.00% 0.00% 1.02% 0.44% 0.69% 1.21% 1.06% 1.23% 2.26% 1.64%
13–17 18–24	M&F M F M&F M F M&F M F M&F	0.00% 0.00% 0.83% 0.41% 0.62% 0.62% 0.73% 0.70% 1.27% 1.31% 1.30%	0.00% 0.00% 1.13% 0.47% 0.80% 0.63% 1.07% 0.94% 1.07% 1.52% 1.42%	0.00% 0.00% 0.47% 0.07% 0.27% 0.39% 0.31% 0.33% 0.77% 0.61% 0.63%	0.02% 0.01% 2.22% 2.32% 2.26% 0.64% 0.80% 0.70% 0.00% 0.00%	0.00% 0.00% 1.02% 0.39% 0.70% 0.69% 0.81% 0.81% 0.83% 1.37% 1.24%	0.00% 0.00% 1.07% 0.32% 0.70% 0.76% 0.97% 0.91% 1.31% 1.26% 1.27%	0.00% 0.00% 0.37% 0.09% 0.22% 0.44% 0.27% 0.32% 0.79% 0.62% 0.65%	0.00% 0.00% 0.27% 0.16% 0.21% 0.45% 0.34% 0.38% 0.82% 0.53% 0.61%	0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%	0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.03%	0.00% 0.00% 0.04% 0.03% 0.04% 0.13% 0.15% 0.13% 0.36% 0.21% 0.27%	0.00% 0.00% 0.37% 0.18% 0.27% 0.66% 0.61% 0.57% 1.25% 0.94%	0.00% 0.00% 1.02% 0.44% 0.69% 1.21% 1.06% 1.23% 2.26% 1.64% 1.68%

	Tal	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	h Natior	nal Bencl	hmarks:	Utiliza	tion Me	asures		
Measure by	C	Ameri-	Blue	Care	TennCare	Unit	tedHealth	care	Nationa	al Medicai	d HEDIS 2	2012 Mear	s and Per	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
	М	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.52%	0.00%	0.00%	0.00%	0.00%	0.00%
≥65	F	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.10%	0.00%	0.00%	0.00%	0.00%	0.00%
	M&F	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.20%	0.00%	0.00%	0.00%	0.00%	0.00%
	М	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	М	0.35%	0.35%	0.20%	0.76%	0.33%	0.39%	0.19%	0.27%	0.00%	0.01%	0.09%	0.39%	0.63%
Total	F	0.44%	0.56%	0.23%	0.76%	0.44%	0.45%	0.21%	0.25%	0.00%	0.01%	0.09%	0.38%	0.67%
	M&F	0.40%	0.47%	0.22%	0.76%	0.39%	0.43%	0.20%	0.26%	0.00%	0.01%	0.09%	0.40%	0.63%
Outpatient/ED									-		_			
	М	0.04%	0.06%	0.04%	0.24%	0.04%	0.04%	0.02%	0.06%	0.00%	0.03%	0.04%	0.06%	0.12%
0–12	F	0.02%	0.04%	0.03%	0.22%	0.04%	0.02%	0.02%	0.04%	0.00%	0.01%	0.02%	0.04%	0.08%
	M&F	0.03%	0.05%	0.03%	0.23%	0.04%	0.03%	0.02%	0.05%	0.01%	0.02%	0.04%	0.05%	0.08%
	М	1.61%	2.35%	1.35%	5.23%	2.35%	1.47%	1.30%	2.45%	0.89%	1.38%	1.90%	3.13%	4.87%
13–17	F	0.91%	1.32%	0.64%	5.17%	1.31%	1.07%	0.46%	1.68%	0.54%	0.81%	1.20%	1.76%	2.78%
	M&F	1.26%	1.84%	0.99%	5.20%	1.83%	1.28%	0.87%	2.06%	0.85%	1.12%	1.62%	2.56%	3.76%
	М	3.74%	4.13%	2.86%	3.49%	3.89%	3.69%	2.92%	6.07%	1.94%	3.25%	5.01%	8.19%	10.74%
18–24	F	3.58%	4.44%	3.00%	3.05%	4.23%	3.82%	2.26%	4.12%	1.49%	2.77%	3.78%	5.12%	6.74%
	M&F	3.63%	4.35%	2.96%	3.33%	4.11%	3.78%	2.47%	4.80%	1.58%	3.00%	4.15%	6.19%	8.07%
	M	8.25%	7.39%	8.47%	1.77%	8.03%	8.98%	7.68%	10.43%	3.60%	6.46%	9.27%	13.33%	19.93%
25–34	F	6.67%	7.68%	5.35%	1.73%	6.47%	8.39%	4.22%	6.40%	2.64%	4.47%	6.22%	8.34%	10.68%
	M&F	7.01%	7.61%	5.78%	1.75%	6.84%	8.51%	4.74%	7.50%	2.96%	5.08%	6.82%	9.63%	13.61%
	М	11.66%	9.35%	10.68%	3.36%	9.92%	12.29%	11.31%	11.12%	4.55%	6.12%	10.84%	14.78%	18.97%
35–64	F	7.82%	6.84%	6.80%	1.49%	6.05%	10.39%	5.16%	6.79%	2.79%	4.64%	6.20%	8.39%	10.95%
	M&F	9.20%	7.66%	7.83%	2.42%	7.59%	11.03%	7.24%	8.44%	3.55%	5.43%	7.82%	10.69%	14.11%
	M	0.00%	0.00%	1.48%	0.00%	2.52%	4.93%	3.70%	3.13%	0.00%	0.00%	0.00%	2.57%	5.31%
≥65	F	0.47%	3.83%	1.34%	0.00%	1.17%	3.35%	1.86%	1.55%	0.00%	0.00%	0.00%	0.60%	1.61%
	M&F	0.28%	2.47%	1.38%	0.00%	1.62%	3.86%	2.39%	2.11%	0.00%	0.00%	0.00%	1.30%	2.77%
	М	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	М	2.48%	2.50%	1.85%	2.28%	2.96%	2.63%	2.27%	3.76%	0.71%	1.25%	2.35%	5.91%	7.63%
Total	F	2.94%	3.42%	2.62%	2.02%	2.91%	3.88%	1.98%	3.03%	1.05%	1.56%	2.43%	4.05%	5.42%
	M&F	2.74%	3.04%	2.31%	2.18%	2.93%	3.35%	2.10%	3.35%	0.89%	1.51%	2.40%	4.84%	6.12%

M&F   6.13%   7.02%   4.42%   22.16%   6.62%   6.25%   3.75%   6.60%   2.60%   3.58%   6.18%   8.43%   11.88%     13.13%   14.43%   9.22%   41.06%   13.43%   12.88%   7.61%   13.05%   5.30%   7.23%   12.03%   17.17%   22.71%     M&F   13.36%   14.43%   9.22%   42.54%   14.04%   12.28%   7.61%   13.05%   5.39%   7.24%   12.35%   16.60%   22.24%     M&F   13.38%   14.43%   9.22%   42.54%   14.04%   12.28%   7.61%   13.05%   5.38%   7.24%   12.35%   16.60%   22.24%     M&F   15.81%   13.59%   10.61%   18.55%   12.54%   14.04%   12.79%   11.51%   12.86%   5.38%   7.22%   14.41%   16.06%   22.44%     M&F   15.07%   12.67%   10.64%   18.55%   12.64%   14.43%   13.26%   9.39%   15.47%   5.88%   7.73%   14.96%   20.00%   27.13%     M&F   15.07%   12.67%   10.64%   18.96%   14.44%   13.26%   9.39%   14.55%   5.77%   9.22%   13.78%   18.06%   24.80%     M&F   15.06%   24.49%   11.39%   0.00%   4.52%   4.63%   3.49%   7.14%   0.00%   0.00%   0.00%   0.73%   6.67%   12.00%     M&F   12.94%   25.22%   10.14%   0.00%   8.72%   7.35%   4.78%   10.30%   0.00%   0.00%   0.00%   0.73%   6.67%   12.00%     M&F   12.94%   25.22%   10.14%   0.00%   8.72%   7.35%   4.78%   10.30%   0.00%   0.00%   0.00%   0.00%   0.73%   6.67%   12.00%     M&F   10.40%   10.33%   10.60%   7.65%   27.38%   11.17%   10.15%   6.53%   10.86%   4.48%   6.47%   9.36%   12.26%   18.45%     Total   F   10.49%   10.60%   7.65%   27.38%   11.17%   10.15%   6.59%   10.86%   4.49%   6.39%   10.04%   13.05%   0.48%     M&F   10.40%   0.05%   0.06%   0.68%   0.05%   0.07%   0.07%   0.03%   0.03%   0.01%   0.05%   0.00%   0.00%   0.03%   0.10%   0.05%   0.03%   0.44%     M&F   0.00%   0.05%   0.06%   0.68%   0.09%   0.09%   0.09%   0.08%   0.09%		Та	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	h Natior	nal Benc	hmarks:	Utilizat	tion Me	asures		
Page	Measure by	C	Ameri-	Blue	Care	TennCare	Unit	tedHealth	care	Nationa	I Medicai	d HEDIS 2	2012 Mear	s and Per	centiles
Any Services	Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
O-12 F					1	Mental He	alth Utili	zation: 1	otal (MF	PT)					
0-12	Any Services														
M&F   6.13%   7.02%   4.42%   23.16%   6.62%   6.25%   3.75%   6.60%   2.60%   3.58%   6.18%   8.43%   11.88%     M   12.62%   14.72%   9.28%   41.06%   13.73%   12.69%   8.76%   12.67%   4.83%   7.74%   12.37%   16.74%   21.81%     F   13.62%   14.13%   9.72%   42.54%   14.04%   12.79%   81.77%   12.86%   5.38%   7.23%   12.03%   17.17%   22.71%     M&F   13.13%   14.43%   9.22%   42.54%   14.04%   12.79%   81.77%   12.86%   5.38%   7.24%   12.35%   16.66%   22.24%     M&F   13.13%   14.43%   9.22%   42.54%   14.04%   12.79%   81.77%   12.86%   5.38%   7.24%   12.35%   16.86%   22.24%     M&F   15.81%   13.59%   10.65%   19.99%   15.44%   14.32%   9.39%   15.47%   5.88%   9.73%   14.496%   20.00%   27.13%     M&F   15.07%   12.67%   10.64%   18.96%   14.44%   13.26%   9.39%   14.55%   5.77%   9.22%   13.78%   18.60%   24.80%     M&F   15.06%   24.49%   11.39%   0.00%   4.52%   4.63%   3.49%   7.14%   0.00%   0.00%   0.00%   0.73%   6.67%   12.00%     M&F   12.94%   25.22%   10.14%   0.00%   7.32%   6.46%   4.41%   8.66%   0.00%   0.00%   0.00%   3.46%   8.18%   15.58%     M&F   NA		М	7.29%	8.34%	5.34%	24.59%	8.03%	7.59%	4.75%	7.99%	3.37%	4.71%	7.50%	10.13%	13.70%
13-17	0–12	F	4.92%	5.65%	3.50%	20.95%	5.16%	4.86%	2.73%	5.10%	1.78%	2.52%	4.65%	6.73%	9.81%
13-17		M&F	6.13%	7.02%	4.42%	23.16%	6.62%	6.25%	3.75%	6.60%	2.60%	3.58%	6.18%	8.43%	11.88%
M&F   13.13%   14.43%   9.22%   42.54%   14.04%   12.79%   8.17%   12.66%   5.38%   7.24%   12.35%   16.86%   22.24%   18–64   M   13.38%   10.39%   10.61%   18.35%   12.54%   10.69%   11.51%   12.69%   4.65%   7.24%   11.41%   16.60%   21.49%   18.64%   18.96%   19.99%   15.44%   14.32%   9.39%   15.47%   15.48%   15.49%   14.65%   7.72%   11.41%   16.60%   21.49%   18.66%   12.69%   18.46%   18.47%   18.40%   18.40%   18.49%   20.00%   27.13%   18.60%   24.49%   13.39%   10.64%   18.96%   14.44%   13.25%   9.98%   14.55%   5.77%   9.22%   13.78%   18.60%   24.00%   24.00%   25.20%   16.66%   24.49%   11.39%   0.00%   8.72%   7.35%   4.68%   10.30%   0.00%   0.00%   0.00%   0.73%   0.65%   12.50%   14.14%   0.00%		М	12.62%	14.72%	9.28%	41.06%	13.73%	12.69%	8.76%	12.67%	4.83%	7.74%	12.37%	16.74%	21.81%
18-64   M	13–17	F	13.62%	14.13%	9.17%	45.14%	14.34%	12.88%	7.61%	13.05%	5.30%	7.23%	12.03%		22.71%
18-64   F   15.81%   13.59%   10.65%   19.99%   15.44%   14.32%   9.39%   15.47%   5.88%   9.73%   14.96%   20.00%   27.13%     M&F   15.07%   12.67%   10.64%   18.96%   14.44%   13.26%   9.98%   14.55%   5.87%   9.22%   13.78%   18.60%   24.80%     ≥65   F   16.06%   24.49%   11.39%   0.00%   4.52%   4.63%   3.49%   7.14%   0.00%   0.00%   0.073%   6.67%   12.06%     M&F   12.94%   25.22%   10.14%   0.00%   7.32%   6.46%   4.41%   8.66%   0.00%   0.00%   0.00%   3.46%   8.18%   15.58%     M&RF   12.94%   25.22%   10.14%   0.00%   7.32%   6.46%   4.41%   8.66%   0.00%   0.00%   0.00%   2.78%   7.91%   14.12%     M&NA   NA   NA   NA   NA   NA   NA   NA		M&F	13.13%	14.43%	9.22%	42.54%	14.04%	12.79%	8.17%	12.86%	5.38%	7.24%	12.35%	16.86%	22.24%
M&F   15.07%   12.67%   10.64%   18.96%   14.44%   13.26%   9.98%   14.55%   5.77%   9.22%   13.78%   18.60%   24.80%     M		М	13.38%	10.39%	10.61%	18.35%	12.54%	10.69%	11.51%	12.69%		7.92%	11.41%	16.60%	21.49%
M	18–64	F													
≥65		M&F													
M&F   12.94%   25.22%   10.14%   0.00%   7.32%   6.46%   4.41%   8.66%   0.00%   0.00%   2.78%   7.91%   14.12%		M													
Mar   NA   NA   NA   NA   NA   NA   NA   N	≥65		16.06%		11.39%	0.00%	8.72%	7.35%	4.78%	10.30%	0.00%	0.00%	3.46%	8.18%	15.58%
Unknown         F         NA         0.10%         0.20%         0.10%         0.20%         0.20%         0.20%         0.20%         0.24%         0.06%         0.10%         0.01%         0.04%         0		M&F				0.00%				8.66%	0.00%	0.00%	2.78%	7.91%	14.12%
M&F         NA         9.36%         12.6%         18.4%         6.53%         10.8%         6.41%         9.93%         13.52%         20.61%         0.01%         0.15%         6.53%         10.8%         4.48%         6.41%         9.93%         13.52%         20.61%         0.02%         0.79%         0.79%         0.59%         0.59%         0.08%         0.93%         0.08%         0.08%         0.08%         0.08%         0.08%         0.09%         0.00%         0.03%         0.03%         0.01%															
Total Magnetic Provided Heaville Provided Heav	Unknown														
Total         F         10.93%         10.60%         7.65%         27.38%         11.17%         10.15%         6.53%         10.86%         4.48%         6.41%         9.93%         13.52%         20.61%           Mage         10.40%         10.31%         7.46%         27.99%         10.77%         9.71%         6.79%         10.58%         4.19%         6.39%         10.04%         13.09%         19.43%           Impatient           0-12         M         0.08%         0.09%         0.08%         0.09%         0.09%         0.08%         0.24%         0.06%         0.10%         0.14%           0-12         F         0.06%         0.05%         0.06%         0.61%         0.04%         0.07%         0.03%         0.13%         0.01%         0.05%         0.16%         0.26%           M&F         0.07%         0.07%         0.07%         0.09%         0.06%         0.18%         0.05%         0.10%         0.25%         0.37%           13-17         F         1.22%         0.91%         0.95%         4.64%         1.01%         1.23%         0.96%         1.39%         0.38%         0.86%         1.30%         1.49%         1.70% <t< td=""><td></td><td>M&amp;F</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td></td><td></td><td></td><td></td><td></td><td></td></t<>		M&F	NA	NA	NA	NA	NA	NA	NA						
Image: Name of the problem		М	9.69%	9.92%	7.18%	28.36%	10.25%	9.11%	7.17%	10.20%	3.81%	6.37%	9.36%	12.26%	18.45%
M   0.08%   0.09%   0.08%   0.09%   0.04%   0.08%   0.24%   0.06%   0.10%   0.19%   0.33%   0.44%	Total	F	10.93%	10.60%	7.65%	27.38%	11.17%	10.15%	6.53%	10.86%	4.48%	6.41%	9.93%	13.52%	20.61%
M   0.08%   0.09%   0.08%   0.86%   0.09%   0.12%   0.08%   0.24%   0.06%   0.10%   0.19%   0.33%   0.44%     F   0.06%   0.05%   0.06%   0.61%   0.04%   0.07%   0.03%   0.13%   0.01%   0.05%   0.10%   0.16%   0.26%     M&F   0.07%   0.07%   0.07%   0.07%   0.07%   0.09%   0.06%   0.18%   0.05%   0.08%   0.16%   0.25%   0.37%     M   0.98%   0.89%   0.78%   3.36%   0.93%   0.97%   1.05%   1.07%   0.25%   0.59%   1.01%   1.49%   1.70%     F   1.22%   0.91%   0.95%   4.64%   1.01%   1.23%   0.96%   1.39%   0.38%   0.86%   1.36%   1.81%   2.37%     M&F   1.10%   0.90%   0.87%   3.83%   0.97%   1.10%   1.00%   1.23%   0.42%   0.73%   1.25%   1.66%   1.94%     M   2.04%   1.63%   2.13%   3.13%   2.09%   1.95%   2.55%   1.81%   0.32%   0.94%   1.58%   2.81%   3.38%     F   1.42%   1.46%   1.15%   2.82%   1.71%   1.62%   1.25%   1.38%   0.45%   0.91%   1.36%   1.80%   2.35%     M&F   1.61%   1.51%   1.38%   3.01%   1.84%   1.71%   1.61%   1.52%   0.56%   0.79%   1.47%   1.98%   2.70%     M   4.87%   25.15%   7.38%   0.00%   2.78%   2.26%   1.50%   1.30%   0.00%   0.00%   0.00%   0.00%   0.47%   2.31%     E   10.39%   21.43%   5.36%   0.00%   2.78%   2.26%   1.50%   1.30%   0.00%   0.00%   0.00%   0.00%   0.47%   2.31%     C   C   C   C   C   C   C   C   C		M&F	10.40%	10.31%	7.46%	27.99%	10.77%	9.71%	6.79%	10.58%	4.19%	6.39%	10.04%	13.09%	19.43%
0-12 F 0.06% 0.05% 0.06% 0.61% 0.04% 0.07% 0.03% 0.13% 0.01% 0.05% 0.10% 0.16% 0.26% M&F 0.07% 0.07% 0.07% 0.07% 0.09% 0.06% 0.18% 0.05% 0.08% 0.16% 0.25% 0.37% 0.98% 0.98% 0.89% 0.78% 3.36% 0.93% 0.97% 1.05% 1.07% 0.25% 0.59% 1.01% 1.49% 1.70% 1.21% 0.91% 0.95% 4.64% 1.01% 1.23% 0.96% 1.39% 0.38% 0.86% 1.36% 1.81% 2.37% M&F 1.10% 0.90% 0.87% 3.83% 0.97% 1.10% 1.00% 1.23% 0.42% 0.73% 1.25% 1.66% 1.94% 1.40% 1.63% 2.13% 3.13% 2.09% 1.95% 2.55% 1.81% 0.32% 0.94% 1.58% 2.81% 3.38% 1.44% 1.51% 1.46% 1.55% 1.62% 1.25% 1.38% 0.45% 0.91% 1.36% 1.80% 2.35% M&F 1.61% 1.51% 1.38% 3.01% 1.84% 1.71% 1.61% 1.52% 0.56% 0.79% 1.47% 1.98% 2.70% M 4.87% 25.15% 7.38% 0.00% 1.39% 1.94% 1.31% 0.94% 0.00% 0.00% 0.00% 0.00% 0.52% 1.90% 1.90% 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% 0.00% 0.00% 0.00% 0.00% 0.47% 2.31% 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% 0.00% 0.00% 0.00% 0.47% 2.31% 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% 0.00% 0.00% 0.00% 0.47% 2.31% 1.00% 1.00% 1.00% 1.00% 0	Inpatient											-	-		
M&F         0.07%         0.07%         0.07%         0.07%         0.07%         0.09%         0.06%         0.18%         0.05%         0.08%         0.16%         0.25%         0.37%           13-17         M         0.98%         0.89%         0.78%         3.36%         0.93%         0.97%         1.05%         1.07%         0.25%         0.59%         1.01%         1.49%         1.70%           13-17         F         1.22%         0.91%         0.95%         4.64%         1.01%         1.23%         0.96%         1.39%         0.38%         0.86%         1.36%         1.81%         2.37%           M&F         1.10%         0.90%         0.87%         3.83%         0.97%         1.10%         1.00%         1.23%         0.42%         0.73%         1.25%         1.66%         1.94%           M&F         1.42%         1.63%         2.13%         3.13%         2.09%         1.95%         2.55%         1.81%         0.32%         0.94%         1.58%         2.81%         3.38%           18-64         F         1.42%         1.46%         1.15%         2.82%         1.71%         1.62%         1.25%         1.38%         0.45%         0.91%         1.36%		М	0.08%	0.09%	0.08%	0.86%	0.09%	0.12%	0.08%	0.24%	0.06%	0.10%	0.19%	0.33%	0.44%
M&F         0.07%         0.07%         0.07%         0.07%         0.07%         0.09%         0.06%         0.18%         0.05%         0.08%         0.16%         0.25%         0.37%           13-17         M         0.98%         0.89%         0.78%         3.36%         0.93%         0.97%         1.05%         1.07%         0.25%         0.59%         1.01%         1.49%         1.70%           13-17         F         1.22%         0.91%         0.95%         4.64%         1.01%         1.23%         0.96%         1.39%         0.38%         0.86%         1.36%         1.81%         2.37%           M&F         1.10%         0.90%         0.87%         3.83%         0.97%         1.10%         1.00%         1.23%         0.42%         0.73%         1.25%         1.66%         1.94%           M&F         1.42%         1.63%         2.13%         3.13%         2.09%         1.95%         2.55%         1.81%         0.32%         0.94%         1.58%         2.81%         3.38%           18-64         F         1.42%         1.46%         1.15%         2.82%         1.71%         1.62%         1.25%         1.38%         0.45%         0.91%         1.36%	0–12	F	0.06%	0.05%	0.06%	0.61%	0.04%	0.07%	0.03%	0.13%	0.01%	0.05%	0.10%	0.16%	0.26%
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		M&F	0.07%												
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$															
M&F       1.10%       0.90%       0.87%       3.83%       0.97%       1.10%       1.00%       1.23%       0.42%       0.73%       1.25%       1.66%       1.94%         M       2.04%       1.63%       2.13%       3.13%       2.09%       1.95%       2.55%       1.81%       0.32%       0.94%       1.58%       2.81%       3.38%         F       1.42%       1.46%       1.15%       2.82%       1.71%       1.62%       1.25%       1.38%       0.45%       0.91%       1.36%       1.80%       2.35%         M&F       1.61%       1.51%       1.38%       3.01%       1.84%       1.71%       1.61%       1.52%       0.56%       0.79%       1.47%       1.98%       2.70%         M       4.87%       25.15%       7.38%       0.00%       1.39%       1.94%       1.31%       0.94%       0.00%       0.00%       0.00%       0.52%       1.90%         ≥65       F       10.39%       21.43%       5.36%       0.00%       2.78%       2.26%       1.50%       1.30%       0.00%       0.00%       0.00%       0.47%       2.31%	13–17														
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	10 17	-													
18-64       F       1.42%       1.46%       1.15%       2.82%       1.71%       1.62%       1.25%       1.38%       0.45%       0.91%       1.36%       1.80%       2.35%         M&F       1.61%       1.51%       1.38%       3.01%       1.84%       1.71%       1.61%       1.52%       0.56%       0.79%       1.47%       1.98%       2.70%         M       4.87%       25.15%       7.38%       0.00%       1.39%       1.94%       1.31%       0.94%       0.00%       0.00%       0.00%       0.52%       1.90%         ≥65       F       10.39%       21.43%       5.36%       0.00%       2.78%       2.26%       1.50%       1.30%       0.00%       0.00%       0.00%       0.47%       2.31%															
M&F     1.61%     1.51%     1.38%     3.01%     1.84%     1.71%     1.61%     1.52%     0.56%     0.79%     1.47%     1.98%     2.70%       M     4.87%     25.15%     7.38%     0.00%     1.39%     1.94%     1.31%     0.94%     0.00%     0.00%     0.00%     0.52%     1.90%       ≥65     F     10.39%     21.43%     5.36%     0.00%     2.78%     2.26%     1.50%     1.30%     0.00%     0.00%     0.00%     0.47%     2.31%	18–64														
M 4.87% 25.15% 7.38% 0.00% 1.39% 1.94% 1.31% 0.94% 0.00% 0.00% 0.00% 0.52% 1.90% ≥65 F 10.39% 21.43% 5.36% 0.00% 2.78% 2.26% 1.50% 1.30% 0.00% 0.00% 0.00% 0.47% 2.31%	10 04														
≥65 F 10.39% 21.43% 5.36% 0.00% 2.78% 2.26% 1.50% 1.30% 0.00% 0.00% 0.00% 0.47% 2.31%															
	>65														
	_00	M&F	8.16%	22.74%	5.99%	0.00%	2.32%	2.15%	1.45%	1.10%	0.00%	0.00%	0.00%	0.57%	2.26%

	Та	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	h Natior	nal Benc	hmarks:	Utilizat	tion Me	asures		
Measure by	Cave	Ameri-	Blue	Care	TennCare	Uni	tedHealth	care	Nationa	al Medicai	d HEDIS 2	2012 Mean	s and Per	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
	М	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	M	0.74%	0.68%	0.66%	2.00%	0.88%	0.74%	0.90%	0.82%	0.27%	0.48%	0.76%	1.04%	1.37%
Total	F	0.84%	0.88%	0.70%	2.09%	1.01%	0.94%	0.74%	0.84%	0.34%	0.53%	0.81%	1.05%	1.23%
	M&F	0.80%	0.79%	0.69%	2.04%	0.95%	0.86%	0.81%	0.83%	0.32%	0.56%	0.79%	1.04%	1.29%
Intensive Outpa	tient/F	Partial Hos	pitalizatio	n										
	М	0.00%	0.04%	0.07%	0.18%	0.01%	0.00%	0.08%	0.37%	0.00%	0.00%	0.05%	0.32%	0.94%
0–12	F	0.00%	0.01%	0.04%	0.13%	0.02%	0.00%	0.02%	0.20%	0.00%	0.00%	0.03%	0.11%	0.45%
	M&F	0.00%	0.02%	0.05%	0.16%	0.01%	0.00%	0.05%	0.29%	0.00%	0.00%	0.05%	0.20%	0.70%
	М	0.05%	0.46%	0.23%	0.70%	0.32%	0.07%	0.22%	0.70%	0.00%	0.00%	0.20%	0.54%	2.09%
13–17	F	0.00%	0.15%	0.18%	0.99%	0.25%	0.00%	0.26%	0.78%	0.00%	0.00%	0.24%	0.60%	2.12%
	M&F	0.03%	0.31%	0.20%	0.80%	0.28%	0.04%	0.24%	0.74%	0.00%	0.00%	0.26%	0.56%	2.28%
	М	0.07%	0.06%	0.14%	0.08%	0.07%	0.02%	0.09%	0.60%	0.00%	0.00%	0.13%	0.50%	1.84%
18–64	F	0.06%	0.17%	0.16%	0.10%	0.14%	0.05%	0.17%	0.67%	0.00%	0.01%	0.17%	0.60%	2.17%
	M&F	0.06%	0.14%	0.16%	0.09%	0.12%	0.04%	0.15%	0.64%	0.00%	0.02%	0.17%	0.58%	2.11%
	М	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.02%	0.00%	0.00%	0.00%	0.00%	0.00%
≥65	F	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.09%	1.21%	0.00%	0.00%	0.00%	0.00%	0.10%
	M&F	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.06%	1.10%	0.00%	0.00%	0.00%	0.00%	0.07%
	М	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	M	0.03%	0.11%	0.11%	0.32%	0.07%	0.02%	0.10%	0.52%	0.00%	0.01%	0.13%	0.39%	1.70%
Total	F	0.03%	0.11%	0.11%	0.36%	0.10%	0.02%	0.12%	0.49%	0.00%	0.02%	0.13%	0.47%	1.52%
	M&F	0.03%	0.11%	0.11%	0.33%	0.09%	0.02%	0.11%	0.51%	0.00%	0.02%	0.16%	0.42%	1.59%
Outpatient/ED														
	M	7.28%	8.32%	5.31%	24.45%	8.02%	7.58%	4.73%	7.91%	3.29%	4.68%	7.45%	10.03%	13.66%
0–12	F	4.90%	5.64%	3.48%	20.74%	5.15%	4.86%	2.73%	5.06%	1.66%	2.52%	4.62%	6.62%	9.77%
	M&F	6.11%	7.01%	4.40%	22.99%	6.61%	6.24%	3.73%	6.54%	2.56%	3.52%	6.18%	8.28%	11.77%
	М	12.37%	14.48%	8.93%	40.13%	13.52%	12.54%	8.47%	12.32%	4.72%	7.57%	11.92%	16.33%	20.29%
13–17	F	13.42%	13.95%	8.88%	43.94%	14.12%	12.67%	7.28%	12.73%	4.90%	7.06%	11.38%	16.72%	22.62%
	M&F	12.90%	14.22%	8.91%	41.51%	13.83%	12.60%	7.86%	12.53%	4.71%	7.37%	11.84%	16.51%	21.36%
	M	12.73%	9.43%	9.57%	16.89%	11.49%	9.89%	10.90%	11.96%	3.64%	7.38%	10.90%	15.77%	21.07%
18–64	F	15.46%	12.81%	10.15%	18.98%	14.67%	13.75%	9.11%	15.02%	5.15%	9.33%	14.79%	19.48%	26.92%
	M&F	14.63%	11.84%	10.02%	17.67%	13.57%	12.63%	9.61%	14.00%	4.43%	8.83%	13.38%	18.02%	24.44%

	Та	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	h Natior	nal Benc	hmarks:	Utiliza	tion Me	asures		
Measure by	Carr	Ameri-	Blue	Care	TennCare	Unit	tedHealth	care	Nationa	al Medicai	d HEDIS 2	2012 Mear	ns and Per	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
	M	3.48%	6.98%	1.48%	0.00%	3.48%	2.84%	2.18%	6.20%	0.00%	0.00%	0.28%	4.74%	11.54%
≥65	F	7.09%	3.06%	6.03%	0.00%	6.94%	5.46%	3.45%	9.20%	0.00%	0.00%	2.32%	6.98%	12.94%
	M&F	5.63%	4.45%	4.61%	0.00%	5.79%	4.60%	3.08%	7.67%	0.00%	0.00%	2.06%	6.00%	11.58%
	M	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	M	9.46%	9.58%	6.86%	27.76%	9.86%	8.86%	6.94%	9.89%	3.69%	6.08%	9.17%	11.98%	18.21%
Total	F	10.72%	10.16%	7.36%	26.76%	10.74%	9.84%	6.34%	10.61%	4.34%	6.30%	9.68%	13.09%	20.55%
	M&F	10.18%	9.92%	7.16%	27.38%	10.35%	9.43%	6.59%	10.30%	4.09%	6.20%	9.70%	12.62%	19.22%
					Antibiot	ic Utiliza	tion: To	tal (ABX)	)					
Antibiotic Utiliz	ation													
Average Scripts	PMPY	for Antibio	otics											
,	М	1.40	1.73	1.26	1.78	1.56	1.43	1.09						
0–9	F	1.43	1.78	1.29	1.98	1.57	1.49	1.09						
	M&F	1.42	1.76	1.28	1.86	1.57	1.46	1.09						
	M	0.86	1.07	0.72	0.89	0.96	0.86	0.63						
10–17	F	1.16	1.41	0.99	1.31	1.30	1.19	0.88						
	M&F	1.01	1.24	0.85	1.04	1.13	1.02	0.76						
	М	0.90	0.92	0.83	0.57	0.94	0.91	0.78						
18–34	F	2.01	1.84	1.98	1.09	1.93	2.04	1.81						
	M&F	1.71	1.60	1.73	0.76	1.63	1.75	1.57						
	M	1.09	1.12	1.21	0.83	1.17	1.29	1.13						
35–49	F	1.83	1.76	1.96	1.08	1.86	1.96	1.75						
	M&F	1.60	1.56	1.81	0.96	1.62	1.76	1.58						
	M	1.23	1.11	1.19	0.73	1.20	1.34	1.17						
50–64	F	1.74	1.66	1.74	1.00	1.86	2.03	1.70						
	M&F	1.51	1.45	1.54	0.87	1.55	1.75	1.45						
	M	0.96	1.28	0.60	0.41	1.75	1.72	1.32						
65–74	F	1.06	1.35	1.16	1.57	2.38	2.40	1.81						
	M&F	1.02	1.32	1.01	1.20	2.14	2.15	1.64						
	M	0.73	0.08	1.08	0.00	1.68	1.34	1.35						
75–84	F	1.87	0.76	0.89	0.00	2.32	2.12	1.45						
	M&F	1.45	0.58	0.96	0.00	2.14	1.90	1.43						

	ıaı	ole A. H			Specific R				IIIIai KS.	Utiliza	tion we	asui es		
Measure by	Sex	Ameri-	Blue	Care	TennCare	Uni	tedHealth	care	Nationa	al Medicai	d HEDIS 2	2012 Mear	s and Per	centiles
Age/as Stated	Jex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P <b>7</b> 5	P90
	M	1.35	0.99	1.01	NA	1.64	2.17	0.51						
≥85	F	1.73	0.33	0.08	NA	1.90	1.53	1.34						
	M&F	1.61	0.51	0.44	NA	1.85	1.65	1.25						
	M	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	M	1.16	1.35	1.04	1.17	1.26	1.20	0.94	0.93	0.65	0.78	0.92	1.05	1.22
Total	F	1.61	1.72	1.56	1.56	1.70	1.70	1.39	1.29	0.95	1.09	1.28	1.42	1.63
	M&F	1.42	1.57	1.35	1.32	1.50	1.49	1.21	1.13	0.81	0.96	1.14	1.25	1.47
Average Days Su	pplied	per Antib	iotic Scrip	t										
	M	9.14	8.99	9.21	10.15	8.93	9.18	9.19						
0–9	F	9.32	9.18	9.36	10.83	9.08	9.29	9.20						
	M&F	9.23	9.09	9.29	10.44	9.00	9.23	9.20						
	M	9.35	9.75	9.51	10.95	9.68	9.43	9.64						
10–17	F	9.02	9.25	9.08	10.61	9.28	8.99	8.89						
	M&F	9.16	9.47	9.26	10.80	9.45	9.18	9.19						
	M	9.57	9.55	9.24	12.26	9.48	9.39	9.26						
18–34	F	8.21	8.35	7.95	10.57	8.35	8.29	7.91						
	M&F	8.40	8.53	8.09	11.38	8.55	8.44	8.07						
	M	10.22	9.46	10.17	13.90	9.59	10.15	10.33						
35–49	F	8.76	8.75	8.82	13.18	8.71	8.81	8.67						
	M&F	9.06	8.90	9.00	13.49	8.93	9.11	8.98						
	M	10.05	10.13	10.65	12.04	9.99	10.09	10.28						
50–64	F	8.91	8.96	9.16	13.53	9.20	9.10	9.08						
	M&F	9.34	9.30	9.60	12.90	9.48	9.40	9.53						
	M	11.78	9.56	8.87	7.00	9.69	9.34	9.00						
65–74	F	9.09	10.70	8.28	8.00	9.98	9.10	9.07						
	M&F	10.25	10.24	8.38	7.89	9.89	9.17	9.05						
	М	5.31	5.00	11.56	NA	8.44	10.85	8.57						
75–84	F	8.92	6.92	9.68	NA	10.11	10.10	7.97						
	M&F	8.26	6.85	10.47	NA	9.73	10.26	8.10						
	M	9.50	7.73	5.40	NA	7.48	10.64	13.60						
≥85	F	8.92	6.70	5.50	NA	10.29	9.05	7.76						
	M&F	9.08	7.24	5.41	NA	9.77	9.42	8.02						

	Та	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	h Nation	nal Benc	hmarks:	Utiliza	tion Me	asures		
Measure by		Ameri-	Blue	Care	TennCare	Uni	tedHealth	care	Nationa	al Medicai	d HEDIS 2	2012 Mear	ns and Per	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
	M	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	М	9.35	9.29	9.40	10.61	9.28	9.38	9.45	9.76	9.24	9.42	9.66	10.04	10.37
Total	F	8.77	8.85	8.65	10.75	8.87	8.82	8.54	8.99	8.59	8.75	8.95	9.18	9.42
	M&F	8.97	9.00	8.88	10.68	9.02	9.01	8.83	9.27	8.88	9.01	9.22	9.50	9.77
Average Scripts	PMPY 1	for Antibio	otics of Co	ncern										
	M	0.72	0.96	0.63	0.94	0.88	0.72	0.53						
0–9	F	0.69	0.93	0.62	0.95	0.82	0.71	0.50						
	M&F	0.71	0.95	0.62	0.95	0.85	0.71	0.51						
	М	0.44	0.56	0.37	0.41	0.51	0.44	0.31						
10–17	F	0.54	0.69	0.46	0.58	0.64	0.56	0.39						
	M&F	0.49	0.62	0.42	0.47	0.57	0.49	0.35						
	М	0.39	0.39	0.39	0.22	0.40	0.41	0.34						
18–34	F	0.80	0.75	0.77	0.42	0.80	0.84	0.70						
	M&F	0.69	0.66	0.69	0.29	0.68	0.73	0.61						
	М	0.52	0.53	0.59	0.33	0.57	0.64	0.52						
35–49	F	0.87	0.86	0.93	0.37	0.93	0.96	0.78						
	M&F	0.76	0.76	0.86	0.35	0.80	0.86	0.71						
	М	0.63	0.58	0.59	0.36	0.62	0.68	0.58						
50–64	F	0.91	0.90	0.93	0.45	1.02	1.09	0.88						
	M&F	0.78	0.78	0.80	0.41	0.83	0.92	0.74						
	M	0.45	0.66	0.26	0.41	1.02	0.98	0.65						
65–74	F	0.48	0.73	0.67	1.18	1.34	1.33	0.97						
	M&F	0.46	0.70	0.56	0.93	1.22	1.20	0.86						
	M	0.56	0.08	0.47	0.00	1.06	0.70	0.77						
75–84	F	1.04	0.49	0.44	0.00	1.23	1.14	0.71						
	M&F	0.86	0.38	0.45	0.00	1.18	1.01	0.72						
	М	0.76	0.72	0.54	NA	0.96	1.29	0.25						
≥85	F	0.95	0.33	0.00	NA	1.01	0.83	0.75						
	M&F	0.89	0.43	0.21	NA	1.00	0.91	0.70						
	M	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						

Measure by	Sex	Ameri-	Blue		TennCare		tedHealth				1	1	s and Per	1
Age/as Stated		group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
	M	0.58	0.72	0.52	0.58	0.67	0.60	0.45	0.40	0.25	0.32	0.40	0.47	0.59
Total	F	0.72	0.82	0.69	0.71	0.82	0.78	0.60	0.53	0.35	0.43	0.51	0.61	0.73
	M&F	0.66	0.78	0.62	0.63	0.75	0.70	0.54	0.47	0.31	0.39	0.46	0.55	0.67
Percentage of An	tibioti	cs of Con	cern of All	Antibiotic	Scripts									
	М	51.58%	55.72%	49.77%	52.74%	56.20%	49.93%	48.51%						
0–9	F	48.15%	52.23%	47.73%	48.06%	52.26%	47.57%	45.62%						
	M&F	49.88%	53.98%	48.75%	50.70%	54.26%	48.74%	47.08%						
	М	51.02%	52.50%	51.27%	46.39%	52.39%	50.74%	48.89%						
10–17	F	46.62%	48.94%	46.79%	44.51%	48.87%	46.69%	43.96%						
	M&F	48.50%	50.50%	48.65%	45.54%	50.35%	48.42%	45.98%						
	М	43.59%	43.09%	46.35%	39.08%	42.55%	44.99%	43.11%						
18–34	F	39.71%	40.72%	39.07%	38.38%	41.52%	40.93%	38.45%						
	M&F	40.25%	41.07%	39.83%	38.71%	41.70%	41.48%	39.01%						
	М	47.86%	47.61%	48.94%	40.17%	48.69%	49.43%	46.48%						
35–49	F	47.32%	49.04%	47.14%	34.19%	49.83%	49.12%	44.77%						
	M&F	47.43%	48.73%	47.39%	36.76%	49.54%	49.19%	45.09%						
	M	51.26%	52.54%	49.94%	50.00%	51.84%	51.06%	50.02%						
50–64	F	52.11%	54.45%	53.24%	44.44%	54.70%	53.65%	51.89%						
	M&F	51.79%	53.91%	52.28%	46.79%	53.68%	52.85%	51.19%						
	М	46.91%	51.61%	43.48%	100.00%	58.47%	57.07%	49.24%						
65–74	F	44.86%	53.85%	58.12%	75.00%	56.22%	55.67%	53.60%						
	M&F	45.74%	52.94%	55.71%	77.78%	56.90%	56.08%	52.39%						
	М	76.92%	100.00%	43.75%	NA	63.09%	52.34%	57.02%						
75–84	F	55.65%	64.00%	50.00%	NA	53.06%	53.67%	48.76%						
	M&F	59.57%	65.38%	47.37%	NA	55.34%	53.40%	50.53%						
	М	56.25%	72.73%	53.33%	NA	58.54%	59.52%	50.00%						
≥85	F	54.65%		0.00%	NA	53.17%	54.35%	56.11%						
	M&F	55.08%	85.71%	47.06%	NA	54.17%	55.56%	55.84%						
	M	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	М		53.10%	49.65%	49.41%	53.04%	49.65%		42.94%	34.74%	39.27%	43.92%	46.79%	49.40%
Total	F	44.92%		44.28%	45.70%	48.36%	45.86%							
		/ 2 /0		0 / 3	.0.,0,0	.0.0070	.0.5070							46.97%

	Tal	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	h Natior	nal Bencl	hmarks:	Utiliza	tion Me	asures		
Measure by	C	Ameri-	Blue	Care	TennCare	Uni	tedHealth	care	Nationa	al Medicai	d HEDIS 2	2012 Mear	ns and Per	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
Antibiotics of C	oncern	Utilizati	on											
Average Scripts	PMPY 1	for Quinol	ones											
	M	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
0–9	F	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
	M	0.01	0.01	0.01	0.02	0.01	0.01	0.01						
10–17	F	0.02	0.03	0.02	0.05	0.03	0.03	0.02						
	M&F	0.02	0.02	0.01	0.03	0.02	0.02	0.01						
	M	0.06	0.07	0.07	0.03	0.07	0.07	0.06						
18–34	F	0.17	0.16	0.18	0.09	0.18	0.19	0.16						
	M&F	0.14	0.14	0.16	0.05	0.14	0.16	0.14						
	М	0.14	0.13	0.17	0.16	0.15	0.17	0.15						
35–49	F	0.25	0.23	0.26	0.16	0.25	0.27	0.22						
	M&F	0.22	0.20	0.24	0.16	0.22	0.24	0.20						
	M	0.23	0.19	0.24	0.15	0.22	0.27	0.21						
50–64	F	0.33	0.29	0.33	0.20	0.35	0.40	0.31						
	M&F	0.29	0.26	0.29	0.17	0.29	0.35	0.26						
	М	0.21	0.21	0.18	0.41	0.42	0.46	0.36						
65–74	F	0.17	0.28	0.26	0.39	0.54	0.61	0.44						
	M&F	0.19	0.25	0.24	0.40	0.49	0.55	0.41						
	M	0.11	0.00	0.27	0.00	0.48	0.31	0.31						
75–84	F	0.55	0.12	0.12	0.00	0.55	0.51	0.38						
	M&F	0.39	0.09	0.18	0.00	0.53	0.45	0.37						
	М	0.46	0.18	0.27	NA	0.45	0.72	0.20						
≥85	F	0.44	0.10	0.00	NA	0.52	0.45	0.42						
	M&F	0.45	0.12	0.10	NA	0.51	0.50	0.40						
	М	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	М	0.03	0.03	0.03	0.02	0.05	0.04	0.04	0.03	0.01	0.02	0.03	0.03	0.04
Total	F	0.10	0.10	0.11	0.04	0.13	0.12	0.10	0.08	0.05	0.06	0.07	0.09	0.11
	M&F	0.07	0.08	0.08	0.03	0.09	0.09	0.08	0.06	0.03	0.04	0.05	0.07	0.08

	Та	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	:h Natior	nal Bencl	hmarks:	Utiliza	tion Me	asures		
Measure by	C	Ameri-	Blue	Care	TennCare	Uni	tedHealth	care	Nationa	al Medicai	d HEDIS 2	2012 Mear	ns and Per	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
Average Scripts	PMPY 1	for Cephal	osporins 2	2nd-4th G	eneration									
	M	0.27	0.31	0.20	0.31	0.27	0.26	0.16						
0–9	F	0.27	0.32	0.21	0.33	0.27	0.28	0.15						
	M&F	0.27	0.31	0.20	0.32	0.27	0.27	0.15						
	М	0.08	0.10	0.07	0.08	0.09	0.09	0.06						
10–17	F	0.11	0.13	0.09	0.12	0.11	0.12	0.06						
	M&F	0.10	0.12	0.08	0.09	0.10	0.10	0.06						
	M	0.03	0.03	0.03	0.02	0.03	0.04	0.02						
18–34	F	0.06	0.05	0.05	0.04	0.06	0.07	0.04						
	M&F	0.05	0.05	0.04	0.03	0.05	0.06	0.04						
	М	0.04	0.03	0.04	0.01	0.05	0.05	0.03						
35–49	F	0.07	0.06	0.05	0.01	0.06	0.08	0.05						
	M&F	0.06	0.05	0.05	0.01	0.06	0.07	0.04						
	M	0.05	0.05	0.04	0.02	0.05	0.05	0.05						
50–64	F	0.07	0.07	0.06	0.02	0.08	0.08	0.05						
	M&F	0.07	0.06	0.05	0.02	0.06	0.07	0.05						
	M	0.04	0.06	0.03	0.00	0.09	0.09	0.05						
65–74	F	0.04	0.04	0.00	0.00	0.13	0.12	0.05						
	M&F	0.04	0.05	0.01	0.00	0.12	0.11	0.05						
	M	0.03	0.08	0.13	0.00	0.13	0.11	0.07						
75–84	F	0.08	0.09	0.04	0.00	0.14	0.16	0.04						
	M&F	0.06	0.09	0.08	0.00	0.14	0.14	0.05						
	M	0.13	0.18	0.13	NA	0.13	0.05	0.00						
≥85	F	0.20	0.10	0.00	NA	0.21	0.12	0.07						
	M&F	0.18	0.12	0.05	NA	0.19	0.11	0.06						
	M	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	M	0.16	0.18	0.13	0.16	0.15	0.16	0.10	0.07	0.01	0.03	0.06	0.09	0.15
Total	F	0.14	0.15	0.11	0.19	0.14	0.15	0.08	0.07	0.02	0.03	0.06	0.09	0.13
	M&F	0.15	0.16	0.11	0.17	0.14	0.16	0.09	0.07	0.02	0.03	0.06	0.09	0.14

	Та	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	:h Natior	nal Bencl	hmarks:	Utiliza	tion Me	asures		
Measure by	C	Ameri-	Blue	Care	TennCare	Uni	tedHealth	care	Nationa	al Medicai	d HEDIS 2	2012 Mear	ns and Per	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
Average Scripts	PMPY 1	for Azithro	omycins ar	nd Clarithr	omycins									
	M	0.26	0.41	0.23	0.34	0.38	0.26	0.20						
0–9	F	0.25	0.39	0.22	0.33	0.36	0.25	0.19						
	M&F	0.25	0.40	0.22	0.33	0.37	0.26	0.20						
	М	0.22	0.30	0.19	0.18	0.28	0.22	0.15						
10–17	F	0.27	0.36	0.23	0.25	0.34	0.28	0.20						
	M&F	0.25	0.33	0.21	0.21	0.31	0.25	0.18						
	М	0.17	0.16	0.16	0.10	0.17	0.17	0.15						
18–34	F	0.35	0.33	0.35	0.18	0.34	0.36	0.31						
	M&F	0.30	0.28	0.31	0.13	0.29	0.31	0.27						
	М	0.19	0.19	0.22	0.08	0.19	0.24	0.20						
35–49	F	0.34	0.34	0.37	0.13	0.37	0.39	0.32						
	M&F	0.30	0.29	0.34	0.10	0.31	0.34	0.29						
	M	0.19	0.19	0.17	0.12	0.18	0.21	0.17						
50–64	F	0.32	0.33	0.32	0.18	0.35	0.39	0.31						
	M&F	0.26	0.28	0.26	0.15	0.27	0.32	0.24						
	М	0.11	0.19	0.03	0.00	0.29	0.21	0.13						
65–74	F	0.21	0.28	0.19	0.39	0.42	0.42	0.32						
	M&F	0.16	0.24	0.14	0.27	0.37	0.34	0.26						
	M	0.22	0.00	0.00	0.00	0.27	0.19	0.13						
75–84	F	0.21	0.09	0.12	0.00	0.34	0.30	0.20						
	M&F	0.22	0.07	0.08	0.00	0.32	0.27	0.19						
	М	0.04	0.27	0.00	NA	0.25	0.34	0.00						
≥85	F	0.16	0.10	0.00	NA	0.16	0.17	0.18						
	M&F	0.12	0.14	0.00	NA	0.18	0.20	0.16						
	M	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	М	0.23	0.31	0.20	0.23	0.29	0.23	0.18	0.18	0.11	0.15	0.18	0.22	0.25
Total	F	0.30	0.36	0.29	0.27	0.35	0.31	0.25	0.24	0.16	0.20	0.23	0.28	0.32
	M&F	0.27	0.34	0.26	0.24	0.32	0.28	0.22	0.21	0.13	0.18	0.21	0.25	0.28

	Та	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	:h Nation	al Bencl	nmarks:	Utiliza	tion Me	asures		
Measure by	C	Ameri-	Blue	Care	TennCare	Uni	tedHealth	are	Nationa	al Medicaio	d HEDIS 2	2012 Mear	ns and Perd	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
Average Scripts	PMPY 1	for Amoxic	cillin/Clav	ulanates										
	М	0.17	0.23	0.16	0.24	0.21	0.17	0.14						
0–9	F	0.15	0.21	0.15	0.23	0.18	0.15	0.12						
	M&F	0.16	0.22	0.15	0.24	0.20	0.16	0.13						
	М	0.09	0.12	0.07	0.09	0.11	0.09	0.07						
10–17	F	0.10	0.13	0.08	0.11	0.12	0.10	0.07						
	M&F	0.10	0.13	0.08	0.10	0.11	0.10	0.07						
	М	0.07	0.08	0.08	0.04	0.08	0.07	0.06						
18–34	F	0.12	0.12	0.11	0.07	0.13	0.12	0.10						
	M&F	0.11	0.11	0.10	0.05	0.11	0.11	0.09						
	М	0.09	0.10	0.10	0.07	0.10	0.10	0.09						
35–49	F	0.13	0.15	0.15	0.06	0.15	0.15	0.12						
	M&F	0.12	0.13	0.14	0.07	0.13	0.13	0.11						
	М	0.11	0.10	0.09	0.05	0.10	0.10	0.09						
50–64	F	0.12	0.14	0.15	0.05	0.15	0.14	0.13						
	M&F	0.11	0.12	0.13	0.05	0.13	0.12	0.11						
	М	0.09	0.19	0.03	0.00	0.15	0.17	0.10						
65–74	F	0.05	0.10	0.13	0.39	0.18	0.11	0.11						
	M&F	0.07	0.14	0.10	0.27	0.17	0.14	0.11						
	М	0.20	0.00	0.07	0.00	0.09	0.08	0.19						
75–84	F	0.20	0.06	0.08	0.00	0.13	0.13	0.05						
	M&F	0.20	0.04	0.08	0.00	0.12	0.11	0.08						
	М	0.13	0.09	0.13	NA	0.08	0.18	0.05						
≥85	F	0.00	0.03	0.00	NA	0.06	0.09	0.03						
	M&F	0.04	0.05	0.05	NA	0.06	0.11	0.03						
	М	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	М	0.13	0.16	0.12	0.14	0.14	0.13	0.10	0.10	0.05	0.07	0.10	0.12	0.14
Total	F	0.13	0.15	0.12	0.16	0.15	0.13	0.10	0.10	0.06	0.08	0.10	0.12	0.14
	M&F	0.13	0.16	0.12	0.14	0.15	0.13	0.10	0.10	0.05	0.08	0.10	0.12	0.14

	Та	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	:h Nation	al Bencl	hmarks:	Utiliza	tion Me	asures		
Measure by		Ameri-	Blue	Care	TennCare	Uni	tedHealtho	are	Nationa	al Medicai	d HEDIS 2	2012 Mear	ns and Pero	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
Average Scripts	PMPY 1	for Ketolic	les											
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
0–9	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
10–17	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
18–34	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
35–49	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
50–64	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
65–74	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
75–84	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	NA	0.00	0.00	0.00						
≥85	F	0.00	0.00	0.00	NA	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	NA	0.00	0.00	0.00						
	М	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

	Tal	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	h Natior	nal Bencl	hmarks:	<b>Utiliza</b>	tion Me	asures		
Measure by	Sex	Ameri-	Blue	Care	TennCare	Uni	tedHealth	care	Nationa	al Medicai	d HEDIS 2	2012 Mear	ns and Pero	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
Average Scripts	PMPY 1	for Clinda	mycins											
	М	0.02	0.01	0.04	0.04	0.01	0.02	0.03						
0–9	F	0.02	0.01	0.04	0.04	0.01	0.03	0.03						
	M&F	0.02	0.01	0.04	0.04	0.01	0.02	0.03						
	М	0.03	0.03	0.03	0.04	0.02	0.03	0.03						
10–17	F	0.03	0.03	0.04	0.05	0.03	0.04	0.04						
	M&F	0.03	0.03	0.04	0.04	0.03	0.03	0.04						
	М	0.05	0.06	0.05	0.02	0.06	0.05	0.04						
18–34	F	0.09	0.09	0.08	0.04	0.09	0.09	0.08						
	M&F	0.08	0.08	0.07	0.03	0.08	0.08	0.07						
	М	0.05	0.07	0.06	0.01	0.08	0.07	0.06						
35–49	F	0.07	0.09	0.09	0.01	0.09	0.09	0.07						
	M&F	0.07	0.08	0.08	0.01	0.08	0.08	0.07						
	М	0.04	0.05	0.06	0.02	0.05	0.05	0.05						
50–64	F	0.05	0.06	0.07	0.01	0.08	0.07	0.07						
	M&F	0.05	0.05	0.07	0.01	0.07	0.06	0.06						
	М	0.00	0.02	0.00	0.00	0.05	0.04	0.01						
65–74	F	0.01	0.01	0.10	0.00	0.06	0.06	0.04						
	M&F	0.01	0.02	0.07	0.00	0.06	0.05	0.03						
	М	0.00	0.00	0.00	0.00	0.07	0.01	0.03						
75–84	F	0.00	0.00	0.08	0.00	0.05	0.04	0.03						
	M&F	0.00	0.00	0.05	0.00	0.06	0.03	0.03						
	М	0.00	0.00	0.00	NA	0.04	0.00	0.00						
≥85	F	0.06	0.00	0.00	NA	0.04	0.01	0.03						
	M&F	0.04	0.00	0.00	NA	0.04	0.00	0.03						
	М	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	M	0.03	0.03	0.04	0.04	0.03	0.03	0.04	0.02	0.01	0.02	0.02	0.03	0.04
Total	F	0.05	0.05	0.06	0.04	0.05	0.06	0.06	0.04	0.02	0.03	0.04	0.05	0.06
	M&F	0.04	0.04	0.05	0.04	0.04	0.05	0.05	0.03	0.02	0.02	0.03	0.04	0.05

	Id			Care	Specific R		tedHealth						o and Daw	antiles.
Measure by Age/as Stated	Sex	Ameri- group	-East	-West	TennCare Select	-East	-Middle	-West	Mean	P10	P25	P50	ns and Pero	P90
	DA4DV.	<b>.</b>				-East	-ivildale	-vvest	Mean	PIU	P25	P30	P/3	P 90
Average Scripts				1		0.00	0.00	2.00						
0.0	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
0–9	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
10–17	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
18–34	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.01	0.00	0.01	0.00	0.01	0.01	0.00						
35–49	F	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.01	0.00	0.00						
	M	0.01	0.00	0.00	0.01	0.01	0.01	0.01						
50–64	F	0.01	0.01	0.00	0.00	0.01	0.01	0.01						
	M&F	0.01	0.01	0.00	0.00	0.01	0.01	0.01						
	M	0.00	0.00	0.00	0.00	0.02	0.00	0.00						
65–74	F	0.00	0.00	0.00	0.00	0.01	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.02	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.02	0.01	0.03						
75–84	F	0.00	0.12	0.00	0.00	0.02	0.00	0.01						
	M&F	0.00	0.09	0.00	0.00	0.02	0.00	0.01						
	М	0.00	0.00	0.00	NA	0.00	0.00	0.00						
≥85	F	0.08	0.00	0.00	NA	0.02	0.00	0.02						
	M&F	0.05	0.00	0.00	NA	0.01	0.00	0.02						
	М	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

	Та	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	h Nation	al Bencl	hmarks:	Utilizat	tion Me	asures		
Measure by	C	Ameri-	Blue	Care	TennCare	Uni	tedHealtho	are	Nationa	al Medicaio	d HEDIS 2	2012 Mear	s and Per	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
All Other Antibi	otics L	Jtilization	1											
Average Scripts	PMPY 1	for Absorb	oable Sulfo	namides										
	М	0.06	0.09	0.07	0.14	0.07	0.07	0.06						
0–9	F	0.11	0.14	0.12	0.21	0.12	0.12	0.09						
	M&F	0.09	0.11	0.09	0.17	0.09	0.09	0.08						
	М	0.06	0.08	0.05	0.08	0.07	0.06	0.04						
10–17	F	0.11	0.14	0.10	0.18	0.13	0.12	0.09						
	M&F	0.09	0.11	0.07	0.11	0.10	0.09	0.07						
	М	0.11	0.11	0.08	0.07	0.11	0.11	0.08						
18–34	F	0.22	0.19	0.19	0.15	0.20	0.22	0.18						
	M&F	0.19	0.17	0.17	0.10	0.17	0.19	0.15						
	M	0.15	0.13	0.13	0.06	0.15	0.18	0.13						
35–49	F	0.21	0.19	0.20	0.07	0.20	0.22	0.18						
	M&F	0.19	0.17	0.18	0.07	0.18	0.21	0.17						
	М	0.17	0.13	0.16	0.09	0.15	0.18	0.13						
50–64	F	0.19	0.16	0.16	0.11	0.17	0.22	0.17						
	M&F	0.18	0.15	0.16	0.10	0.16	0.21	0.15						
	M	0.11	0.19	0.05	0.00	0.15	0.18	0.11						
65–74	F	0.16	0.06	0.06	0.00	0.21	0.25	0.17						
	M&F	0.14	0.11	0.06	0.00	0.19	0.23	0.15						
	М	0.03	0.00	0.13	0.00	0.11	0.24	0.07						
75–84	F	0.18	0.03	0.08	0.00	0.18	0.22	0.17						
	M&F	0.12	0.02	0.10	0.00	0.16	0.23	0.14						
	М	0.21	0.09	0.27	NA	0.12	0.36	0.15						
≥85	F	0.04	0.00	0.00	NA	0.18	0.18	0.15						
	M&F	0.10	0.02	0.10	NA	0.17	0.21	0.15						
	М	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	М	0.08	0.09	0.07	0.10	0.09	0.09	0.07	0.06	0.04	0.04	0.06	0.07	0.08
Total	F	0.16	0.16	0.15	0.19	0.16	0.17	0.13	0.11	0.07	0.09	0.11	0.14	0.15
	M&F	0.13	0.13	0.12	0.13	0.13	0.14	0.11	0.09	0.06	0.07	0.09	0.10	0.12

	Ta				Specific R									
Measure by	Sex	Ameri-	Blue	Care	TennCare		tedHealtho		Nationa	al Medicai	d HEDIS 2	2012 Mear	ns and Pero	centiles
Age/as Stated	Jon	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
Average Scripts	PMPY 1	for Amino	glycosides	:										
	М	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
0–9	F	0.00	0.00	0.00	0.02	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
10–17	F	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
18–34	F	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
5–49	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
50–64	F	0.00	0.01	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.01	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.01	0.00	0.01						
65–74	F	0.02	0.03	0.00	0.00	0.00	0.00	0.00						
	M&F	0.01	0.02	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.01	0.00	0.00						
75–84	F	0.00	0.00	0.00	0.00	0.00	0.01	0.01						
	M&F	0.00	0.00	0.00	0.00	0.00	0.01	0.01						
	М	0.00	0.00	0.00	NA	0.00	0.00	0.00						
≥85	F	0.00	0.00	0.00	NA	0.01	0.00	0.01						
	M&F	0.00	0.00	0.00	NA	0.01	0.00	0.01						
	М	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	М	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total	F	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	M&F	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

	Та	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	h Nation	nal Bencl	hmarks:	Utilizat	tion Me	asures		
Measure by	Carr	Ameri-	Blue	Care	TennCare	Uni	tedHealth	care	Nationa	al Medicaio	d HEDIS 2	2012 Mear	ns and Pero	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
Average Scripts	PMPY 1	for 1st Ge	neration C	ephalospo	rins									
	М	0.06	0.07	0.07	0.07	0.06	0.06	0.05						
0–9	F	0.07	0.08	0.07	0.08	0.07	0.07	0.05						
	M&F	0.07	0.07	0.07	0.07	0.07	0.07	0.05						
	М	0.08	0.08	0.06	0.06	0.07	0.07	0.05						
10–17	F	0.09	0.09	0.07	0.07	0.09	0.09	0.06						
	M&F	0.08	0.08	0.06	0.07	0.08	0.08	0.06						
	М	0.09	0.08	0.07	0.04	0.09	0.09	0.07						
18–34	F	0.14	0.14	0.12	0.07	0.14	0.15	0.11						
	M&F	0.13	0.12	0.11	0.05	0.12	0.13	0.10						
	М	0.11	0.11	0.11	0.13	0.11	0.12	0.11						
35–49	F	0.14	0.13	0.13	0.20	0.14	0.14	0.12						
	M&F	0.13	0.13	0.12	0.17	0.13	0.13	0.12						
	М	0.11	0.10	0.09	0.06	0.10	0.12	0.10						
50–64	F	0.14	0.13	0.14	0.02	0.14	0.16	0.14						
	M&F	0.13	0.12	0.12	0.04	0.12	0.14	0.12						
	М	0.07	0.12	0.08	0.00	0.13	0.16	0.14						
65–74	F	0.07	0.03	0.07	0.00	0.17	0.18	0.16						
	M&F	0.07	0.07	0.07	0.00	0.15	0.17	0.15						
	М	0.00	0.00	0.13	0.00	0.11	0.09	0.21						
75–84	F	0.16	0.03	0.12	0.00	0.18	0.21	0.15						
	M&F	0.10	0.02	0.13	0.00	0.16	0.17	0.16						
	М	0.13	0.09	0.07	NA	0.17	0.16	0.00						
≥85	F	0.34	0.00	0.04	NA	0.08	0.16	0.13						
	M&F	0.27	0.02	0.05	NA	0.10	0.16	0.11						
	М	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	М	0.08	0.08	0.07	0.06	0.08	0.08	0.06	0.07	0.04	0.05	0.06	0.08	0.10
Total	F	0.11	0.11	0.10	0.08	0.11	0.11	0.09	0.09	0.05	0.06	0.08	0.11	0.14
	M&F	0.09	0.10	0.08	0.07	0.09	0.10	0.07	0.08	0.05	0.06	0.08	0.09	0.12

	Tal	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	h Nation	al Bencl	hmarks:	Utiliza	tion Me	asures		
Measure by	Cov	Ameri-	Blue	Care	TennCare	Uni	tedHealth	are	Nationa	al Medicai	d HEDIS 2	2012 Mear	ns and Per	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
Average Scripts	PMPY 1	for Lincos	amides											
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
0–9	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
10–17	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
18–34	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
35–49	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
_	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
50–64	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
65–74	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
75–84	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	NA	0.00	0.00	0.00						
≥85	F	0.00	0.00	0.00	NA	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	NA	0.00	0.00	0.00						
	М	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

	Та	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	:h Nation	al Bencl	hmarks:	Utiliza	tion Me	asures		
Measure by	C	Ameri-	Blue	Care	TennCare	Uni	tedHealtho	are	Nationa	al Medicai	d HEDIS 2	2012 Mear	ns and Pero	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
Average Scripts	PMPY 1	for Macrol	ides (not a	azith. or cl	arith.)									
	М	0.00	0.00	0.00	0.02	0.00	0.00	0.00						
0–9	F	0.00	0.00	0.00	0.02	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.02	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
10–17	F	0.00	0.01	0.00	0.01	0.00	0.00	0.00						
	M&F	0.00	0.01	0.00	0.01	0.00	0.00	0.00						
	M	0.01	0.01	0.01	0.00	0.01	0.00	0.00						
18–34	F	0.01	0.01	0.01	0.01	0.01	0.01	0.01						
	M&F	0.01	0.01	0.01	0.01	0.01	0.01	0.01						
	М	0.01	0.01	0.00	0.00	0.01	0.01	0.01						
35–49	F	0.01	0.01	0.01	0.00	0.01	0.01	0.01						
	M&F	0.01	0.01	0.01	0.00	0.01	0.01	0.01						
	М	0.01	0.01	0.00	0.00	0.01	0.01	0.00						
50–64	F	0.01	0.02	0.01	0.00	0.01	0.01	0.01						
	M&F	0.01	0.01	0.01	0.00	0.01	0.01	0.00						
	М	0.00	0.00	0.00	0.00	0.01	0.00	0.01						
65–74	F	0.00	0.01	0.00	0.00	0.01	0.03	0.00						
	M&F	0.00	0.01	0.00	0.00	0.01	0.02	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
75–84	F	0.00	0.00	0.00	0.00	0.00	0.00	0.01						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.01						
	М	0.00	0.00	0.00	NA	0.00	0.00	0.00						
≥85	F	0.00	0.00	0.00	NA	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	NA	0.00	0.00	0.00						
	М	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	М	0.00	0.00	0.00	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01
Total	F	0.01	0.01	0.01	0.01	0.01	0.01	0.00	0.01	0.00	0.00	0.01	0.01	0.01
	M&F	0.01	0.01	0.00	0.01	0.01	0.00	0.00	0.01	0.00	0.00	0.00	0.01	0.01

	Tal	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	h Nation	al Bencl	hmarks:	Utiliza <sup>-</sup>	tion Me	asures		
Measure by	Sex	Ameri-	Blue	Care	TennCare	Uni	tedHealth	care	Nationa	al Medicai	d HEDIS 2	2012 Mear	ns and Pero	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
Average Scripts	PMPY 1	or Penicil	lins											
	М	0.54	0.60	0.49	0.59	0.54	0.58	0.45						
0–9	F	0.55	0.62	0.48	0.66	0.55	0.58	0.44						
	M&F	0.54	0.61	0.49	0.62	0.54	0.58	0.45						
	М	0.22	0.27	0.18	0.24	0.23	0.23	0.17						
10–17	F	0.29	0.34	0.23	0.30	0.31	0.30	0.22						
	M&F	0.26	0.30	0.20	0.26	0.27	0.26	0.20						
	М	0.18	0.21	0.16	0.12	0.21	0.18	0.17						
18–34	F	0.32	0.32	0.31	0.18	0.33	0.32	0.29						
	M&F	0.28	0.29	0.28	0.14	0.30	0.28	0.26						
	М	0.16	0.19	0.18	0.11	0.19	0.19	0.19						
5-49	F	0.24	0.25	0.27	0.10	0.25	0.26	0.25						
	M&F	0.22	0.24	0.25	0.11	0.23	0.24	0.24						
	М	0.14	0.12	0.16	0.05	0.14	0.16	0.17						
50–64	F	0.18	0.16	0.20	0.07	0.19	0.20	0.21						
	M&F	0.16	0.15	0.19	0.06	0.17	0.18	0.19						
	М	0.07	0.08	0.16	0.00	0.16	0.17	0.20						
65–74	F	0.16	0.13	0.10	0.00	0.19	0.22	0.23						
	M&F	0.12	0.11	0.12	0.00	0.18	0.20	0.22						
	М	0.00	0.00	0.13	0.00	0.13	0.16	0.11						
75–84	F	0.10	0.03	0.04	0.00	0.15	0.14	0.18						
	M&F	0.06	0.02	0.08	0.00	0.15	0.14	0.16						
	М	0.00	0.09	0.00	NA	0.13	0.26	0.10						
≥85	F	0.14	0.00	0.00	NA	0.11	0.11	0.12						
	M&F	0.10	0.02	0.00	NA	0.11	0.13	0.11						
	М	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	M	0.36	0.40	0.33	0.35	0.35	0.38	0.30	0.34	0.23	0.29	0.34	0.39	0.47
Total	F	0.38	0.40	0.34	0.43	0.37	0.39	0.32	0.37	0.27	0.32	0.36	0.42	0.48
	M&F	0.37	0.40	0.34	0.38	0.36	0.39	0.31	0.36	0.25	0.30	0.35	0.41	0.47

	Ta	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	h Nation	nal Bencl	hmarks:	Utiliza	tion Me	asures		
Measure by	Cov	Ameri-	Blue	Care	TennCare	Uni	tedHealtho	care	Nationa	al Medicai	d HEDIS 2	2012 Mear	ns and Per	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
Average Scripts	PMPY 1	for Tetrac	yclines											
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
0–9	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.05	0.08	0.05	0.07	0.07	0.06	0.05						
10–17	F	0.06	0.08	0.07	0.06	0.08	0.06	0.06						
	M&F	0.06	0.08	0.06	0.07	0.07	0.06	0.06						
	M	0.09	0.09	0.10	0.09	0.09	0.09	0.10						
18–34	F	0.13	0.12	0.17	0.09	0.14	0.14	0.15						
	M&F	0.12	0.12	0.15	0.09	0.12	0.13	0.14						
	М	0.10	0.10	0.13	0.17	0.11	0.11	0.12						
5–49	F	0.14	0.14	0.17	0.15	0.16	0.14	0.16						
	M&F	0.13	0.12	0.16	0.16	0.14	0.13	0.15						
	M	0.10	0.12	0.12	0.15	0.12	0.13	0.13						
50–64	F	0.16	0.14	0.15	0.16	0.17	0.16	0.14						
	M&F	0.13	0.13	0.14	0.15	0.14	0.14	0.14						
	М	0.17	0.19	0.03	0.00	0.21	0.16	0.16						
65–74	F	0.13	0.24	0.17	0.20	0.20	0.17	0.15						
	M&F	0.15	0.22	0.13	0.13	0.20	0.16	0.15						
	M	0.08	0.00	0.07	0.00	0.17	0.13	0.11						
75–84	F	0.08	0.03	0.12	0.00	0.24	0.16	0.10						
	M&F	0.08	0.02	0.10	0.00	0.22	0.15	0.10						
	М	0.21	0.00	0.07	NA	0.09	0.08	0.00						
≥85	F	0.06	0.00	0.04	NA	0.14	0.06	0.10						
	M&F	0.11	0.00	0.05	NA	0.13	0.06	0.09						
	М	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	М	0.04	0.05	0.04	0.05	0.05	0.04	0.04	0.04	0.02	0.03	0.04	0.04	0.05
Total	F	0.08	0.08	0.10	0.04	0.09	0.08	0.09	0.06	0.04	0.05	0.06	0.07	0.09
	M&F	0.06	0.07	0.07	0.05	0.07	0.06	0.07	0.05	0.03	0.04	0.05	0.06	0.07

	Ta	ble A. H	EDIS 20	13 Plan-	Specific R	ates wit	h Nation	al Bencl	hmarks:	Utiliza <sup>-</sup>	tion Me	asures		
Measure by	Sex	Ameri-	Blue	Care	TennCare	Uni	tedHealtho	care	Nationa	al Medicai	d HEDIS 2	2012 Mear	ns and Per	centiles
Age/as Stated	Sex	group	-East	-West	Select	-East	-Middle	-West	Mean	P10	P25	P50	P75	P90
Average Scripts	PMPY 1	for Misc. A	ntibiotics											
	М	0.00	0.01	0.00	0.01	0.01	0.00	0.00						
0–9	F	0.01	0.01	0.01	0.04	0.01	0.01	0.01						
	M&F	0.01	0.01	0.00	0.02	0.01	0.01	0.00						
	М	0.01	0.01	0.01	0.01	0.01	0.00	0.00						
10–17	F	0.06	0.07	0.06	0.10	0.06	0.06	0.05						
	M&F	0.03	0.04	0.03	0.05	0.03	0.03	0.03						
	М	0.03	0.02	0.02	0.01	0.02	0.02	0.02						
18–34	F	0.39	0.31	0.40	0.15	0.31	0.37	0.38						
	M&F	0.29	0.23	0.32	0.07	0.22	0.28	0.29						
	М	0.05	0.04	0.06	0.02	0.04	0.04	0.05						
5–49	F	0.22	0.17	0.26	0.18	0.18	0.22	0.24						
	M&F	0.17	0.13	0.22	0.10	0.13	0.17	0.19						
	М	0.06	0.05	0.06	0.02	0.05	0.06	0.05						
50–64	F	0.16	0.14	0.15	0.20	0.16	0.19	0.15						
	M&F	0.11	0.11	0.12	0.11	0.11	0.14	0.10						
	М	0.09	0.04	0.03	0.00	0.07	0.06	0.04						
65–74	F	0.05	0.12	0.09	0.20	0.26	0.21	0.14						
	M&F	0.07	0.09	0.07	0.13	0.19	0.15	0.11						
	М	0.06	0.00	0.13	0.00	0.09	0.02	0.08						
75–84	F	0.31	0.15	0.08	0.00	0.32	0.25	0.13						
	M&F	0.22	0.11	0.10	0.00	0.25	0.18	0.12						
	М	0.04	0.00	0.07	NA	0.16	0.03	0.00						
≥85	F	0.20	0.00	0.00	NA	0.36	0.20	0.10						
	M&F	0.15	0.00	0.03	NA	0.32	0.17	0.09						
	М	NA	NA	NA	NA	NA	NA	NA						
Unknown	F	NA	NA	NA	NA	NA	NA	NA						
	M&F	NA	NA	NA	NA	NA	NA	NA						
	М	0.01	0.01	0.01	0.01	0.02	0.01	0.01	0.01	0.00	0.01	0.01	0.01	0.02
Total	F	0.16	0.14	0.18	0.08	0.14	0.16	0.17	0.12	0.08	0.10	0.12	0.14	0.17
	M&F	0.10	0.09	0.11	0.04	0.09	0.10	0.10	0.07	0.05	0.06	0.07	0.08	0.10

## **APPENDIX B** | HEDIS 2012 National Medicaid Means and Percentiles

Table B. HEDIS 2012 Nati	onal Medi	caid Mea	ans and I	Percentil	es	
Measure	Medicaid			Percentile	•	
ivieasui e	Mean	10th	25th	50th	75th	90th
HEDIS Effecti	iveness of	Care Me	asures			
Prevention and Screening						
Adult BMI Assessment (ABA)	52.57%	4.41%	46.90%	57.94%	70.60%	78.35%
Weight Assessment and Counseling for Nutriti	on and Phy	sical Activ	vity for Ch	ildren/Ad	olescents	(WCC):
BMI Percentile: 3–11 years	45.84%	1.31%	27.99%	47.52%	68.58%	77.97%
12–17 years	46.56%	2.04%	29.50%	49.42%	67.65%	75.00%
Total	45.99%	1.55%	29.20%	47.45%	66.67%	77.13%
Counseling for Nutrition: 3–11 years	51.58%	0.71%	43.32%	57.09%	69.45%	78.79%
12–17 years	46.92%	1.17%	36.38%	50.00%	63.60%	74.81%
Total	50.08%	0.82%	42.82%	54.88%	67.15%	77.61%
Counseling for Physical Activity: 3–11 years	39.37%	0.09%	29.82%	42.17%	54.48%	63.57%
12–17 years	43.23%	0.20%	32.95%	47.00%	60.34%	69.11%
Total	40.63%	0.16%	31.63%	43.29%	56.20%	64.87%
Childhood Immunization Status (CIS):	ı		ı		ı	
DTaP	79.81%	71.53%	75.74%	80.63%	85.16%	88.47%
IPV	90.54%	84.03%	88.19%	92.21%	94.65%	95.86%
MMR	90.87%	85.65%	88.81%	91.65%	93.52%	95.42%
HiB	90.98%	85.12%	88.86%	92.46%	94.79%	96.11%
HepB	88.78%	80.05%	86.86%	90.75%	93.52%	95.38%
VZV	90.47%	85.64%	88.56%	91.22%	93.19%	95.12%
PCV	79.28%	71.59%	74.94%	80.93%	85.16%	87.74%
НерА	39.16%	25.79%	33.09%	38.32%	45.70%	52.78%
RV	62.35%	46.30%	56.87%	63.70%	70.49%	74.07%
Flu	44.81%	24.57%	36.98%	44.90%	54.06%	59.69%
Combination 2	74.48%	64.23%	69.10%	75.35%	80.79%	84.18%
Combination 3	70.64%	58.88%	64.72%	71.93%	77.49%	82.48%
Combination 4	34.19%	20.92%	27.78%	33.92%	40.39%	46.93%
Combination 5	51.88%	36.50%	46.47%	52.92%	59.76%	64.68%
Combination 6	37.93%	20.19%	30.90%	37.57%	45.50%	56.20%
Combination 7	27.09%	15.29%	20.92%	26.03%	33.33%	38.50%
Combination 8	20.89%	10.90%	14.36%	20.88%	25.69%	31.25%
Combination 9	30.48%	14.81%	22.87%	29.79%	38.19%	45.05%
Combination 10	17.30%	8.10%	11.54%	16.51%	21.41%	27.49%

Table B. HEDIS 2012 Nati		caid Mea				
Measure	Medicaid Mean	404		Percentile		0041-
Languagiantiana fan Adalasaanta (1840).	wean	10th	25th	50th	75th	90th
Immunizations for Adolescents (IMA):	(2.100/	42.07.07	F2 040/	(4.220/	72.000/	00.0404
Meningococcal	63.18%	42.86%	53.04%	64.23%	73.89%	82.84%
Tdap/Td	75.80%	53.53%	70.60%	78.83%	85.16%	90.27%
Combination 1	60.54%	39.77%	50.36%	62.29%	70.83%	80.91%
Human Papillomavirus Vaccine for Female Adolescents (HPV)	17.71%	7.03%	12.18%	18.09%	22.27%	26.28%
Lead Screening in Children (LSC)	67.81%	39.23%	57.52%	71.41%	81.86%	86.56%
Breast Cancer Screening (BCS)	50.43%	36.80%	44.82%	50.46%	56.58%	62.76%
Cervical Cancer Screening (CCS)	66.72%	51.85%	61.81%	69.10%	73.24%	78.51%
Chlamydia Screening in Women (CHL):						
16–20 years	54.91%	42.94%	48.80%	54.18%	61.21%	67.38%
21–24 years	63.43%	52.45%	59.09%	64.36%	69.86%	72.67%
Total	58.00%	47.62%	52.70%	58.40%	63.89%	68.83%
Respiratory Conditions				•		
Appropriate Testing for Children With Pharyngitis (CWP)	66.66%	49.98%	58.50%	70.00%	76.37%	83.86%
Appropriate Treatment for Children With Upper Respiratory Infection (URI)	85.32%	77.36%	80.64%	85.34%	89.96%	93.20%
Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis (AAB)	24.30%	16.45%	18.98%	22.14%	26.67%	33.33%
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)	32.02%	20.47%	25.87%	31.90%	38.38%	44.01%
Pharmacotherapy Management of COPD Exace	rbation (Po	CE):		I		
Systemic corticosteroid	64.11%	48.84%	57.14%	66.67%	72.76%	76.27%
Bronchodilator	80.45%	71.32%	75.54%	82.22%	85.71%	88.10%
Use of Appropriate Medications for People Wit	h Asthma (	(ASM):		I		
5–11 years	90.51%	84.95%	88.79%	91.59%	93.83%	95.41%
12–18 years	86.61%	80.95%	83.72%	86.96%	89.56%	92.30%
19–50 years	74.72%	63.78%	69.29%	75.53%	80.99%	84.42%
51–64 years	72.94%	58.11%	65.96%	73.81%	81.51%	85.58%
Total	84.99%	79.72%	82.54%	85.87%	88.19%	90.56%
Medication Management for People With Asthr						
Medication Compliance 50%: 5–11 years	50.35%	39.50%	44.02%	50.89%	55.70%	61.79%
12–18 years	49.01%	39.22%	43.09%	48.92%	53.33%	60.72%
19–50 years	56.13%	43.21%	50.96%	56.51%	61.90%	67.10%
51–64 years	71.11%	61.29%	65.75%	73.03%	77.42%	80.67%
Total	52.31%	42.87%	47.31%	52.31%	56.98%	62.39%

	Medicaid			Percentile	<u> </u>	
Measure	Mean	10th	25th	50th	75th	90th
Medication Compliance 75%: 5–11 years	28.15%	17.00%	22.54%	27.25%	32.18%	40.75%
12–18 years	27.18%	17.57%	21.80%	25.63%	31.48%	37.61%
19–50 years	34.81%	22.50%	28.57%	34.03%	39.68%	47.65%
51–64 years	49.81%	38.60%	41.89%	50.00%	55.71%	64.71%
Total	30.26%	20.39%	24.62%	29.14%	33.71%	40.17%
Asthma Medical Ratio (AMR)*:	1					
5–11 years						
12–18 years						
19–50 years						
51–64 years						
Total						
Cardiovascular Conditions						
Cholesterol Management for Patients With Car	rdiovascula	r Conditio	ns (CMC):			
LDL-C Screening	81.99%	76.00%	78.49%	82.48%	85.12%	88.83%
LDL-C Control (<100 mg/dL)	42.08%	28.40%	35.13%	42.39%	49.18%	55.56%
Controlling High Blood Pressure (CBP)	56.78%	42.22%	50.00%	57.52%	63.65%	69.11%
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)	80.49%	66.67%	72.92%	83.47%	88.24%	91.20%
Diabetes						
Comprehensive Diabetes Care (CDC):						
HbA1c Testing	82.53%	74.90%	78.54%	82.38%	87.01%	91.13%
HbA1c Control (<7.0%)	35.42%	25.40%	30.43%	36.72%	41.64%	44.01%
HbA1c Control (<8.0%)	48.08%	35.04%	42.09%	48.72%	55.70%	59.37%
Retinal Eye Exam Performed	53.35%	36.25%	45.03%	52.88%	61.75%	69.72%
LDL-C Screening	75.00%	64.38%	70.34%	76.16%	80.88%	83.45%
LDL-C Control (<100 mg/dL)	35.23%	23.06%	28.47%	35.86%	41.02%	46.44%
Medical Attention for Nephropathy	77.84%	68.43%	73.48%	78.71%	83.03%	86.93%
Blood Pressure Control (<140/80 mm Hg)	39.41%	27.31%	33.09%	39.10%	46.20%	54.99%
Blood Pressure Control (<140/90 mm Hg)	60.95%	47.02%	54.48%	63.50%	69.82%	75.44%
Musculoskeletal Conditions						
Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)	68.88%	57.45%	63.54%	69.28%	75.09%	80.98%
Use of I maging Studies for Low Back Pain (LBP)	75.78%	69.52%	72.04%	75.67%	79.38%	82.04%
Behavioral Health						
Antidepressant Medication Management (AMM	1):					
Effective Acute Phase Treatment	51.11%	43.40%	46.98%	49.42%	52.74%	61.58%
	_					

Table B. HEDIS 2012 Nati	Table B. HEDIS 2012 National Medicaid Means and Percentiles  Medicaid Percentile  Measure											
Manager	Medicaid			Percentile	•							
Measure	Mean	10th	25th	50th	75th	90th						
Follow-Up Care for Children Prescribed ADHD	Medication	(ADD):										
Initiation Phase	38.83%	22.97%	32.93%	39.19%	44.46%	52.48%						
Continuation and Maintenance Phase	45.87%	21.79%	38.36%	47.09%	56.10%	63.11%						
Follow-Up After Hospitalization for Mental Illn	ess (FUH):											
7-day follow-up	46.50%	24.03%	32.20%	46.06%	57.68%	69.57%						
30-day follow-up	64.99%	36.04%	57.29%	67.65%	77.47%	84.28%						
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (SSD)*												
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD) *												
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)*												
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)*												
Medication Management												
Annual Monitoring for Patients on Persistent N	/ledications	(MPM):										
ACE Inhibitors or ARBs	85.86%	80.15%	83.72%	86.89%	89.18%	91.33%						
Digoxin	90.28%	83.33%	87.93%	90.95%	93.41%	95.56%						
Diuretics	85.39%	78.52%	83.19%	86.40%	88.93%	91.30%						
Anticonvulsants	65.16%	53.72%	61.70%	65.29%	70.27%	74.71%						
Total	83.86%	78.45%	81.16%	84.81%	87.02%	88.55%						
Measures Collected Through CAHPS Health Pla	n Survey											
Medical Assistance With Smoking Cessation (N	/ISC) * *:											
Advising Smokers and Tobacco Users to Quit	74.55%	65.49%	71.41%	75.11%	79.38%	81.36%						
Discussing Cessation Medications	44.29%	32.95%	37.42%	44.50%	50.81%	56.62%						
Discussing Cessation Strategies	40.29%	31.28%	34.03%	40.65%	44.85%	50.66%						
HEDIS Effectiveness of Care Measures	Where Lo	wer Rate	s Indicat	ted Bette	r Perforn	nance						
Comprehensive Diabetes Care (CDC):	I											
HbA1c Poor Control (>9.0%)	43.04%	28.95%	34.33%	41.68%	50.31%	58.24%						
HEDIS Access/A			Measure:	S								
Adults' Access to Preventive/Ambulatory Heal				ı		ı						
20–44 years	80.04%	67.40%	77.96%	82.34%	85.43%	88.52%						
45–64 years	86.05%	78.26%	84.09%	87.31%	89.94%	90.96%						
Children and Adolescents' Access to Primary C	are Practit	ioners (CA	AP):									
12–24 months	96.07%	93.06%	95.56%	97.02%	97.88%	98.39%						
25 months-6 years	88.19%	83.16%	86.62%	89.19%	91.40%	92.63%						
7–11 years	89.54%	83.37%	87.56%	90.58%	92.88%	94.51%						
12–19 years	87.89%	81.78%	86.04%	89.21%	91.59%	93.01%						

Table B. HEDIS 2012 Nati	Table B. HEDIS 2012 National Medicaid Means and Percentiles  Medicaid Percentile  Measure											
Moacuro	Medicaid			Percentile	•							
ivieasure	Mean	10th	25th	50th	75th	90th						
Initiation and Engagement of Alcohol and Oth	er Drug (AC	DD) Deper	ndence Tre	eatment (I	ET):							
Initiation of AOD Treatment: 13–17 years	40.49%	23.14%	32.81%	42.03%	48.13%	56.85%						
≥18 years	39.38%	30.65%	34.57%	39.02%	43.61%	50.13%						
Total	39.19%	29.93%	34.30%	38.80%	43.62%	49.44%						
Engagement of AOD Treatment: 13-17 years	17.37%	2.04%	9.09%	16.57%	27.11%	31.53%						
≥18 years	11.49%	2.48%	5.40%	11.40%	17.81%	20.67%						
Total	11.93%	2.41%	5.84%	11.72%	18.56%	21.24%						
Prenatal and Postpartum Care (PPC):												
Timeliness of Prenatal Care	82.75%	72.02%	80.54%	86.13%	90.39%	93.33%						
Postpartum Care	64.12%	52.43%	58.70%	64.98%	71.05%	74.73%						
Call Answer Timeliness (CAT)	83.21%	68.38%	80.09%	85.37%	89.62%	93.57%						
HEDIS Utilization and	Relative	Resource	Use Mea	sures								
Utilization												
Frequency of Ongoing Prenatal Care (FPC):												
<21%	10.01%	2.43%	4.57%	6.58%	10.71%	19.11%						
21–40%	6.52%	2.01%	3.23%	4.66%	7.30%	13.14%						
41–60%	8.20%	3.89%	5.47%	7.50%	10.34%	14.01%						
61–80%	14.45%	8.10%	11.34%	14.37%	17.79%	21.39%						
≥81%	60.93%	39.42%	52.55%	64.65%	72.99%	82.75%						
Well-Child Visits in the First 15 Months of Life	(W15):											
0 Visits	1.95%	0.46%	0.72%	1.22%	2.43%	3.89%						
1 Visits	1.90%	0.44%	0.97%	1.57%	2.68%	3.65%						
2 Visits	3.14%	1.20%	1.97%	2.92%	3.94%	5.14%						
3 Visits	5.40%	2.62%	3.66%	4.74%	6.75%	9.49%						
4 Visits	9.50%	5.11%	7.18%	8.78%	11.34%	13.14%						
5 Visits	16.19%	10.00%	13.10%	16.30%	19.71%	21.96%						
6 or More Visits	61.75%	43.80%	54.31%	62.95%	70.70%	77.31%						
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34)	72.03%	61.07%	65.51%	72.26%	79.32%	83.04%						
Adolescent Well-Care Visits (AWC)	49.71%	35.52%	42.11%	49.65%	57.61%	64.72%						
*First vear measurement												

<sup>\*</sup>First year measurement

<sup>\*\*</sup>The three MSC rates were included in the 2012 Quality Compass; all other Medicaid national rates were taken from NCQA's 2012 HEDIS Audit Means, Percentiles and Rations.

## **APPENDIX C** | MCO Population Reported in Member Months

					Т	able C. H	EDIS 20	13 MCO F	opulatio	n Report	ted in Me	mber Mor	nths by A	ge and S	ех						
Age Group	Amerigroup			BlueCare-East			BlueCare-West			TennCare <i>Select</i>			UnitedHealthcare-East			UnitedHealthcare-Middle			UnitedHealthcare-West		
Age	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
<1	54295	51176	105,471	51921	48376	100,297	45434	42852	88,286	7360	7054	14,414	43639	41380	85,019	53610	52065	105,675	43122	40289	83,411
1–4	191952	183086	375,038	184094	177622	361,716	167319	161737	329,056	42679	34529	77,208	157652	150855	308,507	191335	185104	376,439	157452	154222	311,674
5–9	198550	193735	392,285	196883	191436	388,319	170660	171429	342,089	71870	43246	115,116	181242	175766	357,008	199504	194468	393,972	164436	165110	329,546
10–14	160356	156056	316,412	164099	157312	321,411	144332	146677	291,009	84543	46015	130,558	149547	149380	298,927	158155	153168	311,323	133905	134469	268,374
15–17	75326	79100	154,426	83441	84377	167,818	71991	74276	146,267	62721	35568	98,289	72575	75852	148,427	74772	73058	147,830	68626	73874	142,500
18–19	41256	54990	96,246	43882	57355	101,237	41678	51708	93,386	38092	21039	59,131	41478	52895	94,373	39258	48203	87,461	41097	55521	96,618
0-19 Subtotal	721,735	718,143	1,439,878	724,320	716,478	1,440,798	641,414	648,679	1,290,093	307,265	187,451	494,716	646,133	646,128	1,292,261	716,634	706,066	1,422,700	608,638	623,485	1,232,123
0-19 Subtotal %	77.58%	58.20%	66.53%	76.01%	53.74%	63.02%	82.61%	55.13%	66.05%	93.96%	92.65%	93.46%	70.42%	54.30%	61.32%	76.98%	55.49%	64.57%	77.75%	55.15%	64.39%
20–24	40215	118416	158,631	34283	127664	161,947	29539	117147	146,686	14166	9123	23,289	43712	101475	145,187	34805	113277	148,082	38129	121986	160,115
25–29	25667	101970	127,637	31654	121010	152,664	17630	111807	129,437	1150	1074	2,224	24781	85524	110,305	26379	112382	138,761	14516	93517	108,033
30-34	27271	90037	117,308	33163	102846	136,009	16524	100110	116,634	957	998	1,955	28451	85207	113,658	29628	98991	128,619	17216	85210	102,426
35–39	24103	67309	91,412	29099	78254	107,353	13583	67149	80,732	570	723	1,293	29637	68717	98,354	25637	71188	96,825	17095	63739	80,834
40-44	21531	46962	68,493	25420	55945	81,365	11608	43263	54,871	588	711	1,299	28850	49859	78,709	22861	49953	72,814	15878	42616	58,494
20-44 Subtotal	138,787	424,694	563,481	153,619	485,719	639,338	88,884	439,476	528,360	17,431	12,629	30,060	155,431	390,782	546,213	139,310	445,791	585,101	102,834	407,068	509,902
20-44 Subtotal %	14.92%	34.42%	26.04%	16.12%	36.43%	27.97%	11.45%	37.35%	27.05%	5.33%	6.24%	5.68%	16.94%	32.84%	25.92%	14.96%	35.03%	26.56%	13.14%	36.01%	26.65%
45-49	19379	31281	50,660	22581	43320	65,901	11356	30148	41,504	679	602	1,281	26887	37966	64,853	20559	35542	56,101	16253	29630	45,883
50–54	19982	25159	45,141	21205	35003	56,208	12907	24144	37,051	677	614	1,291	29871	35334	65,205	18784	29303	48,087	18751	24434	43,185
55–59	17556	19374	36,930	17837	28701	46,538	12960	19158	32,118	563	538	1,101	27784	30025	57,809	16845	22323	39,168	18677	19356	38,033
60–64	11142	12810	23,952	12452	22525	34,977	8144	13329	21,473	313	382	695	17666	21941	39,607	10742	16921	27,663	12202	13055	25,257
45-64 Subtotal	68,059	88,624	156,683	74,075	129,549	203,624	45,367	86,779	132,146	2,232	2,136	4,368	102,208	125,266	227,474	66,930	104,089	171,019	65,883	86,475	152,358
45-64 Subtotal %	7.32%	7.18%	7.24%	7.77%	9.72%	8.91%	5.84%	7.37%	6.77%	0.68%	1.06%	0.83%	11.14%	10.53%	10.79%	7.19%	8.18%	7.76%	8.42%	7.65%	7.96%
65–69	733	830	1,563	427	639	1,066	335	971	1,306	45	45	90	6190	9490	15,680	3556	5995	9,551	2712	4512	7,224
70–74	281	376	657	153	171	324	122	238	360	15	41	56	3527	6914	10,441	2108	3643	5,751	1482	3392	4,874
75–79	255	345	600	94	201	295	91	145	236	13	17	30	2056	4851	6,907	1185	2698	3,883	688	2266	2,954
80–84	173	393	566	52	193	245	87	153	240	1	6	7	1138	3008	4,146	727	1999	2,726	391	1406	1,797
85–89	169	324	493	92	178	270	84	149	233	0	0	0	623	2106	2,729	333	1333	1,666	133	980	1,113
≥90	115	272	387	41	186	227	94	135	229	0	4	4	276	1280	1,556	131	827	958	103	1000	1,103
≥65 Subtotal	1,726	2,540	4,266	859	1,568	2,427	813	1,791	2,604	74	113	187	13,810	27,649	41,459	8,040	16,495	24,535	5,509	13,556	19,065
≥65 Subtotal: %	0.19%	0.21%	0.20%	0.09%	0.12%	0.11%	0.10%	0.15%	0.13%	0.02%	0.06%	0.04%	1.51%	2.32%	1.97%	0.86%	1.30%	1.11%	0.70%	1.20%	1.00%
Total	930,307	1,234,001	2,164,308	952,873	1,333,314	2,286,187	776,478	1,176,725	1,953,203	327,002	202,329	529,331	917,582	1,189,825	2,107,407	930,914	1,272,441	2,203,355	782,864	1,130,584	1,913,448